US20020164690A1 - Receptor based antagonists and methods of making and using - Google Patents

Receptor based antagonists and methods of making and using Download PDF

Info

Publication number
US20020164690A1
US20020164690A1 US09/935,868 US93586801A US2002164690A1 US 20020164690 A1 US20020164690 A1 US 20020164690A1 US 93586801 A US93586801 A US 93586801A US 2002164690 A1 US2002164690 A1 US 2002164690A1
Authority
US
United States
Prior art keywords
trap
component
cytokine
receptor
fusion polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/935,868
Inventor
Neil Stahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/935,868 priority Critical patent/US20020164690A1/en
Priority to US10/287,035 priority patent/US7083949B2/en
Publication of US20020164690A1 publication Critical patent/US20020164690A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Definitions

  • ciliary neurotrophic factor CNTF
  • LIF leukemia inhibitory factor
  • OSM oncostatin M
  • IL-6 interleukin-6
  • CNTF family cytokines
  • cytokines are grouped together because of their distant structural similarities [Bazan, J. Neuron 7: 197-208 (1991); Rose and Bruce, Proc. Natl. Acad. Sci. USA 88: 8641-8645 (1991)], and, perhaps more importantly, because they share “ ⁇ ” signal-transducing receptor components [Baumann, et al., J. Biol. Chem.
  • IL-6 receptor activation requires homodimerization of gp130 [Murakami, et al. Science 260: 1808-1810 (1993), Hibi, et al., Cell 63: 1149-1157 (1990)], a protein initially identified as the IL-6 signal transducer [Hibi, et al., Cell 63:1149-1157 (1990)].
  • LIF and OSM receptor activation results from heterodimerization between gp130 and a second gp130-related protein known as LIFR ⁇ [Davis, et al., Science 260: 1805-1808 (1993)], that was initially identified by its ability to bind LIF [Gearing et al., EMBO J. 10: 2839-2848 (1991)].
  • cytokines In addition to the ⁇ components, some of these cytokines also require specificity-determining “ ⁇ ” components that are more limited in their tissue distribution than the ⁇ components, and thus determine the cellular targets of the particular cytokines [Stahl and Yancopoulos, Cell 74: 587-590 (1993)].
  • LIF and OSM are broadly acting factors that may only require the presence of gp130 and LIFR ⁇ on responding cells, while CNTF requires CNTFR ⁇ [Stahl and Yancopoulos, Cell 74: 587-590 (1993)] and IL-6 requires IL-6R ⁇ [Kishimoto, et al., Science 258: 593-597 (1992)].
  • CNTFR ⁇ (Davis et al., Science 259:1736-1739 (1993) and IL-6R ⁇ [Hibi, et al. Cell 63:1149-1157, Murakami, et al., Science 260:1808-1810 (1990); Taga, et al., Cell 58:573-581 (1989)] can function as soluble proteins, consistent with the notion that they do not interact with intracellular signaling molecules but that they serve to help their ligands interact with the appropriate signal transducing ⁇ subunits [Stahl and Yancopoulos, Cell 74: 587-590 (1993)].
  • GH Growth hormone
  • Crystallographic studies have revealed that each GH molecule contains two distinct receptor binding sites, both of which are recognized by the same binding domain in the receptor, allowing a single molecule of GH to engage two receptor molecules [de Vos, et al., Science 255: 306-312 (1992)]. Dimerization occurs sequentially, with site 1 on the GH first binding to one receptor molecule, followed by the binding of site 2 to a second receptor molecule [Fuh, et al., Science 256: 1677-1680 (1992)].
  • EPO erythropoietin
  • a second important feature is that formation of the final receptor complex by the CNTF family of cytokines occurs through a mechanism whereby the ligand successively binds to receptor components in an ordered manner [Davis, et al. Science 260:1805-1818 (1993); Stahl and Yancopoulos, Cell 74: 587-590 (1993)].
  • CNTF first binds to CNTFR ⁇ , forming a complex which then binds gp130 to form an intermediate (called here the ⁇ 1 intermediate) that is not signaling competent because it has only a single ⁇ component, before finally recruiting LIFR ⁇ to form a heterodimer of ⁇ components which then initiates signal transduction.
  • a similar intermediate containing IL-6 bound to IL-6R ⁇ and a single molecule of gp130 has not been directly isolated, we have postulated that it does exist by analogy to its distant relative, CNTF, as well as the fact that the final active IL-6 receptor complex recruits two gp130 monomers.
  • each cytokine can have up to 3 receptor binding sites: a site that binds to an optional ⁇ specificity-determining component ( ⁇ site), a site that binds to the first ⁇ signal-transducing component ( ⁇ 1 site), and a site that binds to the second ⁇ signal-transducing component ( ⁇ 2 site) [Stahl and Yancopoulos, Cell 74: 587-590 (1993)]. These 3 sites are used in sequential fashion, with the last step in complex formation—resulting in ⁇ component dimerization—critical for initiating signal transduction [Davis, et al. Science 260:1805-1818 (1993)].
  • CNTF is a high affinity antagonist for IL-6 under certain circumstances, and provides the strategic basis for designing ligand or receptor-based antagonists for the CNTF family of cytokines as detailed below.
  • Jak/Tyk kinases a newly discovered family of non-receptor tyrosine kinases that includes Jak1, Jak2, and Tyk2 (referred to as the Jak/Tyk kinases) [Firmbach-Kraft, et al., Oncogene 5:1329-1336 (1990); Wilks, et al., Mol. Cell. Biol. 11: 2057-2065 (1991] and that are involved in signal transduction with other cytokines [Argetsinger, et al., Cell 74:237-244 (1993); Silvennoinen, et al., Proc. Natl. Acad. Sci.
  • the CNTF family of cytokines play important roles in a wide variety of physiological processes that provide potential therapeutic applications for both antagonists and agonists.
  • An object of the present invention is the production of cytokine antagonists that are useful in the treatment of cytokine-related diseases or disorders.
  • Another object of the invention is the use of the disclosed cytokine antagonists for the treatment of cytokine-related diseases or disorders.
  • an IL-6 antagonist described herein may be used for the treatment of osteoporosis, the primary and second effects of cancers, including multiple myeloma, or cachexia.
  • Another object of the invention is the development of screening systems useful for identifying novel agonists and antagonists of cytokine receptors.
  • Another object of the invention is the development of screening systems useful for identifying small molecules that act as agonists or antagonists of the cytokines.
  • Another object of the invention is the development of screening systems useful for identifying novel agonists and antagonists of members of the CNTF family of cytokines.
  • Another object of the invention is the development of screening systems useful for identifying small molecules that act as agonists or antagonists of the CNTF family of cytokines.
  • FIG. 1 Ordered binding of receptor components in a model of a generic cytokine receptor.
  • the model indicates that cytokines contain up to 3 receptor binding sites and interact with their receptor components by binding first the optional ⁇ component, followed by binding to ⁇ 1, and then ⁇ 2.
  • the ⁇ components for many cytokine receptors interact through membrane proximal regions (shaded boxes) with the Jak/Tyk family of cytoplasmic protein tyrosine kinases. Only upon dimerization of ⁇ components is signal transduction initiated, as schematized by the tyrosine phosphorylations (P) of the ⁇ components and the Jak/Tyk kinases.
  • P tyrosine phosphorylations
  • FIG. 2 CNTF inhibits IL-6 responses in a PC12 cell line (called PC12D) that expresses IL6R ⁇ , gp130, CNTFR ⁇ , but not LIFR ⁇ .
  • PC12D PC12 cell line
  • Serum-deprived PC12D cells were incubated +IL-6 (50 ng/mL) in the presence or absence of CNTF as indicated.
  • Some plates also received soluble IL6R ⁇ (1 mg/mL) or soluble CNTFR ⁇ (1 mg/mL) as indicated.
  • Cell lysates were subjected to immunoprecipitation with anti-gp130 and immunoblotted with anti-phosphotyrosine. Tyrosine phosphorylation of gp130 is indicative of IL-6 induced activation of the IL-6 receptor system, which is blocked upon coaddition of CNTF.
  • FIG. 3 Scatchard analysis of iodinated CNTF binding on PC12D cells.
  • PC12D cells were incubated with various concentrations of iodinated CNTF in the presence or absence of excess non-radioactive competitor to determine the specific binding.
  • the figure shows a Scatchard plot of the amount of iodinated CNTF specifically bound, and gives data consistent with two binding sites with dissociation constants of 9 pM and 3.4 nM.
  • FIGS. 4 A and 4 B The amino acid sequence of human gp130-Fc-His 6 .
  • Amino acids 1 to 619 are from human gp130 (Hibi et al., Cell 63:1149-1157 (1990). Note that amino acid number 2 has been changed from a Leu to a Val in order to accommodate a Kozak sequence in the coding DNA sequence.
  • the signal peptide of gp130-Fc-His6 has been italicized (amino acids 1 to 22).
  • the Ser-Gly bridge is shown in bold type (amino acids 620, 621).
  • Amino acids 662 to 853 are from the Fc domain of human IgG1 (Lewis, et al., J.
  • FIG. 5 The amino acid sequence of human IL-6R ⁇ -Fc. Key: Amino acids 1 to 358 are from human IL-6R ⁇ (Yamasaki, et al., Science 241:825-828 (1988). Note that amino acid number 2 has been changed from a Leu to a Val in order to accommodate a Kozak sequence in the coding DNA sequence. The signal peptide of IL-6R ⁇ -Fc has been italicized (amino acids 1 to 19). The Ala-Gly bridge is shown in bold type (amino acids 359, 360). Amino acids 361 to 592 are from the Fc domain of human IgG1 (Lewis et al., J. Immunol.
  • FIG. 6 The CNTF/IL-6/IL-11 receptor system.
  • the ordered formation of the hexameric signal transducing receptor complex is depicted schematically.
  • the cytokine associates with the R ⁇ component to form an obligatory cytokine.R ⁇ complex (Kd is about 5 nM).
  • This low affinity complex next associates with the first signal transducing component, marked ⁇ 1, to form a high affinity cytokine.R ⁇ . ⁇ 1 complex (Kd is about 10 pM).
  • this component is gp130.
  • This trimeric high affinity complex subsequently associates with another such complex.
  • FIG. 7 Design of heterodimeric receptor-based ligand traps for IL-6.
  • the heterodimeric ligand trap is comprised of two interdisulfide linked proteins, gp130-Fc and IL-6R ⁇ -Fc.
  • the gp130-Fc.IL-6R ⁇ -Fc complex (upper panel) is shown to mimic the high affinity cytokine.R ⁇ . ⁇ 1 complex (lower panel).
  • the ligand trap functions as an antagonist by sequestering IL-6 and thus rendering unavailable to interact with the native receptors on IL-6-responsive cells.
  • FIGS. 9 A and 9 B Amino acid sequence of gp130-C ⁇ 1.
  • Amino acids 1 to 619 are from human gp130 (Hibi, et al., Cell 63:1149-1157 (1990). Ser-Gly bridge is shown in bold type.
  • Amino acids 662 to 651 are from the constant region of human IgG1 (Lewis et al., J. Immunol. 151:2829-2838 (1993). (*) shows the position of the STOP codon.
  • FIG. 10 Amino acid sequence of gp130 ⁇ 3fibro. Key: Amino acids 1 to 330 are from human gp130 (Hibi et al., Cell 63:1149-1157 (1990). Other symbols as described in FIG. 9.
  • FIG. 11 Amino acid sequence of J-CH1. Key: The Ser-Gly bridge is shown in bold, the J-peptide is shown in italics, the C H 1 domain is underlined.
  • FIG. 12 Amino acid sequence of C ⁇ 4. Key: The Ser-Gly bridge is shown in bold type. Amino acids 2 to 239 comprise the C ⁇ 4 sequence.
  • FIG. 13 Amino acid sequence of K-domain. Key: The Ser-Gly bridge is shown in bold type. Amino acids 2 to 108 comprise the ⁇ domain. The C-terminal cysteine (amino acid 108) is that involved in the disulfide bond of the ⁇ domain with the C H 1 domain of C ⁇ .
  • FIG. 14 Amino acid sequence of ⁇ -domain. Key: The Ser-Gly bridge is shown in bold type. Amino acids 2 to 106 comprise the ⁇ domain (Cheung, et al., J. Virol. 66: 6714-6720 (1992). The C-terminal cysteine (amino acid 106) is that involved in the disulfide bond of the ⁇ domain with the C H 1 domain of C ⁇ .
  • FIG. 15 Amino acid sequence of the soluble IL-6R ⁇ domain. Key: Amino acids 1 to 358 comprise the soluble IL-6R ⁇ domain (Yamasaki, et al., Science 241:825-828 (1988). The Ala-Gly bridge is shown in bold type.
  • FIG. 16 Amino acid sequence of the soluble IL-6R ⁇ domain: Key: Amino acids 1 to 313 comprise the truncated IL-6R ⁇ domain (IL-6R ⁇ 313). The Thr-Gly bridge is shown in bold type.
  • FIG. 17 Purification of gp130-C ⁇ 1.IL-6R ⁇ - ⁇ . 4% to 12% SDS-PAGE gradient gel run under non-reducing conditions. Proteins were visualized by staining with silver. Lane 1: approximately 100 ng of material purified over Protein A Sepharose (Pharmacia). Lane 2: Molecular size standards (Amersham). Lane 3: The Protein A-purified material shown here after further purification over an IL-6 affinity chromatography step.
  • the positions of the gp130-C ⁇ 1 dimer [(gp130-C ⁇ 1) 2 ], the gp130-C ⁇ 1 dimer associated with one IL-6R ⁇ - ⁇ [(gp130-C ⁇ 1) 2 .(IL-6R ⁇ - ⁇ ) 1 ], and the gp130-C ⁇ 1 dimer associated with two IL-6R ⁇ - ⁇ [(gp130-C ⁇ 1) 2 .(IL-6R ⁇ - ⁇ ) 2 ] are shown, as well as the sizes for the molecular size standards in kilodaltons (200, 100, and 46).
  • FIG. 18 IL-6 dissociates slowly from the ligand trap.
  • the dissociation rate of IL-6 from a heavy/light chain receptor-based ligand trap (gp130-C ⁇ 1.IL-6R ⁇ - ⁇ ) was compared to that obtained with the neutralizing monoclonal antibody B-E8 (BE8 MAb).
  • FIG. 19 IL-6 can induce multimerization of the ligand trap.
  • A Two different ligand traps are depicted schematically and listed according to their ability to bind protein A.
  • gp130-Fc.IL-6R ⁇ -Fc (GF6F) binds protein A via its Fc-domains, whereas gp130-C H 1.IL-6R ⁇ - ⁇ (G16K) does not bind to protein A.
  • B Anti-kappa western blotting of proteins precipitated with Protein A-Sepharose from mixtures of GF6F ⁇ IL-6, G16K ⁇ IL-6, or GF6F plus G16K ⁇ IL-6, as marked.
  • FIG. 20 Inhibition of IL-6-dependent XG-1 cell proliferation.
  • XG-1 cells [Zhang, et al., Blood 83:3654-3663 (1994)] were prepared for a proliferation assay by starving the cells from IL-6 for 5 hours. Assays were set up in 96-well tissue culture dishes in RPMI+10% fetal calf serum+penicillin/streptomycin+0.050 nM 2-mercaptoethanol+glutamine. 0.1 ml of that media was used per well. Cells were suspended at a density of 250,000 per ml at the start of the assay.
  • FIGS. 21 A- 21 D Nucleotide sequence encoding and deduced amino acid sequence of fusion polypeptide designated 424 which is capable of binding the cytokine IL-4 to form a nonfunctional complex.
  • FIGS. 22 A- 22 D Nucleotide sequence encoding and deduced amino acid sequence of fusion polypeptide designated 603 which is capable of binding the cytokine IL-4 to form a nonfunctional complex.
  • FIGS. 23 A- 23 D Nucleotide sequence encoding and deduced amino acid sequence of fusion polypeptide designated 622 which is capable of binding the cytokine IL-4 to form a nonfunctional complex.
  • FIGS. 24 A- 24 F Nucleotide sequence encoding and deduced amino acid sequence of fusion polypeptide designated 412 which is capable of binding the cytokine IL-6 to form a nonfunctional complex.
  • FIGS. 25 A- 25 F Nucleotide sequence encoding and deduced amino acid sequence of fusion polypeptide designated 616 which is capable of binding the cytokine IL-6 to form a nonfunctional complex.
  • FIGS. 26 A- 26 E Nucleotide sequence encoding and deduced amino acid sequence of fusion polypeptide designated 569 which is capable of binding the cytokine IL-1 to form a nonfunctional complex.
  • FIG. 27 Shows that an IL-4 trap designated 4SC375, which is a fusion polypeptide of IL-2R ⁇ -scb-IL4R ⁇ -Fc ⁇ C1, is several orders of magnitude better as an IL-4 antagonist than IL4R ⁇ Fc ⁇ C1 alone in the TF1 cell bioassay.
  • FIG. 28 Shows that an IL-4 trap designated 4SC375 displays antagonistic activity in the TF1 cell bioassay equivalent to an IL-4 trap designated 4SC424 (described in FIGS. 21 A- 21 D) which is a fusion polypeptide of IL-2R ⁇ -IL4R ⁇ -Fc ⁇ C1 having the IL-2R ⁇ component flush with the IL-4R ⁇ component.
  • FIG. 29 Shows that the IL6 trap (6SC412 IL6R-scb-gpx-Fc ⁇ C1) described in FIGS. 24 A- 24 F is a better antagonist of IL-6 in the XG1 bioassay than the neutralizing monoclonal antibody to human IL-6-BE8.
  • FIG. 30 Shows that the trap 1SC569 (described in FIGS. 26 A- 26 E) is able to antagonize the effects of IL-1 and block the IL-6 production from MRC 5 cells upon treatment with IL-1.
  • FIGS. 31 A- 31 G The nucleotide and encoded amino acid sequence of the IL-4R ⁇ .IL-13R ⁇ 1.Fc single chain trap construct is set forth.
  • FIGS. 32 A- 32 G The nucleotide and encoded amino acid sequence of the IL-13R ⁇ 1.IL-4R ⁇ .Fc single chain trap construct is set forth.
  • FIG. 33 Blocking of IL-13 by IL-4R ⁇ .IL-13R ⁇ 1.Fc and IL-13R ⁇ 1.IL-4R ⁇ .Fc. Addition of either IL-4R ⁇ .IL-13R ⁇ 1.Fc or IL-13R ⁇ 1.IL-4R ⁇ .Fc trap at a concentration of 10 nM blocks IL-13-induced growth up to ⁇ 2 nM. At an IL-13 concentration of ⁇ 4-5 nM the growth of TF1 cells is inhibited by 50%.
  • FIG. 34 Blocking of IL-4 by IL-4R ⁇ .IL-13R ⁇ 1.Fc and IL-13R ⁇ 1.IL-4R ⁇ .Fc. Addition of either IL-4R ⁇ .IL-13R ⁇ 1.Fc or IL-13R ⁇ 1.IL-4R ⁇ .Fc at a concentration of 10 nM blocks IL-4-induced growth up to ⁇ 1 nM. At an IL-4 concentration of ⁇ 3-4 nM the growth of TF1 cells is inhibited by 50%.
  • FIG. 35 Human IL-1 trap blocks the in vivo effects of exogenously administered huIL-1.
  • FIG. 36A & FIG. 36B Human IL-4 trap antagonizes the effects of human IL-4 in monkeys.
  • FIG. 37 Murine IL-4 trap partially prevented IL-4-mediated IgE increase in mice.
  • BALB/C mice injected with anti-mouse IgD 100 ⁇ l/mouse, s.c.
  • mice injected with anti-mouse IgD 100 ⁇ l/mouse, s.c.
  • ANOVA p 0.0002; Tukey-Kramer: vehicle vs. IL-4 trap, p ⁇ 0.01; vehicle vs. IL-4 antibody, p ⁇ 0.001; IL-4 trap vs. IL-4 antibody, not significant).
  • FIGS. 38 A- 38 H Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 933.
  • FIGS. 39 A- 39 G Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 943.
  • FIGS. 40 A- 40 I Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1126.
  • FIGS. 41 A- 41 H Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1128.
  • FIGS. 42 A- 42 I Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1130.
  • FIGS. 43 A- 43 G Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1132.
  • FIGS. 44 A- 44 I Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1199.
  • FIGS. 45 A- 45 I Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1244.
  • FIGS. 46 A- 46 I Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1245.
  • FIGS. 47 A- 47 J Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1246.
  • FIG. 48 The IL-4/IL-13 Trap 1132 can block IL-13 more potently than the IL-4/IL-13 Trap 943.
  • Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 ( E. coli ; Preprotech) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ⁇ 3 days at 37° C., 5% CO 2 .
  • MTS was added to each well, incubated at 37° C., 5% CO 2 for 4 hrs. and cell proliferation was measured as OD at 490 nm.
  • IL-4/IL-13 Trap 1132 exhibits an IC 50 of 64 pM as compared to 184 pM for Trap 943.
  • FIG. 49 The IL-4/IL-13 Trap 1132 can block IL-4 more potently than the IL-4/IL-13 Trap 943.
  • Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 40 pM recombinant human IL-4 ( E. coli ; Applicants' own material) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ⁇ 3 days at 37° C., 5% CO 2 .
  • MTS was added to each well, incubated at 37° C., 5% CO 2 for 4 hrs. and cell proliferation was measured as OD at 490 nm.
  • IL-4/IL-13 Trap 1132 exhibits an IC 50 of 95 pM as compared to 222 pM for Trap 943.
  • FIG. 50 IL-4/IL-13 Trap 1132 displays a higher affinity for Applicants' rhIL13.
  • Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 Applicants' own material (CHO) or Pharmingen ( E. coli ) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ⁇ 3 days at 37° C., 5% CO 2 .
  • MTS was added to each well, incubated at 37° C., 5% CO 2 for 4hrs. and cell proliferation was measured as OD at 490 nm.
  • IL-4/IL-13 Trap 1132 has an IC 50 of 16 pM which indicates a Kd of ⁇ 9 pM.
  • FIG. 51 IL-4/IL-13 Trap 1132 can block hIL13 more potently than IL-4/IL-13 Trap 943 with Applicants' rhIL13.
  • Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 (CHO; Applicants' own material) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ⁇ 3 days at 37° C., 5% CO 2 .
  • MTS was added to each well, incubated at 37° C., 5% CO 2 for 4hrs. and cell proliferation was measured as OD at 490 nm.
  • IL-4/IL-13 Trap 1132 has an IC 50 of 17 pM as compared to 33 pM for 943.
  • the present invention provides an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex comprising:
  • cytokine binding portion is the minimal portion of the extracellular domain necessary to bind the cytokine. It is accepted by those of skill in the art that a defining characteristic of a cytokine receptor is the presence of the two fibronectin-like domains that contain canonical cysteines and of the WSXWS box (Bazan, J. F., 1990, PNAS 87: 6934-6938). Sequences encoding the extracellular domains of the binding component of the cytokine's receptor and of the signal transducing component of the cytokine's receptor may also be used to create the fusion polypeptide of the invention.
  • fusion polypeptides comprising the minimal portion of the extracellular domain necessary to bind the cytokine as the cytokine binding portion.
  • the invention comprises a “specificity determining component” of a cytokine's receptor and a “signal transducing component” of the cytokine's receptor. Regardless of the nomenclature used to designate a particular component or subunit of a cytokine receptor, one skilled in the art would recognize which component or subunit of a receptor is responsible for determining the cellular target of the cytokine, and thus would know which component constitutes the “specificity determining component.”
  • the “signal transducing component” is a component of the native receptor which is not the specificity determining component and which does not bind or weakly binds the cytokine in the absence of the specificity determining component. In the native receptor, the “signal transducing component” may participate in signaling.
  • IL-4 receptor has a signal transducing component referred to as IL-2R ⁇ .
  • IL-2R ⁇ signal transducing component
  • nucleic acid comprising a nucleotide sequence encoding a first fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the specificity determining component of the IL-4 receptor (IL-4R ⁇ ); a nucleotide sequence encoding a second fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the signal transducing component of the IL-4 receptor (IL-2R ⁇ ); and a nucleotide sequence encoding a third fusion polypeptide component comprising the amino acid sequence of a multimerizing component (for example, an Fc domain of IgG) to create a high affinity trap for IL-4.
  • a multimerizing component for example, an Fc domain of IgG
  • Table 1 Some further examples of the receptor components that may be used to prepare cytokine antagonists according to the invention are set forth in Table 1.
  • Table 1 sets forth, by way of example but not by way of limitation, some of the varied nomenclature used in the scientific literature to describe those components which function as specificity determining components and those which function as signal transducing components of certain cytokine receptors.
  • Specificity determining Signal transducing Cytokine Component Component Interleukin-1 (IL-1) Type I IL-1R (ref. 8) IL-1R AcP (refs. 8, 11) Type II IL-1R (ref. 8) IL-1R1 (ref. 11) IL-1RII (ref.
  • Interleukin-4 IL-4R
  • IL-4R Interleukin-4R
  • IL-2R Interleukin-2R ⁇
  • Interleukin-5 IL-5R ⁇
  • ⁇ c Ref. 1 ⁇ -subunit (ref. 2) ⁇ -subunit (ref .2) ⁇ -receptor component ⁇ -chain (ref. 2) (ref. 5) ⁇ -receptor component (ref. 5)
  • Granulocyte ⁇ -receptor component ⁇ -receptor component macrophage-colony (ref. 5) (ref. 5) stimulating factor ⁇ -subunit (ref. 2) ⁇ -subunit (ref.
  • GMR ⁇ (refs. 1, 2) ⁇ -chain (ref. 3) ⁇ c (ref. 1) GMR ⁇ (refs. 1, 2) Leukemia inhibitory LIFBP (ref. 1) gp130 (refs. 1, 3) factor (LIF) ⁇ -receptor component ⁇ -receptor component (ref. 5) (ref. 5) Interleukin-11 ⁇ -chain (ref. 4) gp130 (ref. 4) (IL-11) NR1 (ref. 4) Interleukin-15 IL-15R ⁇ (ref. 10) IL-2R ⁇ (ref. 10) (IL-15) IL-2R ⁇ (ref. 10) (IL-15) IL-2R ⁇ (ref.
  • IFN ⁇ Interferon- ⁇
  • IFN- ⁇ R Ref. 7
  • AF-1 Ref. 7
  • IFN- ⁇ R1 Ref. 7
  • IFN- ⁇ R2 Ref. 7
  • TGF ⁇ Type II Refs. 6, 9
  • the first, second, and third components of the fusion polypeptide are encoded in a single strand of nucleotides which, when expressed by a host vector system, produces a monomeric species of the fusion polypeptide.
  • the monomers thus expressed then multimerize due to the interactions between the multimerizing components (the third fusion polypeptide components).
  • Producing the fusion polypeptides in this manner avoids the need for purification of heterodimeric mixtures that would result if the first and second components were produced as separate molecules and then multimerized.
  • PCT International Application WO 96/11213 published Apr. 18, 1996 entitled Dimeric IL-4 Inhibitors states that the applicant has prepared homodimers in which two IL-4 receptors are bound by a polymeric spacer and has prepared heterodimers in which an IL-4 receptor is linked by a polymeric spacer to an IL-2 receptor gamma chain.
  • the polymeric spacer described is polyethylene glycol (PEG).
  • the two receptor components, IL-4R and IL-2Rgamma are separately expressed and purified.
  • Pegylated homodimers and heterodimers are then produced by joining the components together using bi-functional PEG reagents. It is an advantage of the present invention that it avoids the need for such time consuming and costly purification and pegylation steps.
  • the nucleotide sequence encoding the first component is upstream of the nucleotide sequence encoding the second component. In another embodiment of the invention, the nucleotide sequence encoding the first component is downstream of the nucleotide sequence encoding the second component. Further embodiments of the invention may be prepared in which the order of the first, second and third fusion polypeptide components are rearranged.
  • the order of the components in the isolated nucleic acid of the invention as read from 5′ to 3′ may be any of the following six combinations: 1,2,3; 1,3,2; 2,1,3; 2,3,1; 3,1,2; or 3,2,1.
  • the cytokine bound by the fusion polypeptide may be a member of the hematopoietin family of cytokines selected from the group consisting of interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-9, interleukin-11, interleukin-13, interleukin-15, granulocyte macrophage colony stimulating factor, oncostatin M, leukemia inhibitory factor, and cardiotrophin-1.
  • cytokines selected from the group consisting of interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-9, interleukin-11, interleukin-13, interleukin-15, granulocyte macrophage colony stimulating factor, oncostatin M, leukemia inhibitory factor, and cardiotrophin-1.
  • the cytokine bound by the fusion polypeptide may be a member of the interferon family of cytokines selected from the group consisting of IFN-gamma, IFN-alpha, and IFN-beta.
  • the cytokine bound by the fusion polypeptide may be a member of the immunoglobulin superfamily of cytokines selected from the group consisting of B7.1 (CD80) and B7.2 (B70).
  • the cytokine bound by the fusion polypeptide may be a member of the TNF family of cytokines selected from the group consisting of TNF-alpha, TNF-beta, LT-beta, CD40 ligand, Fas ligand, CD 27 ligand, CD 30 ligand, and 4-1BBL.
  • the cytokine bound by the fusion polypeptide may be a cytokine selected from the group consisting of interleukin-1, interleukin-10, interleukin-12, interleukin-14, interleukin-18, and MIF.
  • the specificity determining component, the signal transducing component, or both may be substituted for by a single chain Fv.
  • a single chain Fv (scFv) is a truncated Fab having only the V region of a heavy chain linked by a stretch of synthetic peptide to a V region of a light chain. See, for example, U.S. Pat. Nos. 5,565,332; 5,733,743; 5,837,242; 5,858,657; and 5,871,907 assigned to Cambridge Antibody Technology Limited incorporated by reference herein.
  • an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex
  • a nucleotide sequence encoding a first fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the specificity determining component of the cytokine's receptor
  • a nucleotide sequence encoding a second fusion polypeptide component comprising the amino acid sequence of an scFv capable of binding the cytokine at a site different from the site at which the cytokine binding portion of the extracellular domain of the specificity determining component of the cytokine's receptor binds
  • a nucleotide sequence encoding a third fusion polypeptide component comprising the amino acid sequence of a multimerizing component.
  • the specificity determining component may be substituted for by a scFv that binds to a site on the cytokine different from the site at which the signal transducing component binds.
  • the invention contemplates an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex comprising a nucleotide sequence encoding a first fusion polypeptide component comprising the amino acid sequence of a scFv that binds to a site on the cytokine different from the site at which the cytokine binding portion of the extracellular domain of the signal transducing component of the cytokine's receptor binds; a nucleotide sequence encoding a second fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the signal transducing component of the cytokine's receptor; and a nucleotide sequence encoding a third fusion polypeptid
  • the invention contemplates an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex comprising a nucleotide sequence encoding a first fusion polypeptide component comprising the amino acid sequence of a first scFv that binds to a site on the cytokine; a nucleotide sequence encoding a second fusion polypeptide component comprising the amino acid sequence a second scFv that binds to a site on the cytokine different from the site at which the first scFv binds; and a nucleotide sequence encoding a third fusion polypeptide component comprising the amino acid sequence of a multimerizing component.
  • the invention also contemplates embodiments in which the nucleotide sequence encoding the first component is upstream of the nucleotide sequence encoding the second component; embodiments in which the nucleotide sequence encoding the first component is downstream of the nucleotide sequence encoding the second component; and further embodiments of the invention in which the order of the first, second and third fusion polypeptide components is rearranged.
  • the order of the components in the isolated nucleic acid of the invention as read from 5′ to 3′ may be any of the following six combinations: 1,2,3; 1,3,2; 2,1,3; 2,3,1; 3,1,2; or 3,2,1.
  • the multimerizing component comprises an immunoglobulin derived domain. More specifically, the immunoglobulin derived domain may be selected from the group consisting of the Fc domain of IgG, the heavy chain of IgG, and the light chain of IgG.
  • the multimerizing component may be an Fc domain from which the first five amino acids (including a cysteine) have been removed to produce a multimerizing component referred to as Fc( ⁇ C1).
  • the multimerizing component may be an Fc domain in which a cysteine within the first five amino acids has been substituted for by another amino acid such as, for example, serine or alanine.
  • the present invention also provides for fusion polypeptides encoded by the isolated nucleic acid molecules of the invention.
  • the fusion polypeptides are in multimeric form, due to the function of the third multimerizing component.
  • the multimer is a dimer.
  • Suitable multimerizing components are sequences encoding an immunoglobulin heavy chain hinge region (Takahashi et al., 1982, Cell 29:671-679); immunoglobulin gene sequences, and portions thereof.
  • immunoglobulin gene sequences, especially one encoding the Fc domain are used to encode the third multimerizing component.
  • the present invention also contemplates a vector which comprises the nucleic acid molecule of the invention as described herein.
  • the present invention also provides for methods of producing the fusion polypeptides of the invention by growing cells of the host-vector systems described herein, under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced.
  • the present invention provides novel antagonists which are based on receptor components that are shared by cytokines such as the CNTF family of cytokines.
  • the invention described herein contemplates the production of antagonists to any cytokine that utilizes an ⁇ specificity determining component which, when combined with the cytokine, binds to a first ⁇ signal transducing component to form a nonfunctional intermediate which then binds to a second ⁇ signal transducing component causing ⁇ -receptor dimerization and consequent signal transduction.
  • the soluble ⁇ specificity determining component of the receptor (sR ⁇ ) and the extracellular domain of the first ⁇ signal transducing component of the cytokine receptor ( ⁇ 1) are combined to form heterodimers (sR ⁇ : ⁇ 1) that act as antagonists to the cytokine by binding the cytokine to form a nonfunctional complex.
  • CNTF and IL-6 share the ⁇ 1 receptor component gp130.
  • the fact that CNTF forms an intermediate with CNTFR ⁇ and gp130 can be demonstrated (Example 1) in cells lacking LIFR ⁇ , where the complex of CNTF and CNTFR ⁇ binds gp130, and prevents homodimerization of gp130 by IL-6 and IL-6R ⁇ , thereby blocking signal transduction.
  • IL-6 antagonists described herein, as they show that if, in the presence of a ligand, a nonfunctional intermediate complex, consisting of the ligand, its ⁇ receptor component and its ⁇ 1 receptor component, can be formed, it will effectively block the action of the ligand.
  • Other cytokines may use other ⁇ 1 receptor components, such as LIFR ⁇ , which may also be used to produce antagonists according to the present invention.
  • effective antagonists of IL-6 or CNTF consist of heterodimers of the extracellular domains of the ⁇ specificity determining components of their receptors (sIL-6R ⁇ and sCNTFR ⁇ , respectively) and the extracellular domain of gp130.
  • the resultant heterodimers which are referred to hereinafter as sIL-6R ⁇ : ⁇ 1 and sCNTFR ⁇ : ⁇ 1, respectively, function as high-affinity traps for IL-6 or CNTF, respectively, thus rendering the cytokine inaccessible to form a signal transducing complex with the native membrane-bound forms of their receptors.
  • the IL-6 and CNTF receptors are unusual in that the ⁇ receptor components constitute ligand binding domains that, in concert with their ligands, function effectively in soluble form as receptor agonists [Davis, et al. Science 259:1736-1739 (1993); Taga, et al., Cell 58: 573-581 (1989)].
  • the sR ⁇ : ⁇ 1 heterodimers prepared according to the present invention provide effective traps for their ligands, binding these ligands with affinities in the picomolar range (based on binding studies for CNTF to PC12D cells) without creating functional intermediates.
  • antagonists according to the invention include antagonists of interleukins 1 through 5 [IL-1, Greenfeder, et al. J. Biol. Chem. 270:13757-13765 (1995); Guo, et al. J. Biol. Chem. 270:27562-27568 (1995)], IL-2; [Taniguchi, et al. European Patent Nos.
  • the ⁇ and ⁇ receptor extracellular domains may be prepared using methods known to those skilled in the art.
  • the CNTFR ⁇ receptor has been cloned, sequenced and expressed [Davis, et al. (1991) Science 253:59-63 which is incorporated by reference in its entirety herein].
  • the cloning of LIFR ⁇ and gp130 are described in Gearing et al. in EMBO J. 10:2839-2848 (1991), Hibi, et al. Cell 63:1149-1157 (1990) and in published PCT application WO 93/10151 published May 27, 1993, all of which are incorporated by reference in their entirety herein.
  • the receptor molecules useful for practicing the present invention may be prepared by cloning and expression in a prokaryotic or eukaryotic expression system.
  • the recombinant receptor gene may be expressed and purified utilizing any number of methods.
  • the gene encoding the factor may be subcloned into a bacterial expression vector, such as for example, but not by way of limitation, pCP110.
  • the extracellular domains are engineered using leucine zippers.
  • the leucine zipper domains of the human transcription factors c-jun and c-fos have been shown to form stable heterodimers [Busch and Sassone-Corsi, Trends Genetics 6: 36-40 (1990); Gentz, et al., Science 243:1695-1699 (1989)] with a 1:1 stoichiometry.
  • jun-jun homodimers have also been shown to form, they are about 1000-fold less stable than jun-fos heterodimers.
  • Fos-fos homodimers have not been detected.
  • the leucine zipper domain of either c-jun or c-fos are fused in frame at the C-terminus of the soluble or extracellular domains of the above mentioned receptor components by genetically engineering chimeric genes.
  • the fusions may be direct or they may employ a flexible linker domain, such as the hinge region of human IgG, or polypeptide linkers consisting of small amino acids such as glycine, serine, threonine or alanine, at various lengths and combinations.
  • the chimeric proteins may be tagged by His-His-His-His-His-His (His6), [SEQ. ID NO. 1] to allow rapid purification by metal-chelate chromatography, and/or by epitopes to which antibodies are available, to allow for detection on western blots, immunoprecipitation, or activity depletion/blocking in bioassays.
  • the sR ⁇ : ⁇ 1 heterodimer is prepared using a similar method, but using the Fc-domain of human IgG1 [Aruffo, et al., Cell 67:35-44 (1991)].
  • formation of heterodimers must be biochemically achieved, as chimeric molecules carrying the Fc-domain will be expressed as disulfide-linked homodimers.
  • homodimers may be reduced under conditions that favor the disruption of inter-chain disulfides but do not effect intra-chain disulfides.
  • monomers with different extracellular portions are mixed in equimolar amounts and oxidized to form a mixture of homo- and heterodimers.
  • this type of heterodimers may be biased by genetically engineering and expressing molecules that consist of the soluble or extracellular portion of the receptor components followed by the Fc-domain of hIgG, followed by either the c-jun or the c-fos leucine zippers described above [Kostelny, et al., J. Immunol. 148: 1547-1553 (1992)]. Since these leucine zippers form predominately heterodimers, they may be used to drive formation of the heterodimers where desired. As for the chimeric proteins described using leucine zippers, these may also be tagged with metal chelates or an epitope. This tagged domain can be used for rapid purification by metal-chelate chromatography, and/or by antibodies, to allow for detection on western blots, immunoprecipitation, or activity depletion/blocking in bioassays.
  • heterodimers may be prepared using other immunoglobulin derived domains that drive the formation of dimers.
  • Such domains include, for example, the heavy chains of IgG (C ⁇ 1 and C ⁇ 4), as well as the constant regions of kappa ( ⁇ ) and lambda ( ⁇ ) light chains of human immunoglobulins.
  • the heterodimerization of C ⁇ with the light chain occurs between the CH1 domain of C ⁇ and the constant region of the light chain (C L ), and is stabilized by covalent linking of the two domains via a single disulfide bridge. Accordingly, as described in Example 4, constructs may be prepared using these immunoglobulin domains.
  • the immunoglobulin domains include domains that may be derived from T cell receptor components which drive dimerization.
  • the sR ⁇ : ⁇ 1 heterodimers are prepared by expression as chimeric molecules utilizing flexible linker loops.
  • a DNA construct encoding the chimeric protein is designed such that it expresses two soluble or extracellular domains fused together in tandem (“head to head”) by a flexible loop.
  • This loop may be entirely artificial (e.g. polyglycine repeats interrupted by serine or threonine at a certain interval) or “borrowed” from naturally occurring proteins (e.g. the hinge region of hIgG).
  • molecules may be engineered in which the order of the soluble or extracellular domains fused is switched (e.g. sIL6R ⁇ /loop/sgp130 or sgp130/loop/sIL-6R ⁇ ) and/or in which the length and composition of the loop is varied, to allow for selection of molecules with desired characteristics.
  • sIL6R ⁇ /loop/sgp130 or sgp130/loop/sIL-6R ⁇ e.g. sIL6R ⁇ /loop/sgp130 or sgp130/loop/sIL-6R ⁇
  • the heterodimers made according to the present invention may be purified from cell lines cotransfected with the appropriate ⁇ and ⁇ components. Heterodimers may be separated from homodimers using methods available to those skilled in the art. For example, limited quantities of heterodimers may be recovered by passive elution from preparative, nondenaturing polyacrylamide gels. Alternatively, heterodimers may be purified using high pressure cation exchange chromatography. Excellent purification has been obtained using a Mono S cation exchange column.
  • the present invention also contemplates the use of engineered, mutated versions of IL-6 with novel properties that allow it to bind to IL-6R ⁇ and a single gp130 molecule, but fail to engage the second gp130 to complete ⁇ component homodimerization, and thus act as an effective IL-6 antagonist on any IL-6 responsive cell.
  • Our model for the structure of the IL-6 and CNTF receptor complexes indicates that these cytokines have distinct sites for binding the ⁇ , ⁇ 1, and ⁇ 2 receptor components [Stahl and Yancopoulos, Cell 74: 587-590 (1993)].
  • Mutations of critical amino acid residues comprising each of these sites gives rise to novel molecules which have the desired antagonistic properties. Ablation of the ⁇ 1 site would give a molecule which could still bind to the ⁇ receptor component but not the ⁇ 1 component, and thereby comprise an antagonist with nanomolar affinity. Mutations of critical amino acid residues comprising the ⁇ 2 site of IL-6 (IL-6 ⁇ 2-) would give a molecule that would bind to IL-6R ⁇ and the first gp130 monomer, but fail to engage the second gp130 and thus be functionally inactive.
  • a variety of means are used to generate and identify mutations of IL-6 or CNTF that have the desired properties. Random mutagenesis by standard methods of the DNA encoding IL-6 or CNTF may be used, followed by analysis of the collection of products to identify mutated cytokines having the desired novel properties as outlined below. Mutagenesis by genetic engineering has been used extensively in order to elucidate the structural organization of functional domains of recombinant proteins. Several different approaches have been described in the literature for carrying out deletion or substitution mutagenesis. The most successful appear to be alanine scanning mutagenesis [Cunningham and Wells (1989), Science 244:
  • Targeted mutagenesis of the IL-6 or CNTF nucleic acid sequences using such methods can be used to generate CNTF ⁇ 2- or IL-6 ⁇ 2-candidates.
  • the choice of regions appropriate for targeted mutagenesis is done systematically, or determined from studies whereby panels of monoclonal antibodies against each factor are used to map regions of the cytokine that might be exposed after binding of the cytokine to the a receptor component alone, or to the ⁇ 1 heterodimeric soluble receptors described above.
  • chemical modification or limited proteolysis of the cytokine alone or in a complex bound to the ⁇ receptor component or the ⁇ 1 heterodimeric soluble receptors described above, followed by analysis of the protected and exposed regions could reveal potential ⁇ 2 binding sites.
  • Assays for identifying CNTF or IL-6 mutants with the desired properties involve the ability to block with high affinity the action of IL-6 or CNTF on appropriately responsive cell lines [Davis, et al., Science 259: 1736-1739 (1993); Murakami, et al., Proc. Natl. Acad. Sci. USA 88:11349-11353 (1991)].
  • Such assays include cell proliferation, survival, or DNA synthesis driven by CNTF or IL-6, or the construction of cell lines where binding of factor induces production of reporters such as CAT or ⁇ -galactosidase [Savino, et al., Proc. Natl. Acad. Sci. USA 90:4067-4071 (1993)].
  • the properties of various mutants may be assessed with a receptor-based assay.
  • One such assay consists of screening mutants for their ability to bind the sR ⁇ : ⁇ 1 receptor heterodimers described above using epitope-tagged [Davis et al., Science 253: 59-63 (1991)] sR ⁇ : ⁇ 1 reagents.
  • epitope-tagged e.g., avis et al., Science 253: 59-63 (1991)]
  • sR ⁇ : ⁇ 1 reagents e.g., sR ⁇ : ⁇ 1 reagents.
  • one can probe for the presence or absence of the ⁇ 2 site by assessing whether an epitope-tagged soluble ⁇ 2 reagent will bind to the cytokine in the presence of the ⁇ 1 heterodimer.
  • CNTF only binds to LIFR ⁇ (the ⁇ 2 component) in the presence of both CNTFR ⁇ and gp130 [Davis, et al. Science 260:1805-1808 (1993); Stahl, et al. J. Biol. Chem. 268: 7628-7631 (1993)].
  • LIFR ⁇ the ⁇ 2 component
  • gp130 the soluble LIFR ⁇ reagent would only bind to CNTF in the presence of the soluble sR ⁇ : ⁇ 1 dimer sCNTFR ⁇ : ⁇ 1.
  • the sR ⁇ : ⁇ 1 reagent would be IL-6R ⁇ : ⁇ 1, and the probe for the ⁇ 2 site would be epitope-tagged sgp130.
  • ⁇ 2-mutants of CNTF would be identified as those that bound the sR ⁇ : ⁇ 1 reagent, demonstrating that the ⁇ and ⁇ 31 site of the cytokine were intact, yet failed to bind the ⁇ 2 reagent.
  • the present invention provides for methods of detecting or measuring the activity of potential ⁇ 2-mutants by measuring the phosphorylation of a ⁇ -receptor component or a signal transduction component selected from the group consisting of Jak1, Jak2 and Tyk2 or any other signal transduction component, such as the CLIPs, that are determined to be phosphorylated in response to a member of the CNTF family of cytokines.
  • a cell that expresses the signal transduction component(s) described herein may either do so naturally or be genetically engineered to do so.
  • Jak1 and Tyk-2-encoding nucleic acid sequences obtained as described in Velazquez, et al., Cell, Vol. 70:313-322 (1992) may be introduced into a cell by transduction, transfection, microinjection, electroporation, via a transgenic animal, etc., using any known method known in the art.
  • cells are exposed to a potential antagonist and the tyrosine phosphorylation of either the ⁇ -component(s) or the signal transduction component(s) are compared to the tyrosine phosphorylation of the same component(s) in the absence of the potential antagonist.
  • the tyrosine phosphorylation that results from contacting the above cells with the potential antagonist is compared to the tyrosine phosphorylation of the same cells exposed to the parental CNTF family member.
  • the cell must either express the extracellular receptor ( ⁇ -component) or the cells may be exposed to the test agent in the presence of the soluble receptor component.
  • the cell may express the ⁇ -component CNTFR ⁇ , the ⁇ -components gp130 and LIFR ⁇ and a signal transducing component such as Jak1.
  • the cell is exposed to test agents, and the tyrosine phosphorylation of either the ⁇ -components or the signal transducing component is compared to the phosphorylation pattern produced in the presence of CNTF.
  • the tyrosine phosphorylation which results from exposure to a test agent is compared to the phosphorylation which occurs in the absence of the test agent.
  • an assay system for example, for IL-6 may involve exposing a cell that expresses the ⁇ -component gp130 and a signal transducing protein such as Jak1, Jak2 or Tyk2 to a test agent in conjunction with the soluble IL-6 receptor.
  • a signal transducing protein such as Jak1, Jak2 or Tyk2
  • the above approaches are used to develop a method for screening for small molecule antagonists that act at various steps in the process of ligand binding, receptor complex formation, and subsequent signal transduction.
  • Molecules that potentially interfere with ligand-receptor interactions are screened by assessing interference of complex formation between the soluble receptors and ligand as described above.
  • cell-based assays in which IL-6 or CNTF induce response of a reporter gene are screened against libraries of small molecules or natural products to identify potential antagonists.
  • Those molecules showing antagonist activity are rescreened on cell-based assays responding to other factors (such as GM-CSF or factors like Neurotrophin-3 that activate receptor tyrosine kinases) to evaluate their specificity against the CNTF/IL-6/OSM/LIF family of factors.
  • factors such as GM-CSF or factors like Neurotrophin-3 that activate receptor tyrosine kinases
  • Such cell-based screens are used to identify antagonists that inhibit any of numerous targets in the signal transduction process.
  • the specific target for antagonists is the interaction of the Jak/Tyk family of kinases [Firmbach-Kraft, Oncogene 5: 1329-1336 (1990); Wilks, et al., Mol. Cell. Biol. 11:2057-2065 (1991)] with the receptor ⁇ subunits.
  • LIFR ⁇ and gp130 preassociate with members of the Jak/Tyk family of cytoplasmic protein tyrosine kinases, which become activated in response to ligand-induced ⁇ component dimerization Stahl, et al. Science 263:92-95 (1993).
  • small molecules that could enter the cell cytoplasm and disrupt the interaction between the ⁇ component and the Jak/Tyk kinase could potentially block all subsequent intracellular signaling.
  • Such activity could be screened with an in vitro scheme that assessed the ability of small molecules to block the interaction between the relevant binding domains of purified ⁇ component and Jak/Tyk kinase.
  • the interaction between two proteins induces production of a convenient marker such as ⁇ - galactosidase. Collections of small molecules are tested for their ability to disrupt the desired interaction without inhibiting the interaction between two control proteins. The advantage of this screen would be the requirement that the test compounds enter the cell before inhibiting the interaction between the P component and the Jak/Tyk kinase.
  • CNTF family antagonists described herein either bind to, or compete with the cytokines CNTF and IL-6. Accordingly, they are useful for treating diseases or disorders mediated by CNTF or IL-6.
  • IL-6 antagonists would include the following:
  • IL-6 appears to be a critical mediator of osteoclastogenesis, leading to bone resorption [Horowitz, Science 260: 626-627 (1993); Jilka, et al., Science 257: 88-91 (1992)].
  • IL-6 only appears to play a major role in the estrogen-depleted state, and apparently is minimally involved in normal bone maintenance. Consistent with this, experimental evidence indicates that function-blocking antibodies to IL-6 can reduce the number of osteoclasts [Jilka, et al. Science 257: 88-91 (1992)].
  • estrogen replacement therapy is also used, there appear to be side effects that may include increased risk of endometrial and breast cancer.
  • IL-6 antagonists as described herein would be more specific to reduce osteoclastogenesis to normal levels.
  • IL-6 appears to be directly involved in multiple myeloma by acting in either an autocrine or paracrine fashion to promote tumor formation [van Oers, et al., Ann Hematol. 66: 219-223 (1993)]. Furthermore, the elevated IL-6 levels create undesirable secondary effects such as bone resorption, hypercalcemia, and cachexia; in limited studies function-blocking antibodies to IL-6 or IL-6Ra have some efficacy [Klein, et al., Blood 78: 1198-1204 (1991); Suzuki, et al., Eur. J. Immunol. 22:1989-1993 (1992)]. Therefore, IL-6 antagonists as described herein would be beneficial for both the secondary effects as well as for inhibiting tumor growth.
  • IL-6 may be a mediator of tumor necrosis factor (TNF) that leads to cachexia associated with AIDS and cancer [Strassmann, et al., J. Clin. Invest. 89: 1681-1684 (1992)], perhaps by reducing lipoprotein lipase activity in adipose tissue [Greenberg, et al., Cancer Research 52: 4113-4116 (1992)]. Accordingly, antagonists described herein would be useful in alleviating or reducing cachexia in such patients.
  • TNF tumor necrosis factor
  • compositions for use according to the invention include the antagonists described above in a pharmacologically acceptable liquid, solid or semi-solid carrier, linked to a carrier or targeting molecule (e.g., antibody, hormone, growth factor, etc.) and/or incorporated into liposomes, microcapsules, and controlled release preparation (including antagonist expressing cells) prior to administration in vivo.
  • a carrier or targeting molecule e.g., antibody, hormone, growth factor, etc.
  • the pharmaceutical composition may comprise one or more of the antagonists in an aqueous solution, such as sterile water, saline, phosphate buffer or dextrose solution.
  • the active agents may be comprised in a solid (e.g. wax) or semi-solid (e.g. gelatinous) formulation that may be implanted into a patient in need of such treatment.
  • the administration route may be any mode of administration known in the art, including but not limited to intravenously, intrathecally, subcutaneously, by injection into involved tissue, intraarterially, intranasally, orally, or via an implanted device.
  • Administration may result in the distribution of the active agent of the invention throughout the body or in a localized area.
  • intravenous or intrathecal administration of agent may be desirable.
  • an implant containing active agent may be placed in or near the lesioned area.
  • Suitable implants include, but are not limited to, gelfoam, wax, or microparticle-based implants.
  • PC12D PC12 cells that respond to IL-6
  • Rat CNTF was prepared as described [Masiakowski, et al., J. Neurochem. 57:1003-10012 (1991)].
  • IL-6 and sIL-6R ⁇ were purchased from R & D Systems.
  • Antisera was raised in rabbits against a peptide derived from a region near the C-terminus of gp130 (sequence: CGTEGQVERFETVGME) [SEQ. ID. NO. 2] by the method described (Stahl, et al. J. Biol. Chem. 268:7628-7631 (1993).
  • Anti-phosphotyrosine monoclonal 4G10 was purchased from UBI, and reagents for ECL from Amersham.
  • PC12D PC12 cell line
  • IL-6R ⁇ expresses IL-6R ⁇ , gp130, and CNTFR ⁇ , but not LIFR ⁇ .
  • IL-6R ⁇ expresses IL-6R ⁇ , gp130, and CNTFR ⁇ , but not LIFR ⁇ .
  • LIFR ⁇ is a required component for CNTF signal transduction [Davis, et al., Science 260: 59-63 (1993)].
  • PC12D cells give tyrosine phosphorylation of gp130 (as well as a variety of other proteins called CLIPs) in response to 2 nM IL-6 (FIG. 2).
  • CLIPs 2 nM IL-6
  • Addition of recombinant soluble IL-6R ⁇ (sIL-6R ⁇ ) enhances the level of gp130 tyrosine phosphorylation, as has been reported in some other systems [(Taga, et al., Cell 58: 573-581 (1989)].
  • addition of 2 nM CNTF simultaneously with IL-6 severely diminishes the tyrosine phosphorylation of gp130.
  • CNTF is a rather potent antagonist of IL-6 action.
  • 125 I-CNTF was prepared and purified as described [Stahl et al. JBC 268: 7628-7631 (1993)]. Saturation binding studies were carried out in PC12 cells, using concentrations of 125 I-CNTF ranging from 20 pM to 10 nM. Binding was performed directly on a monolayer of cells. Medium was removed from wells and cells were washed once with assay buffer consisting of phosphate buffered saline (PBS; pH 7.4), 0.1 mM bacitracin, 1 mM PMSF, 1 mg/ml leupeptin, and 1 mg/ml BSA.
  • PBS phosphate buffered saline
  • the equilibrium constant for binding of CNTF to CNTFR ⁇ : ⁇ 1 was estimated from Scatchard analysis of iodinated CNTF binding on PC12D cells (FIG. 3). The data is consistent with a 2 site fit having dissociation constants of 9 pM and 3.4 nM.
  • the low affinity site corresponds to interaction of CNTF with CNTFR ⁇ , which has a Kd near 3 nM [(Panayotatos, et al., J. Biol. Chem. 268: 19000-19003 (1993)].
  • We interpret the high affinity complex as the intermediate containing CNTF, CNTFR ⁇ , and gp130.
  • EW-1 Ewing sarcoma cell line
  • CNTF binds with equally high affinity to a complex containing only CNTFR ⁇ and gp130, as it does to a complex which additionally contains LIFR ⁇ , thus demonstrating the feasibility of creating the sR ⁇ : ⁇ antagonists described herein.
  • SF21 insect cells obtained from Spodoptera frugiperda were grown at 27° C. in Gibco SF900 II medium to a density of 1 ⁇ 10 6 cells/mL.
  • the individual virus stock for either GP130-Fc-His 6 (FIGS. 4A and 4B) or IL6Ra-Fc (FIG. 5) was added to the bioreactor to a low multiplicity 0.01-0.1 PFU/cell to begin the infection.
  • the infection process was allowed to continue for 5-7 days allowing maximum virus replication without incurring substantial cell lysis.
  • the cell suspension was aseptically aliquoted into sterile centrifuge bottles and the cells removed by centrifugation. The cell-free supernatant was collected in sterile bottles and stored at 4° C. until further use.
  • the virus titer was determined by plaque assay as described by O'Reilly, Miller and Luckow. The method is carried out in 60 mm tissue-culture dishes which are seeded with 2 ⁇ 10 6 cells. Serial dilutions of the virus stock are added to the attached cells and the mixture incubated with rocking to allow the virus to adsorb to individual cells. An agar overlay is added and plates incubated for 5-7 days at 27° C. Staining of viable cells with neutral red revealed circular plaques resulting which were counted to give the virus titer.
  • Uninfected SF21 Cells were grown in a 60L ABEC bioreactor containing 40 L of SF900 II medium. Temperature was controlled at 27° C. and the dissolved oxygen level was maintained at 50% of saturation by controlling the flowrate of oxygen in the inlet gas stream. When a density of 2 ⁇ 10 6 cells/mL was reached, the cells were concentrated within the bioreactor to a volume of 20 L using a low shear steam sterilizable pump with a tangential flow filtration device with Millipore Prostak 0.65 micron membranes. After concentration fresh sterile growth medium is slowly added to the bioreactor while the filtration system continues to remove the spent growth medium by diafiltration. After two volume exchanges (40 L) have been carried out an additional 20 L of fresh medium was added to the bioreactor to resuspend the cells to the original volume of 40 L. The cell density was determined once again by counting viable cells using a hemacytometer.
  • each virus stock was calculated based on the cell density, virus titer and the desired multiplicity of infection (MOI).
  • MOI multiplicity of infection
  • Virus stock ratios of 5:1, 5:2, 10:2 and 10:4, IL6R ⁇ -Fc to GP130-Fc-His 6 all resulted in production of significant amounts of heterodimer.
  • the ideal virus stock ratio is highly dependent on the ease of purification of the heterodimer from each of the two homodimers.
  • the IL6R ⁇ -Fc homodimer is relatively easy to remove downstream by immobilized metal affinity chromatography.
  • Virus infection ratios have been chosen to minimize the formation of the GP130-Fc-His 6 homodimer which is more difficult to clear downstream.
  • the relative amount of GP130-Fc-His 6 virus stock chosen for infection has increased with successive batches as the purification method for clearing the resultant homodimer has improved.
  • the virus stocks were aseptically mixed in a single vessel then transferred to the bioreactor. This results in synchronous infection of the SF21 cells. The infection is allowed to proceed for three to four days, allowing sufficient time for maximal production of the heterodimer protein.
  • the cells were concentrated in the bioreactor using a 10 ft 2 Millipore Prostak filter (0.65 micron) pore size.
  • the cell-free permeate passing through the filter was collected in a clean process vessel.
  • the pH of permeate stream, containing the protein product was adjusted to 8.0 with 10N NaOH.
  • the resultant precipitate was removed by forcing the extract through a 0.8 micron depth filter (Sartorious), followed by a 0.2 micron filter. Sufficient 0.5M EDTA stock was added to give a final concentration of 5 mM.
  • the filtered protein solution was loaded onto a 10 cm diameter column containing 100-200 mL of Pharmacia Protein A Sepharose 4 Fast Flow, equilibrated with PBS.
  • Protein A has a very high affinity for the Fc-Fc domain of each of the 3 recombinant protein products, allowing them to bind while other proteins in the cell-free extract flow through the column.
  • the column was washed to baseline with PBS containing an additional 350 mM NaCl.
  • the IgG-Fc tagged proteins were eluted at low pH, either with 0.5M acetic acid or with a decreasing pH gradient of 0.1M citric acid and 0.2M disodium phosphate buffers. Tris base or disodium phosphate was added to the eluted protein to avoid prolonged exposure to low pH conditions.
  • the pooled protein was diafiltered into PBS or HEPES buffer and derivitized with 1 mM iodoacetamide to protect the exposed sulfhydryl group on the free cysteine near the hinge region of each Fc domain. This prevents disulfide mediated aggregation of proteins.
  • a 6 ft 2 Millipore spiral wound ultrafiltration membrane with nominal 30 kiloDalton cutoff was used to perform the buffer exchange.
  • the total protein was determined by UV absorbance at 280 nm using the diafiltration buffer as a blank.
  • the relative amounts of heterodimer and two homodimer proteins were determined by SDS PAGE gel electrophoresis using a 6% Tris-Glycine gel (Novex).
  • the six histidine residues on the C-terminus of the GP130-Fc-His 6 fusion protein provides an excellent molecular handle for separation of the heterodimeric IL6 antagonist from the two homodimers.
  • the imidazole group on each of the C-terminal histidines of the GP130-Fc-His 6 moiety has a strong binding constant with several divalent metals, including copper, nickel, zinc, cobalt, iron and calcium. Since the IL6R ⁇ -Fc homodimer has no C-terminal histidine residues, it clearly has the lowest affinity.
  • the IL6Ra-Fc-GP130-Fc-His 6 heterodimer has a single stand set six histidines giving it greater affinity for the metal, while the GP130-Fc-His 6 homodimer has two sets of six histidines each giving it the highest affinity of the three IgG tagged proteins to the metal affinity column. Selective elution of the three proteins with increasing amounts of imidazole in the elution buffer therefore elutes the proteins in the following order:
  • a 26 mm diameter column containing 100 mL of Pharmacia Chelating Sepharose Fast Flow was saturated with a solution of nickel sulfate until a significant green color is observed in the column eluate.
  • the column is then washed with several column volumes of deionized water, then equilibrated with 50 mM HEPES, 40 mM imidazole, pH 8.0.
  • the binding of imidazole to the immobilized nickel results in a green to blue color change.
  • Imidazole was added to the protein load to a final concentration of 40 mM. Addition of imidazole to the protein load reduces the binding of IL6R ⁇ -Fc homodimer, increasing the surface area available for the remaining two species.
  • cytokine As described above, receptor activation by CNTF, and analogously by IL-6 and IL-11, follows an ordered sequence of binding events (FIG. 6).
  • the cytokine.R ⁇ complex associates with the first signal transducing component, gp130, to form a high affinity complex (Kd in the order of 10 pM for the CNTF.CNTFR ⁇ .9gp 130 complex).
  • This complex does not transduce signal, as it is the dimerization of the signal transducing components that brings about signaling (Stahl and Yancopoulos, J. Neurobiology 25: 1454-1466 (1994); Stahl et al., Science 267:1349-1353 (1995); Davis et al., Science 260:1805-1808 (1993); Stahl et al., Science 263:92-95 (1994); Murakami, et al. Science 260:1808-1810 (1993).
  • the cytokine.R ⁇ .signal transducer heterotrimeric complex subsequently associates with another like complex, to form a hexameric complex (FIG. 6) (Ward et al., J.
  • the initial heterodimeric molecules made comprised a soluble R ⁇ -component linked to the extracellular domain of gp130. These molecules were shown to mimic the high affinity cytokine.R ⁇ .gp130 complex and behave as a high affinity antagonist of their cognate cytokine (FIG. 7). To make these molecules, the extracellular domain of gp130 was paired with the extracellular domain of the ⁇ -receptor components for IL-6 and CNTF, IL-6R ⁇ and CNTFR ⁇ respectively. To link the R ⁇ with the extracellular domain of gp130, the soluble R ⁇ -components and gp130 were fused to the Fc portion of human IgG1 to produce R ⁇ -Fc and gp130-Fc respectively.
  • the Fc domain was chosen primarily but not solely because it naturally forms disulfide-linked dimers.
  • Heterodimeric molecules comprising R ⁇ -Fc.gp130-Fc were expressed, purified and shown to behave as highly potent antagonists of their cognate ligand. Furthermore, these molecules were found to be highly specific for their cognate cytokine since it is the choice of the ⁇ -receptor component which specifies which cytokine is bound and trapped (there is no measurable binding of the cytokine to gp130 in the absence of the appropriate R ⁇ ).
  • the IL-6 traps described here were engineered using human gp130, human IL-6 ⁇ -receptor (IL-6R ⁇ ), the constant region of the heavy chains (C ⁇ ) of human IgG1 (C ⁇ 1) (Lewis et al., Journal of Immunology 151:2829-2838 (1993) or IgG4 (C ⁇ 4) with or without a join-region (J), and the constant regions of kappa ( ⁇ ) and lambda ( ⁇ ) (Cheung, et al., Journal of Virology 66:6714-6720 (1992) light chains of human immunoglobulin (Ig), also with or without a different j-peptide (j).
  • This design takes advantage of the natural ability of the C ⁇ domain to heterodimerize with ⁇ or ⁇ light chains.
  • the heterodimerization of C ⁇ with the light chain occurs between the CH1 domain of C ⁇ and the constant region of the light chain (C L ), and is stabilized by covalent linking of the two domains via a single disulfide bridge.
  • C L constant region of the light chain
  • constructs employing the full length C ⁇ region would, much like antibodies, form homodimers of the C ⁇ chain, giving rise to antibody-like molecules comprising of two “light chains” and two “heavy chains” (FIG. 8).
  • the potential advantage of this design is that it may more closely mimic the IL-6.IL-6R ⁇ .gp130 complex and may display a higher affinity for the ligand than comparable single heterodimers.
  • An additional design is incorporated by using truncated versions of C ⁇ , comprised only of the C H 1 domain. These will form heterodimeric molecules with receptors fusion proteins, and will thus resemble the Fab fragment of antibodies.
  • All the soluble receptor-Ig chimeric genes may be engineered in plasmid vectors including, but not limited to, vectors suitable for mammalian expression (COS monkey kidney cells, Chinese Hamster Ovary cells [CHO], and ras-transformed fibroblasts [MG-ras]) and include a Kozak sequence (CGC CGC CAC CAT GGT G) at the beginning of each chimeric gene for efficient translation.
  • CGC CGC CAC CAT GGT G Kozak sequence at the beginning of each chimeric gene for efficient translation.
  • Engineering was performed using standard genetic engineering methodology. Each construct was verified by DNA sequencing, mammalian expression followed by western blotting with suitable antibodies, biophysical assays that determine ligand binding and dissociation, and by growth inhibition assays (XG-1, as described later).
  • domains utilized to engineer these chimeric proteins are flanked by appropriate restriction sites, it is possible to use these domains to engineer other chimeric proteins, including chimeras employing the extracellular domains of the receptors for factors such as IL-1, IL-2, IL-3, IL-4, IL-5, GM-CSF, LIF, IL-i1, IL-15, IFN ⁇ , TGF ⁇ , and others.
  • the amino acid coordinates for each component utilized in making the IL-6 traps are listed below (Note: numbering starts with the initiating methionine as #1; long sequences are listed using the single letter code for the twenty amino acids):
  • gp130-C ⁇ 1 was engineered by fusing in frame the extracellular domain of gp130 (amino acids 1 to 619) to a Ser-Gly bridge, followed by the 330 amino acids which comprise C ⁇ 1 and a termination codon (FIGS. 9A and 9B).
  • gp130-J-C ⁇ 1 was engineered in the same manner as gp130-C ⁇ 1 except that a J-peptide (amino acid sequence: GQGTLVTVSS) was inserted between the Ser-Gly bridge and the sequence of C ⁇ 1 (see FIGS. 9A and 9B).
  • a J-peptide amino acid sequence: GQGTLVTVSS
  • gp130 ⁇ 3fibro-C ⁇ 1 was engineered by fusing in frame the extracellular domain of gp130 without its three fibronectin-like domains (FIG. 10). The remaining part of this chimeric protein is identical to gp130-C ⁇ 1.
  • gp130-J-C H 1 was engineered in a manner identical for that described for gp130-C ⁇ 1, except that in place of the C ⁇ 1 region only the C H 1 part of C ⁇ 1 has been used (FIG. 11).
  • the C-terminal domain of this construct includes the part of the hinge that contains the cysteine residue responsible for heterodimerization of the heavy chain of IgG with a light chain.
  • the part of the hinge that contains the two cysteines involved in C ⁇ 1 homodimerization has been deleted along with the C H 2 and C H 3 domains.
  • gp130-C ⁇ 4 was engineered in a manner identical to that described for gp130-C ⁇ 1, except that C ⁇ 4 was used in place of C ⁇ 1 (FIG. 12).
  • an RsrII DNA restriction site was engineered at the hinge region of the C ⁇ 4 domain by introducing two silent base mutations. The RsrsII site allows for other desired genetic engineering manipulations, such as the construction of the C H 1 equivalent of gp130-Cy4.
  • gp130- ⁇ was engineered in a manner identical to that described for gp130-C ⁇ 1, except that the constant region of the ⁇ light chain of human Ig was used in place of C ⁇ 1 (FIG. 13).
  • gp130-J- ⁇ was engineered in a manner identical to that described for gp130-J- ⁇ , except that a j-peptide (amino acid sequence: TFGQGTKVEIK) was inserted between the Ser-Gly bridge and the ⁇ -region.
  • gp130- ⁇ was engineered in a manner identical to that described for gp130-C ⁇ 1, except that the constant region of the ⁇ light chain (Cheung, et al., Journal of Virology 66:6714-6720 (1992) of human Ig was used in place of C ⁇ 1 (FIG. 14).
  • IL6R ⁇ -C ⁇ 1 was engineered by fusing in frame amino acids 1 to 358 of IL-6R ⁇ (Yamasaki et al., Science 241:825-828 (1988), which comprise the extracellular domain of IL-6R ⁇ (FIG. 15), to an Ala-Gly bridge, followed by the 330 amino acids which comprise C ⁇ 1 and a termination codon.
  • IL6R ⁇ - ⁇ was engineered as described for IL6R ⁇ -C ⁇ 1, except that the ⁇ -domain (FIG. 13) utilized for gp130-K was used in place of C ⁇ 1.
  • IL6R ⁇ -j- ⁇ was engineered as described for IL6R ⁇ -K except that the j-peptide described for gp130-j- ⁇ was placed between the Ala-Gly bridge and the ⁇ -domain.
  • IL6R ⁇ 313-C ⁇ 1, IL6R ⁇ 313- ⁇ , and IL6R ⁇ 313-j- ⁇ were engineered as using a truncated form of IL-6R ⁇ comprised of amino acids 1 to 313 (FIG. 16).
  • Each of these constructs were made by fusing in frame IL6R ⁇ 313 with a Thr-Gly bridge followed by the C ⁇ 1, ⁇ -, and j- ⁇ -domains described above.
  • These constructs were engineered in order to complement the gp130 ⁇ 3fibro-derived constructs.
  • gp130-Ig chimeric proteins were co-expressed with appropriate IL-6R ⁇ -Ig chimeric proteins in complementing pairs. Co-expression was achieved by co-transfecting the corresponding expression vectors into suitable mammalian cell lines, either stably or transiently. The resulting disulfide-linked heterodimers were purified from conditioned media by several different methods, including but not limited to affinity chromatography on immobilized Protein A or Protein G, ligand-based affinity chromatography, ion exchange, and gel filtration.
  • the material generated in this step was further purified by a second affinity chromatography step over a 1 ml NHS-activated Sepharose (Pharmacia) which was derivatized with recombinant human IL-6, in order to remove gp130-C ⁇ 1 dimer from gp130-C ⁇ 1.IL-6R ⁇ - ⁇ complexes (the gp130-C ⁇ 1 dimer does not bind IL-6). Proteins generated by this method were more than 90% pure, as evidenced by SDS-PAGE followed by silver-staining (FIG. 17). Similar protocols have been employed successfully towards the purification of other heavy/light receptor heterodimers.
  • the purified ligand traps were tested for their ability to bind IL-6 in a variety of different assays. For example, the dissociation rate of IL-6 bound to the ligand trap was measured in parallel with the dissociation rate of IL-6 from the anti-IL-6 monoclonal neutralizing antibody B-E8 [Brochier, et al., Int. J. Immunopharmacology 17:41-48 (1995), and references within]. An example of this type of experiment is shown in FIG. 18.
  • FIG. 19 IL-6-induced association of gp130-Fc.IL-6R ⁇ -Fc with gp130-C H 1.IL-6R ⁇ - ⁇ was determined by testing whether gp130-C H 1.IL-6R ⁇ - ⁇ , which does not by itself bind Protein A, could be precipitated by Protein A-Sepharose in the presence of gp130-Fc.IL-6R ⁇ -Fc in an IL-6-depended manner (FIG. 9).
  • Precipitation of gp130-C H 1.IL-6R ⁇ - ⁇ by Protein A-Sepharose was determined by western blotting with an anti-kappa specific HRP conjugate, which does not detect gp130-Fc.IL-6R ⁇ -Fc.
  • gp130-C H 1.IL-6R ⁇ - ⁇ could be precipitated by Protein A-Sepharose only when both gp130-Fc.IL-6R ⁇ -Fc and IL-6 were present.
  • This result conclusively indicates that IL-6 can induce ligand trap multimerization, and further indicate that the ligand trap can mimic the hexameric cytokine.R ⁇ .signal transducer complex (FIG. 1).
  • Ligand-induced multimerization may play a significant role in the clearance of cytokine ligand trap complexes in vivo.
  • XG-1 is a cell line derived from a human multiple myeloma (Zhang, et al., Blood 83:3654-3663 (1994).
  • XG1 depends on exogenously supplied human IL-6 for survival and proliferation.
  • the EC 50 of IL-6 for the XG-1 line is approximately 50 pmoles/ml.
  • IL-6 traps The ability of several different IL-6 traps to block IL-6-depended proliferation of XG-1 cells was tested by incubating increasing amounts of purified ligand traps with 50 pg/ml IL-6 in XG-1 cultures.
  • the ligand traps which were tested had been expressed and purified by methods similar to those described above. All of the ligand traps tested were found to inhibit IL-6-dependent proliferation of XG1 in a dose dependent manner (FIG. 20). Of the five different traps tested gp130-C ⁇ 1.IL-6R ⁇ - ⁇ was the most active and essentially display the same neutralizing activity towards IL-6 as the antibody B-E8.
  • nucleotides 15 through 776 (corresponding to amino acids 1-233) from the Genbank sequence, D11086, were cloned.
  • nucleotides 52 through 1044 (corresponding to the amino acids 1-331) from the Genbank sequence, X52425, were cloned.
  • nucleotides 322 through 2112 (corresponding to the amino acids 30-619) from the Genbank sequence, M57230, were cloned.
  • nucleotides 1 through 1074 (corresponding to the amino acids 1-358) from the Genbank sequence, AB006357, were cloned.
  • nucleotides 55 through 999 (corresponding to the amino acids 19-333) from the Genbank sequence, X16896, were cloned.
  • nucleotide sequences encoding the cytokine traps were constructed from the individual cloned DNAs (described supra) by standard cloning and PCR techniques. In each case, the sequences were constructed in frame such that the sequence encoding the first fusion polypeptide component was fused to the sequence encoding the second fusion polypeptide component followed by an Fc domain (hinge, CH2 and CH3 region of human IgG1) as the multimerizing component. In some cases extra nucleotides were inserted in frame between sequences encoding the first and second fusion polypeptide components to add a linker region between the two components (See FIG. 21A-FIG. 21D-trap 424; FIG. 24A-FIG. 24F-trap 412; and FIG. 26A-FIG. 26E-trap 569).
  • the IL-2R ⁇ component is 5′, followed by the IL4R ⁇ component and then the Fc component.
  • the IL-6 traps 412 (FIG. 24A-FIG. 24F) and 616 (FIG. 25A-FIG. 25F)
  • the IL-6R ⁇ component is 5′ followed by the gp130 component and then the Fc domain.
  • the IL-1 trap 569 (FIG. 26A-FIG. 26E)
  • the IL-1RAcP component is 5′ followed by the IL-1RI component and then the Fc domain.
  • the final constructs were cloned into the mammalian expression vector pCDNA3.1 (STRATAGENE).
  • nucleotides 1-1074 encode the IL1RAcP component
  • nucleotides 1075-1098 encode a linker region
  • nucleotides 1099-2043 encode the IL1RI component
  • nucleotides 2044-2730 encode the Fc domain.
  • nucleotides 1-993 encode the IL6R ⁇ component
  • nucleotides 994-1023 encode a linker region
  • nucleotides 1024-2814 encode the gp130 component
  • nucleotides 2815-3504 encode the Fc domain.
  • nucleotides 1-993 encode the IL6R ⁇ component
  • nucleotides 994-2784 encode the gp130 component
  • nucleotides 2785-3474 encode the Fc domain.
  • nucleotides 1-762 encode the IL2R ⁇ component
  • nucleotides 763-771 encode a linker region
  • nucleotides 772-1395 encode the IL4R ⁇ component
  • nucleotides 1396-2082 encode the Fc domain.
  • nucleotides 1-762 encode the IL2R ⁇ component
  • nucleotides 763-1386 encode the IL4R ⁇ component
  • nucleotides 1387-2073 encode the Fc domain.
  • DNA constructs were either transiently transfected into COS cells or stably transfected into CHO cells by standard techniques well known to one of skill in the art. Supernatants were collected and purified by Protein A affinity chromatography and size exclusion chromatography by standard techniques. (See for example Harlow and Lane, Antibodies—A Laboratory Manual, Cold Spring Harbor Laboratory, 1988).
  • Working concentration Dissolve 5 mg of anhydrous MTT in 200 ml PBS without Ca +2 , Mg +2 .
  • [0215] 1. Prepare sterile 96 well tissue culture plates to contain 50 ⁇ l of growth medium per well with various concentrations of IL-4 and 10 nM IL-4 antagonist. This can be done by preparing a working dilution of IL-4 that is 4 times the highest concentration to be assayed. In separate tubes, do a two-fold serial dilution of the IL-4. Add 25 ⁇ l of each dilution to one row across the plate (i.e. row A gets highest concentration, row G gets lowest concentration). Add 25 ⁇ l of growth medium without IL-4 to row H. Prepare the antagonists to be tested by making a stock that is 4 times the final concentration. Add 25 ⁇ l to a triplicate set of IL-4 containing wells (columns 1,2,3, A through H). Be sure to include antagonist in row H.
  • FIG. 27 shows that an IL-4 trap designated 4SC375, which is a fusion polypeptide of IL-2R ⁇ -scb-IL4R ⁇ -Fc ⁇ C1, is several orders of magnitude better as an IL-4 antagonist than IL4R ⁇ Fc ⁇ C1 alone in the TF1 cell bioassay.
  • FIG. 28 shows that the IL-4 trap designated 4SC375 shows antagonistic activity in the TF1 cell bioassay equivalent to an IL-4 trap designated 4SC424 which is a fusion polypeptide of IL-2R ⁇ -IL4R ⁇ -Fc ⁇ C1 having the IL-2R ⁇ component flush with the IL-4R ⁇ component.
  • Working concentration Dissolve 5 mg of anhydrous MTT in 200 ml PBS without Ca +2 , Mg +2 .
  • [0246] Prepare sterile 96 well tissue culture plates to contain 5 ⁇ l of growth medium per well with various concentrations of IL-6 and 10 nM IL-6 antagonist. This can be done by preparing a working dilution of IL-6 that is 4 times the highest concentration to be assayed. In separate tubes, do a two-fold serial dilution of the IL-6. Add 25 ⁇ l of each dilution to one row across the plate (i.e. row A gets highest concentration, row G gets lowest concentration). Add 25 ⁇ l of growth medium without IL-6 to row H. Prepare the antagonists to be tested by making a stock that is 4 times the final concentration.
  • FIG. 29 shows that the IL6 trap (6SC412 IL6R-scb-gpx-Fc ⁇ C1) described in FIG. 24A-FIG. 24F is a better antagonist of IL-6 in the XG1 bioassay than the neutralizing monoclonal antibody to human IL-6-BE8.
  • MRC5 human lung fibroblast cells respond to IL-1 by secreting IL-6 and thus were utilized to assay the ability of IL-1 traps to block the IL-1-dependent production of IL-6.
  • IL1 Trap 1SC569 (FIG. 26A-FIG. 26E) was tested against IL-1-RI.Fc which is the extracellular domain of the IL-1 Type I receptor fused to an Fc domain.
  • MRC5 cells are suspended at 1 ⁇ 10 5 cells per ml in medium and 0.1 ml of cells are plated (10,000 cells per well) into the wells of a 96 well tissue culture plate. Plates are incubated for 24 hours at 37° C. in a humidified 5% CO 2 incubator.
  • IL-1 trap and recombinant human IL-1 at varying doses are pre-incubated in a 96 well tissue culture dish and incubated for 2 hours at 37° C. 0.1 ml of this mixture is then added to the 96 well plate containing the MRC5 cells such that the final concentration of IL-1 Trap is 10 nM and the final concentrations of the IL-1 ranges from 2.4 pM to 5 nM. Control wells contain trap alone or nothing.
  • Plates are then incubated at 37° C. for 24 hours in a humidified 5% CO 2 incubator. Supernatant is collected and assayed for levels of IL-6 using R&D Systems Quantikine Immunoassay Kit according to the manufacturer's instructions.
  • FIG. 30 shows that the trap 569 (FIG. 26A-FIG. 26E) is able to antagonize the effects of IL-1 and block the IL-6 production from MRC 5 cells upon treatment with IL-1.
  • the trap 569 At a concentration of 10 nM, the trap 569 is able to block the production of IL-6 up to an IL-1 concentration of 3 nM.
  • the IL-1RI.Fc is a much poorer antagonist of IL-1. It is only able to block the effects of IL-1 up to about 10-20 pM.
  • the trap 569 is approximately 100 ⁇ better at blocking IL-1 than IL1RI.Fc.
  • IL-13R ⁇ 1.IL-4R ⁇ .Fc the IL-13R ⁇ 1 extracellular domain (corresponding to nucleotides #1-1029 of FIG. 32A-FIG. 32G) and the human IL-4R ⁇ (corresponding to nucleotides # 1060-1692 of FIG. 32A-FIG. 32G) were amplified by standard PCR techniques and ligated into the expression vector pJFE14, which contains the human Fc sequence (corresponding to nucleotides #1699-2382 of FIG. 32A-FIG.
  • Plating media was Gibco Ham's F-12 w/10% Hyclone Fetal Bovine Serum (FBS)+ penicillin/streptomycin and supplemented with glutamine. The following day each plate was transfected with 6 ⁇ g of pCAE801, or pCAE802, using Gibco Optimem and Gibco Lipofectamine in 12 ml volume, following the manufacturer's protocol. Four hours after adding the transfection mix to the cells 12 ml/plate of Optimem w/ 10% FBS was added. Plates were incubated at 37° C. in a 5% CO 2 incubator overnight. The following day the media was removed from each plate and 25 ml expression media (Gibco CHO-S-SFM II w/ glutamine+1 mM sodium butyrate) was added. The plates were incubated at 37° C. for 3 days.
  • the conditioned media was sterile filtered (0.22 ⁇ m pore size) prior to loading onto a pre-equilibrated, 5 mL HiTrap® Protein A affinity column (Amersham Pharmacia Biotech) in Dulbecco's PBS buffer (Life Technologies), pH 7.4 at 4° C. The flow rate was ⁇ 1-2 mL/min. The column was extensively washed with PBS buffer to remove nonspecifically bound proteins from the column. IL-4R ⁇ .IL-13R ⁇ 1. Fc was eluted using 20 mM sodium citrate, 150 mM NaCl, pH 3.5. The eluate was immediately neutralized by titrating with 1 M Tris-OH.
  • the fractions containing protein were pooled and immediately dialyzed in PBS buffer, pH 7.4 at 4° C. The recovery from Protein A purification was 6.8 mg (73%). IL-4R ⁇ .IL-13R ⁇ 1.Fc was further purified by size exclusion chromatography using a superose 6 column (25 mL bed volume; Amersham Pharmacia Biotech) pre-equilibrated in PBS, 5% v/v glycerol, pH 7.4 at ambient temperature. The flow rate was 0.5 mL/min. Protein fractions were assessed from a Coomassie stained non-reduced and reduced SDS-PAGE (Novex NuPAGE 4-12% Bis-Tris gels). Fractions were conservatively pooled to reduce the amount of aggregated protein.
  • the overall yield was 51% (4.4 mg) with a purity of 97% as judged by SDS-PAGE.
  • Purified IL-4R ⁇ .IL-13R ⁇ 1.Fc was analyzed by non-reduced and reduced SDS-PAGE (4-12% Bis-Tris), analytical size exclusion chromatography (Tosohaas TSKG4000SWXL), N-terminal sequencing, and immunoblotting with goat anti-hIgG-HRP conjugate (Promega W403B), and also mouse monoclonal anti-hIL-4R (R&D MAB230) followed by anti-mIgG-HRP conjugate (Promega W402B) as the secondary antibody.
  • Human IL-13R ⁇ 1.IL-4R ⁇ .Fc was transiently expressed in CHO cells and supernatants were harvested from plate transfections as described supra. Expression of the secreted protein was determined by a sandwich ELISA using goat anti-hIgG ( ⁇ chain specific; Sigma 1-3382) and goat anti-hIgG (Fc specific)-FITC conjugate (Sigma F9512) capture and report antibodies, respectively. The yield was 8.8 mg per liter of conditioned media. CompleteTM protease inhibitor tablets (Roche Diagnostics Corp.) were dissolved into the media (1 tablet/L).
  • the conditioned media was sterile filtered (0.22 ⁇ m pore size) prior to loading onto a pre-equilibrated, 5 mL HiTrap® Protein A affinity column (Amersham Pharmacia Biotech) in Dulbecco's PBS buffer (Life Technologies), pH 7.4 at 4° C. The flow rate was ⁇ 1-2 mL/min. The column was extensively washed with PBS buffer to remove nonspecifically bound proteins from the column. IL-13R ⁇ 1.IL-4R ⁇ .Fc was eluted using 20 mM sodium citrate, 150 mM NaCl, pH 3.5. The eluate was immediately neutralized by titrating with 1 M Tris-OH.
  • the fractions containing protein were pooled and immediately dialyzed in PBS buffer, pH 7.4 at 4° C. The recovery from Protein A purification was 3.8 mg (43%). IL-13R ⁇ 1.IL-4R ⁇ .Fc was further purified by size exclusion chromatography using a superose 6 column (25 mL bed volume; Amersham Pharmacia Biotech) pre-equilibrated in PBS, 5% v/v glycerol, pH 7.4 at ambient temperature. The flow rate was 0.5 mL/min. Protein fractions were assessed from a Coomassie stained non-reduced and reduced SDS-PAGE (Novex NuPAGE 4-12% Bis-Tris gels). Fractions were conservatively pooled to reduce the amount of aggregated protein.
  • the overall yield was 17% (1.5 mg) with a purity of 95% as judged by SDS-PAGE.
  • Purified IL-13R ⁇ 1.IL-4R ⁇ .Fc was analyzed by non-reduced and reduced SDS-PAGE (4-12% Bis-Tris), analytical size exclusion chromatography (Tosohaas TSKG4000SWXL), N-terminal sequencing, and immunoblotting with goat anti-hIgG-HRP conjugate (Promega W403B), and also mouse monoclonal anti-hIL-4R ⁇ (R&D MAB230) followed by anti-mIgG-HRP conjugate (Promega W402B) as the secondary antibody.
  • TF1 Bioassay TF1 cells were maintained in growth media (10 ng/ml GM-CSF, RPMI 1640, 10% FBS, L-glutamine, Penicillin, Streptomycin). For the bioassay, cells were washed 2 times in assay media (as above but without GM-CSF) and then plated at 2 ⁇ 10 5 cells in 50 ⁇ l of assay media. The purified IL-4Ra.IL-13R ⁇ 1.Fc and IL-13R ⁇ 1.IL-4R ⁇ .Fc proteins were diluted into assay media at a concentration of 40 nM. 25 ul of each of the traps was added to the cells.
  • Either IL-13 or IL-4 were diluted to 40 nM in assay media and then 2-fold dilution series in assay media were made. 25 ⁇ l of either IL-13 or IL-4 was then added to the wells containing the cells and the traps. Cells were then incubated at 37° C., 5% CO 2 for ⁇ 70 hrs. The extent of TF1 cell proliferation was measured by the MTS assay according to the manufacturer's protocol (Promega, Inc.).
  • IL-4R ⁇ .IL-13R ⁇ 1.Fc and IL-13R ⁇ 1.IL-4R ⁇ .Fc traps were measured in the TF1 bioassay described supra.
  • IL-13 stimulates proliferation of TF1 cells, with half-maximal growth at a concentration of 0.2 nM.
  • IL-13 concentration of ⁇ 4-5 nM the growth of TF1 cells is inhibited by 50%.
  • TF1 cells are more sensitive to IL-4, which stimulates their proliferation with half-maximal growth at ⁇ 0.02 nM.
  • Addition of either IL-4R ⁇ .IL-13R ⁇ 1.Fc or IL-13R ⁇ 1.IL-4R ⁇ .Fc at a concentration of 10 nM blocks IL-4-induced growth up to ⁇ 1 nM (FIG. 34).
  • IL-4 concentration of ⁇ 3-4 nM the growth of TF1 cells is inhibited by 50%.
  • IL-1 is a pro-inflammatory cytokine.
  • Systemic administration of IL-1 has been shown to elicit acute responses in animals, including transient hyperglycemia, hypoinsulinemia, fever, anorexia, and increased serum levels of interleukin-6 (IL-6) (Reimers, 1998).
  • IL-6 interleukin-6
  • mice are responsive to both murine and human IL-1, human IL-1 can be used and in vivo binding effects of human specific IL-1 antagonists can be evaluated.
  • This acute mouse model was used to determine the ability of a human IL-1 trap to antagonize the in vivo effects of exogenously administered human IL-1. This provides a rapid indication of in vivo efficacy of the human IL-1 trap and can be used as an assay to help molecule selection.
  • mice were given subcutaneous injections of human IL-1 (0.3 ag/kg). Twenty-four hours prior to human IL-1 injection, the animals were pre-treated with either vehicle or 150-fold molar excess of human IL-1 trap (0.54 mg/kg). Two hours prior to sacrifice (26 hrs), the mice were given a second injection of human IL-1 (0.3 Ag/kg). Blood samples were collected at various time points and sera were assayed for IL-6 levels.
  • the experiment consisted of 3 parts: human IL-4 +vehicle (part 1), human IL-4+IL-4 Trap (part 2), and human IL-4 +vehicle (part 3).
  • Human IL-4 (25 ⁇ g/kg) was injected subcutaneously twice daily for 4 days and IL-4 Trap (8 mg/kg) and vehicle were given intravenously daily for 5 days, beginning 1 day prior to human IL-4 administration.
  • Whole blood was collected daily for flow cytometry analysis for CD16 and plasma was obtained to assay for the cytokine monocyte chemotactic protein 1 (MCP-1).
  • CD16 and MCP-1 are markers of IL-4-mediated inflammation in both humans and monkeys.
  • mice injected with anti-mouse IgD (100 ⁇ l/mouse, s.c.) were randomly divided into 3 groups. Each received (on days 3-5) either vehicle, murine IL-4 trap (1 mg/kg, s.c.), or a monoclonal antibody to mouse IL-4 (1 mg/kg, s.c.). Serum was collected at various time points and assayed for IgE levels.
  • the IL-4/IL-13 Trap 933 sequence consists of the extracellular domain of human IL-13R ⁇ 1 (nucleotides #-78 to 951 of FIG. 38A- 38 H), followed by the extracellular domain of human IL-4R ⁇ (nucleotides #952-1575 of FIGS. 38 A- 38 H) containing a mutation at nucleotide # 1501 (T->A) to change a cysteine to a serine, followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides # 1576-2265 of FIGS. 38 A- 38 H).
  • the IL-4/IL-13 Trap 943 sequence consists of the extracellular domain of human IL-4R ⁇ (nucleotides # -69 to 624 of FIGS. 39 A- 39 G) containing a mutation at nucleotide #550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13R ⁇ 1 (nucleotides #625-1575 of FIGS. 39 A- 39 G) followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides #1576-2262 of FIGS. 39 A- 39 G).
  • the IL-4/IL-13 Trap 1126 sequence consists of the extracellular domain of human IL-13R ⁇ 1 (nucleotides #-78 to 951 of FIGS. 40 A- 40 I), containing a mutation at nucleotide #58 (T to A) to change a cysteine to a serine, followed by the extracellular domain of human IL-4R ⁇ (nucleotides #952-1575 of FIGS. 40 A- 40 I) containing a mutation at nucleotide #1501 (T->A) to change a cysteine to a serine, followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides # 1576-2265 of FIGS. 40 A- 40 I).
  • the IL-4/IL-13 Trap 1128 sequence consists of the extracellular domain of human IL-4R ⁇ (nucleotides # -69 to 624 of FIGS. 41 A- 41 P) containing a mutation at nucleotide #550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13R ⁇ 1 (nucleotides #625-1575 of FIGS. 41 A- 41 P) containing a mutation at nucleotide #682 (T to A) to change a cysteine to a serine, followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides #1576-2262 of FIGS. 41 A- 41 H).
  • the IL-4/IL-13 Trap 1130 sequence consists of the extracellular domain of human IL-13R ⁇ 1 (nucleotides # -78 to 951 of FIGS. 42 A- 42 I), containing a mutation at nucleotides #58-60 (TGC to GCG) to change a cysteine to an alanine, followed by the extracellular domain of human IL-4R ⁇ (nucleotides #952-1575 of FIGS.
  • the IL-4/IL-13 Trap 1132 sequence consists of the extracellular domain of human IL-4R ⁇ (nucleotides #-69 to 624 of FIGS. 43 A- 43 G) containing a mutation at nucleotide #550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13R ⁇ 1 (nucleotides #625-1575 of FIGS.
  • the IL-4/IL-13 Trap 1199 sequence consists of the extracellular domain of human IL-4R ⁇ (nucleotides #-69 to 624 of FIGS. 44 A- 44 I) containing a mutation at nucleotide #550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13R ⁇ 1 (nucleotides #625-1575 of FIGS. 44 A- 44 I) containing a mutation at nucleotide #682-684 (TGC to GCG) to change a cysteine to an alanine, followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides # 1576-2268 of FIG. 44A- 44 I).
  • the IL-4/IL-13 Trap 1244 sequence consists of the extracellular domain of human IL-13R ⁇ 1 (nucleotides #-78 to 951 of FIGS. 45 A- 45 I), containing a mutation at nucleotide #58-60 (TGC to GCG) to change a cysteine to an alanine, followed by the extracellular domain of human IL-4R ⁇ (nucleotides #952-1575 of FIGS. 45 A- 45 I) containing a mutation at nucleotide #1501 (T->A)to change a cysteine to a serine, followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides # 1576-2271 of FIGS. 45 A- 45 I).
  • the IL-4/IL-13 Trap 1245 sequence consists of the extracellular domain of human IL-4R ⁇ (nucleotides #-69 to 624 of FIGS. 46 A- 46 I) containing a mutation at nucleotide #550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13R ⁇ 1 (nucleotides #625-1575 of FIGS. 46 A- 46 I) containing a mutation at nucleotide #682 (T to A) to change a cysteine to an serine, followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides # 1576-2268 of FIGS. 46 A- 46 I).
  • the IL-4/IL-13 Trap 1246 sequence consists of the extracellular domain of human IL-13R ⁇ 1 (nucleotides #-78 to 951 of FIG. 47A- 47 J) containing a mutation at nucleotide #58 (T to A) to change a cysteine to a serine, followed by the extracellular domain of human IL-4R ⁇ (nucleotides #952-1575 of FIGS. 47 A- 47 J) containing a mutation at nucleotide #1501 (T->A) to change a cysteine to a serine, followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides # 1576-2271 of FIGS. 47 A- 47 J).
  • IL-4/IL-13 Trap 943 blocked IL-4 and IL-13 in a TF1 bioassay more potently than the IL-4/IL-13 Trap 933.
  • IL-4/IL-13 Trap 943 had a slightly higher protein expression level.
  • IL-4/IL-13 Trap constructs 1126, 1128, 1130, and 1132 in which the cysteine at position 20 of mature human IL-13R ⁇ 1 was mutated to either an alanine or a serine, exhibited less aggregation upon expression, had ⁇ 2 to 3-fold better activity than IL-4/IL-13 Trap 943 in the TF1 bioassay in blocking both IL-4 and IL-13, and exhibited a consistent and homogenous pattern of disulfide formation.
  • the IL-4/IL-13 Trap 1132 molecule had additional advantages over IL-4/IL-13 Traps 1126, 1128, and 1130. A higher percentage of the total protein (>95%) had the correct N-terminal sequence as compared to the IL-4/IL-13 Traps 1126 or 1130 (80-90%). Stoichiometric studies indicated a stoichiometry of 1 for the IL-4/IL-13 Trap 1132 whereas the IL-4/IL-13 Trap 1130 showed a stoichiometry of 1.5.
  • IL-4/IL-13 Trap 1132 molecule has a higher C max (maximal serum concentration) and a longer t 1/2 (serum half-life) than the others.
  • the IgG4 versions of the IL-4/IL-13 Traps containing the cysteine mutations may be preferred if it is desired to reduce the effector functions of the Fc portion of the Traps.
  • the cysteine to serine mutation in IL-4/IL-13 Traps 1126 and 1128 molecules creates a novel N-glycosylation site which may be desirable in certain circumstances.
  • TF1 cells 20,000 cells/well
  • 15 pM recombinant human IL-13 E. coli; Preprotech
  • IL-4/IL-13 Trap 943 or 1132 Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 (E. coli; Preprotech) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ⁇ 3 days at 37° C., 5% CO 2 .
  • MTS was added to each well, incubated at 37° C., 5% CO 2 for 4 hrs. and cell proliferation was measured as OD at 490 nm.
  • FIG. 48 shows the results of this experiment.
  • the IL-4/IL-13 Trap 1132 can block IL-13 more potently than the IL-4/IL-13 Trap 943.
  • IL-4/IL-13 Trap 1132 exhibits an IC 50 of 64 pM as compared to 184 pM for Trap 943.
  • IL-13 was produced and purified from a mammalian cell line (CHO).
  • the CHO-derived human IL-13 was then utilized in the TF1 bioassay to determine the ability of the IL-4/IL-13 Trap to bind and block activity.
  • TF1 cells 20,000 cells/well
  • 40 pM recombinant human IL-4 E. coli; Applicants' own material
  • IL-4/IL-13 Trap 943 or 1132 Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 40 pM recombinant human IL-4 ( E. coli; Applicants' own material) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ⁇ 3 days at 37° C., 5% CO 2 .
  • MTS was added to each well, incubated at 37° C., 5% CO 2 for 4hrs. and cell proliferation was measured as OD at 490 nm.
  • FIG. 49 shows the results of this experiment.
  • the IL-4/IL-13 Trap 1132 can block IL-4 more potently than the IL-4/IL-13 Trap 943.
  • IL-4/IL-13 Trap 1132 exhibits an IC 50 of 95 pM as compared to 222 pM for Trap 9
  • IL-4/IL-13 Trap 1132 displays a higher affinity for Applicants' rhIL13.
  • Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 Applicants' own material (CHO) or Pharmingen ( E. coli ) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ⁇ 3 days at 37° C., 5% CO 2 .
  • MTS was added to each well, incubated at 37° C., 5% CO 2 for 4hrs. and cell proliferation was measured as OD at 490nm.
  • IL-4/IL-13 Trap 1132 has an IC 50 of 16 pM which indicates a Kd of ⁇ 9 pM.
  • IL-4/IL-13 Trap 1132 can block hIL13 more potently than IL-4/IL-13 Trap 943 with Applicants' own rhIL13.
  • Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 (CHO; Applicants' own material) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ⁇ 3 days at 37° C., 5% CO 2 .
  • MTS was added to each well, incubated at 37° C., 5% CO 2 for 4hrs. and cell proliferation was measured as OD at 490 nm.
  • IL-4/IL-13 Trap 1132 has an IC 50 of 17 pM as compared to 33 pM for 943.

Abstract

The present invention provides a fusion polypeptide that forms a multimer that is capable of binding a cytokine to form a nonfunctional complex. It also provides a nucleic acid sequence encoding the fusion polypeptide and methods of making and uses for the fusion polypeptide.

Description

  • This application is a Continuation-in-Part of U.S. application Ser. No. 09/787,835, filed Mar. 22, 2001, which is a §371 U.S. National Stage Application of International Application No. PCT/US99/22045, filed Sep. 22, 1999, which is a Continuation-in-Part of and claims priority of U.S. application Ser. No. 09/313,942, filed May 19, 1999, which claims priority of U.S. Provisional Application No. 60/101,858 filed Sep. 25, 1998, now abandoned. Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application.[0001]
    • BACKGROUND OF THE INVENTION
  • Although discovered for varying biological activities, ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M (OSM) and interleukin-6 (IL-6) comprise a defined family of cytokines (referred to herein as the “CNTF family” of cytokines). These cytokines are grouped together because of their distant structural similarities [Bazan, J. Neuron 7: 197-208 (1991); Rose and Bruce, Proc. Natl. Acad. Sci. USA 88: 8641-8645 (1991)], and, perhaps more importantly, because they share “β” signal-transducing receptor components [Baumann, et al., J. Biol. Chem. 265:19853-19862 (1993); Davis, et al., Science 260: 1805-1808 (1993); Gearing et al., Science 255:1434-1437 (1992); Ip et al., Cell 69: 1121-1132 (1992); Stahl, et al., J. Biol. Chem. 268: 7628-7631 (1993); Stahl and Yancopoulos, Cell 74: 587-590 (1993)]. Receptor activation by this family of cytokines results from either homo- or hetero-dimerization of these β components [Davis, et al. Science 260: 1805-1808 (1993), Murakami, et al., Science 260: 1808-1810 (1993); Stahl and Yancopoulos, Cell 74: 587-590 (1993)]. IL-6 receptor activation requires homodimerization of gp130 [Murakami, et al. Science 260: 1808-1810 (1993), Hibi, et al., Cell 63: 1149-1157 (1990)], a protein initially identified as the IL-6 signal transducer [Hibi, et al., Cell 63:1149-1157 (1990)]. CNTF, LIF and OSM receptor activation results from heterodimerization between gp130 and a second gp130-related protein known as LIFRβ [Davis, et al., Science 260: 1805-1808 (1993)], that was initially identified by its ability to bind LIF [Gearing et al., EMBO J. 10: 2839-2848 (1991)]. [0002]
  • In addition to the β components, some of these cytokines also require specificity-determining “α” components that are more limited in their tissue distribution than the β components, and thus determine the cellular targets of the particular cytokines [Stahl and Yancopoulos, Cell 74: 587-590 (1993)]. Thus, LIF and OSM are broadly acting factors that may only require the presence of gp130 and LIFRβ on responding cells, while CNTF requires CNTFRα [Stahl and Yancopoulos, Cell 74: 587-590 (1993)] and IL-6 requires IL-6Rα [Kishimoto, et al., Science 258: 593-597 (1992)]. Both CNTFRα (Davis et al., Science 259:1736-1739 (1993) and IL-6Rα [Hibi, et al. Cell 63:1149-1157, Murakami, et al., Science 260:1808-1810 (1990); Taga, et al., Cell 58:573-581 (1989)] can function as soluble proteins, consistent with the notion that they do not interact with intracellular signaling molecules but that they serve to help their ligands interact with the appropriate signal transducing β subunits [Stahl and Yancopoulos, Cell 74: 587-590 (1993)]. [0003]
  • Additional evidence from other cytokine systems also supports the notion that dimerization provides a common mechanism by which all cytokine receptors initiate signal transduction. Growth hormone (GH) serves as perhaps the best example in this regard. Crystallographic studies have revealed that each GH molecule contains two distinct receptor binding sites, both of which are recognized by the same binding domain in the receptor, allowing a single molecule of GH to engage two receptor molecules [de Vos, et al., Science 255: 306-312 (1992)]. Dimerization occurs sequentially, with [0004] site 1 on the GH first binding to one receptor molecule, followed by the binding of site 2 to a second receptor molecule [Fuh, et al., Science 256: 1677-1680 (1992)]. Studies with the erythropoietin (EPO) receptor are also consistent with the importance of dimerization in receptor activation, as EPO receptors can be constitutively activated by a single amino acid change that introduces a cysteine residue and results in disulfide-linked homodimers [Watowich, et al., Proc. Natl. Acad. Sci. USA 89:2140-2144 (1992)].
  • In addition to homo- or hetero-dimerization of β subunits as the critical step for receptor activation, a second important feature is that formation of the final receptor complex by the CNTF family of cytokines occurs through a mechanism whereby the ligand successively binds to receptor components in an ordered manner [Davis, et al. Science 260:1805-1818 (1993); Stahl and Yancopoulos, Cell 74: 587-590 (1993)]. Thus CNTF first binds to CNTFRα, forming a complex which then binds gp130 to form an intermediate (called here the αβ1 intermediate) that is not signaling competent because it has only a single β component, before finally recruiting LIFRβ to form a heterodimer of β components which then initiates signal transduction. Although a similar intermediate containing IL-6 bound to IL-6Rα and a single molecule of gp130 has not been directly isolated, we have postulated that it does exist by analogy to its distant relative, CNTF, as well as the fact that the final active IL-6 receptor complex recruits two gp130 monomers. Altogether, these findings led to a proposal for the structure of a generic cytokine receptor complex (FIG. 1) in which each cytokine can have up to 3 receptor binding sites: a site that binds to an optional α specificity-determining component (α site), a site that binds to the first β signal-transducing component (β1 site), and a site that binds to the second β signal-transducing component (β2 site) [Stahl and Yancopoulos, Cell 74: 587-590 (1993)]. These 3 sites are used in sequential fashion, with the last step in complex formation—resulting in β component dimerization—critical for initiating signal transduction [Davis, et al. Science 260:1805-1818 (1993)]. Knowledge of the details of receptor activation and the existence of the non-functional β1 intermediate for CNTF has led to the finding that CNTF is a high affinity antagonist for IL-6 under certain circumstances, and provides the strategic basis for designing ligand or receptor-based antagonists for the CNTF family of cytokines as detailed below. [0005]
  • Once cytokine binding induces receptor complex formation, the dimerization of β components activates intracellular tyrosine kinase activity that results in phosphorylation of a wide variety of substrates [Ip, et al. Cell 69:121-1132 (1992)]. This activation of tyrosine kinase appears to be critical for downstream events since inhibitors that block the tyrosine phosphorylations also prevent later events such as gene inductions [Ip, et al., Cell 69:121-1132 (1992); Nakajima and Wall, Mol. Cell. Biol. 11:1409-1418 (1991)]. Recently, we have demonstrated that a newly discovered family of non-receptor tyrosine kinases that includes Jak1, Jak2, and Tyk2 (referred to as the Jak/Tyk kinases) [Firmbach-Kraft, et al., Oncogene 5:1329-1336 (1990); Wilks, et al., Mol. Cell. Biol. 11: 2057-2065 (1991] and that are involved in signal transduction with other cytokines [Argetsinger, et al., Cell 74:237-244 (1993); Silvennoinen, et al., Proc. Natl. Acad. Sci. USA 90:8429-8433 (1993); Velazquez, et al., Cell 70: 313-322 (1992); Witthuhn, et al., Cell 74:227-236 (1993)], preassociate with the cytoplasmic domains of the β subunits gp130 and LIFRβ in the absence of ligand, and become tyrosine phosphorylated and activated upon ligand addition [Stahl et al., Science 263:92-95 (1994)]. Therefore these kinases appear to be the most proximal step of intracellular signal transduction activated inside the cell as a result of ligand binding outside of the cell. Assay systems for screening collections of small molecules for specific agonist or antagonist activities based on this system are described below. [0006]
  • The CNTF family of cytokines play important roles in a wide variety of physiological processes that provide potential therapeutic applications for both antagonists and agonists. [0007]
    • SUMMARY OF THE INVENTION
  • An object of the present invention is the production of cytokine antagonists that are useful in the treatment of cytokine-related diseases or disorders. [0008]
  • Another object of the invention is the use of the disclosed cytokine antagonists for the treatment of cytokine-related diseases or disorders. For example, an IL-6 antagonist described herein may be used for the treatment of osteoporosis, the primary and second effects of cancers, including multiple myeloma, or cachexia. [0009]
  • Another object of the invention is the development of screening systems useful for identifying novel agonists and antagonists of cytokine receptors. [0010]
  • Another object of the invention is the development of screening systems useful for identifying small molecules that act as agonists or antagonists of the cytokines. [0011]
  • Another object of the invention is the development of screening systems useful for identifying novel agonists and antagonists of members of the CNTF family of cytokines. [0012]
  • Another object of the invention is the development of screening systems useful for identifying small molecules that act as agonists or antagonists of the CNTF family of cytokines.[0013]
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1: Ordered binding of receptor components in a model of a generic cytokine receptor. The model indicates that cytokines contain up to 3 receptor binding sites and interact with their receptor components by binding first the optional α component, followed by binding to β1, and then β2. The β components for many cytokine receptors interact through membrane proximal regions (shaded boxes) with the Jak/Tyk family of cytoplasmic protein tyrosine kinases. Only upon dimerization of β components is signal transduction initiated, as schematized by the tyrosine phosphorylations (P) of the β components and the Jak/Tyk kinases. [0014]
  • FIG. 2: CNTF inhibits IL-6 responses in a PC12 cell line (called PC12D) that expresses IL6Rα, gp130, CNTFRα, but not LIFRβ. Serum-deprived PC12D cells were incubated +IL-6 (50 ng/mL) in the presence or absence of CNTF as indicated. Some plates also received soluble IL6Rα (1 mg/mL) or soluble CNTFRα (1 mg/mL) as indicated. Cell lysates were subjected to immunoprecipitation with anti-gp130 and immunoblotted with anti-phosphotyrosine. Tyrosine phosphorylation of gp130 is indicative of IL-6 induced activation of the IL-6 receptor system, which is blocked upon coaddition of CNTF. [0015]
  • FIG. 3: Scatchard analysis of iodinated CNTF binding on PC12D cells. PC12D cells were incubated with various concentrations of iodinated CNTF in the presence or absence of excess non-radioactive competitor to determine the specific binding. The figure shows a Scatchard plot of the amount of iodinated CNTF specifically bound, and gives data consistent with two binding sites with dissociation constants of 9 pM and 3.4 nM. [0016]
  • FIGS. [0017] 4A and 4B: The amino acid sequence of human gp130-Fc-His6. Amino acids 1 to 619 are from human gp130 (Hibi et al., Cell 63:1149-1157 (1990). Note that amino acid number 2 has been changed from a Leu to a Val in order to accommodate a Kozak sequence in the coding DNA sequence. The signal peptide of gp130-Fc-His6 has been italicized (amino acids 1 to 22). The Ser-Gly bridge is shown in bold type (amino acids 620, 621). Amino acids 662 to 853 are from the Fc domain of human IgG1 (Lewis, et al., J. Immunol. 151:2829-2838 (1993). (+) mark the two cysteines (amino acids number 632 and 635) of the IgG hinge preceding the Fc that form the inter-chain disulfide bridges that link two Fc domains. The hexahistine tag is shown in bold/italic type (amino acids 854 to 859). (.) shows the position of the STOP codon.
  • FIG. 5: The amino acid sequence of human IL-6Rα-Fc. Key: [0018] Amino acids 1 to 358 are from human IL-6Rα (Yamasaki, et al., Science 241:825-828 (1988). Note that amino acid number 2 has been changed from a Leu to a Val in order to accommodate a Kozak sequence in the coding DNA sequence. The signal peptide of IL-6Rα-Fc has been italicized (amino acids 1 to 19). The Ala-Gly bridge is shown in bold type (amino acids 359, 360). Amino acids 361 to 592 are from the Fc domain of human IgG1 (Lewis et al., J. Immunol. 151:2829-2838 (1993). (†) mark the two cysteines (amino acids number 371 and 374) of the IgG hinge preceding the Fc that form the inter-chain disulfide bridges that link two Fc domains. (.) shows the position of the STOP codon.
  • FIG. 6: The CNTF/IL-6/IL-11 receptor system. The ordered formation of the hexameric signal transducing receptor complex is depicted schematically. The cytokine associates with the Rα component to form an obligatory cytokine.Rα complex (Kd is about 5 nM). This low affinity complex next associates with the first signal transducing component, marked β1, to form a high affinity cytokine.Rα.β1 complex (Kd is about 10 pM). In the case of IL-6Rα, this component is gp130. This trimeric high affinity complex subsequently associates with another such complex. Formation of this complex results in signal transduction as it involves dimerization of two signal transducing components, marked β1 and β2 respectively (adapted from (Ward et al., J. Bio. Chem. 269:23286-23289 (1994); Stahl and Yancopoulos, J. Neurobiology 25:1454-1466 (1994); Stahl and Yancopoulos, Cell 74:587-590 (1993). [0019]
  • FIG. 7: Design of heterodimeric receptor-based ligand traps for IL-6. The heterodimeric ligand trap is comprised of two interdisulfide linked proteins, gp130-Fc and IL-6Rα-Fc. The gp130-Fc.IL-6Rα-Fc complex (upper panel) is shown to mimic the high affinity cytokine.Rα.β1 complex (lower panel). The ligand trap functions as an antagonist by sequestering IL-6 and thus rendering unavailable to interact with the native receptors on IL-6-responsive cells. [0020]
  • FIG. 8: Heteromeric immunoglobulin Heavy/Light Chain Receptor Fusions. An example of a heavy/light chain receptor fusion molecule is schematically depicted. The extracellular domain of gp130 is fused to Cγ, whereas the extracellular domain of IL-6Rα is fused to the constant region of the kappa chain (κ). The inter-chain disulfide bridges are also depicted (S-S). [0021]
  • FIGS. [0022] 9A and 9B: Amino acid sequence of gp130-Cγ1. Key: Amino acids 1 to 619 are from human gp130 (Hibi, et al., Cell 63:1149-1157 (1990). Ser-Gly bridge is shown in bold type. Amino acids 662 to 651 are from the constant region of human IgG1 (Lewis et al., J. Immunol. 151:2829-2838 (1993). (*) shows the position of the STOP codon.
  • FIG. 10: Amino acid sequence of gp130Δ3fibro. Key: [0023] Amino acids 1 to 330 are from human gp130 (Hibi et al., Cell 63:1149-1157 (1990). Other symbols as described in FIG. 9.
  • FIG. 11: Amino acid sequence of J-CH1. Key: The Ser-Gly bridge is shown in bold, the J-peptide is shown in italics, the [0024] C H1 domain is underlined.
  • FIG. 12: Amino acid sequence of Cγ4. Key: The Ser-Gly bridge is shown in bold type. [0025] Amino acids 2 to 239 comprise the Cγ4 sequence.
  • FIG. 13: Amino acid sequence of K-domain. Key: The Ser-Gly bridge is shown in bold type. [0026] Amino acids 2 to 108 comprise the κ domain. The C-terminal cysteine (amino acid 108) is that involved in the disulfide bond of the κ domain with the C H1 domain of Cγ.
  • FIG. 14: Amino acid sequence of λ-domain. Key: The Ser-Gly bridge is shown in bold type. [0027] Amino acids 2 to 106 comprise the λ domain (Cheung, et al., J. Virol. 66: 6714-6720 (1992). The C-terminal cysteine (amino acid 106) is that involved in the disulfide bond of the λ domain with the C H1 domain of Cγ.
  • FIG. 15: Amino acid sequence of the soluble IL-6Rα domain. Key: [0028] Amino acids 1 to 358 comprise the soluble IL-6Rα domain (Yamasaki, et al., Science 241:825-828 (1988). The Ala-Gly bridge is shown in bold type.
  • FIG. 16: Amino acid sequence of the soluble IL-6Rα domain: Key: [0029] Amino acids 1 to 313 comprise the truncated IL-6Rα domain (IL-6Rα313). The Thr-Gly bridge is shown in bold type.
  • FIG. 17: Purification of gp130-Cγ1.IL-6Rα-κ. 4% to 12% SDS-PAGE gradient gel run under non-reducing conditions. Proteins were visualized by staining with silver. Lane 1: approximately 100 ng of material purified over Protein A Sepharose (Pharmacia). Lane 2: Molecular size standards (Amersham). Lane 3: The Protein A-purified material shown here after further purification over an IL-6 affinity chromatography step. The positions of the gp130-Cγ1 dimer [(gp130-Cγ1)[0030] 2], the gp130-Cγ1 dimer associated with one IL-6Rα-κ [(gp130-Cγ1)2.(IL-6Rα-κ)1], and the gp130-Cγ1 dimer associated with two IL-6Rα-κ [(gp130-Cγ1)2.(IL-6Rα-κ)2] are shown, as well as the sizes for the molecular size standards in kilodaltons (200, 100, and 46).
  • FIG. 18: IL-6 dissociates slowly from the ligand trap. The dissociation rate of IL-6 from a heavy/light chain receptor-based ligand trap (gp130-Cγ1.IL-6Rα-κ) was compared to that obtained with the neutralizing monoclonal antibody B-E8 (BE8 MAb). [0031]
  • FIG. 19: IL-6 can induce multimerization of the ligand trap. (A) Two different ligand traps are depicted schematically and listed according to their ability to bind protein A. gp130-Fc.IL-6Rα-Fc (GF6F) binds protein A via its Fc-domains, whereas gp130-C[0032] H1.IL-6Rα-κ (G16K) does not bind to protein A. (B) Anti-kappa western blotting of proteins precipitated with Protein A-Sepharose from mixtures of GF6F±IL-6, G16K±IL-6, or GF6F plus G16K±IL-6, as marked.
  • FIG. 20: Inhibition of IL-6-dependent XG-1 cell proliferation. XG-1 cells [Zhang, et al., Blood 83:3654-3663 (1994)] were prepared for a proliferation assay by starving the cells from IL-6 for 5 hours. Assays were set up in 96-well tissue culture dishes in RPMI+10% fetal calf serum+penicillin/streptomycin+0.050 nM 2-mercaptoethanol+glutamine. 0.1 ml of that media was used per well. Cells were suspended at a density of 250,000 per ml at the start of the assay. 72 hours post addition of IL-6±ligands traps or antibodies, an MTT assay was performed as described (Panayotatos et al. Biochemistry 33:5813-5818 (1994). The different ligand traps utilized are listed. [0033]
  • FIGS. [0034] 21A-21D: Nucleotide sequence encoding and deduced amino acid sequence of fusion polypeptide designated 424 which is capable of binding the cytokine IL-4 to form a nonfunctional complex.
  • FIGS. [0035] 22A-22D: Nucleotide sequence encoding and deduced amino acid sequence of fusion polypeptide designated 603 which is capable of binding the cytokine IL-4 to form a nonfunctional complex.
  • FIGS. [0036] 23A-23D: Nucleotide sequence encoding and deduced amino acid sequence of fusion polypeptide designated 622 which is capable of binding the cytokine IL-4 to form a nonfunctional complex.
  • FIGS. [0037] 24A-24F: Nucleotide sequence encoding and deduced amino acid sequence of fusion polypeptide designated 412 which is capable of binding the cytokine IL-6 to form a nonfunctional complex.
  • FIGS. [0038] 25A-25F: Nucleotide sequence encoding and deduced amino acid sequence of fusion polypeptide designated 616 which is capable of binding the cytokine IL-6 to form a nonfunctional complex.
  • FIGS. [0039] 26A-26E: Nucleotide sequence encoding and deduced amino acid sequence of fusion polypeptide designated 569 which is capable of binding the cytokine IL-1 to form a nonfunctional complex.
  • FIG. 27: Shows that an IL-4 trap designated 4SC375, which is a fusion polypeptide of IL-2Rγ-scb-IL4Rα-FcΔC1, is several orders of magnitude better as an IL-4 antagonist than IL4RαFcΔC1 alone in the TF1 cell bioassay. [0040]
  • FIG. 28: Shows that an IL-4 trap designated 4SC375 displays antagonistic activity in the TF1 cell bioassay equivalent to an IL-4 trap designated 4SC424 (described in FIGS. [0041] 21A-21D) which is a fusion polypeptide of IL-2Rγ-IL4Rα-FcΔC1 having the IL-2Rγ component flush with the IL-4Rα component.
  • FIG. 29: Shows that the IL6 trap (6SC412 IL6R-scb-gpx-FcΔC1) described in FIGS. [0042] 24A-24F is a better antagonist of IL-6 in the XG1 bioassay than the neutralizing monoclonal antibody to human IL-6-BE8.
  • FIG. 30: Shows that the trap 1SC569 (described in FIGS. [0043] 26A-26E) is able to antagonize the effects of IL-1 and block the IL-6 production from MRC 5 cells upon treatment with IL-1.
  • FIGS. [0044] 31A-31G: The nucleotide and encoded amino acid sequence of the IL-4Rα.IL-13Rα1.Fc single chain trap construct is set forth.
  • FIGS. [0045] 32A-32G: The nucleotide and encoded amino acid sequence of the IL-13Rα1.IL-4Rα.Fc single chain trap construct is set forth.
  • FIG. 33: Blocking of IL-13 by IL-4Rα.IL-13Rα1.Fc and IL-13Rα1.IL-4Rα.Fc. Addition of either IL-4Rα.IL-13Rα1.Fc or IL-13Rα1.IL-4Rα.Fc trap at a concentration of 10 nM blocks IL-13-induced growth up to ˜2 nM. At an IL-13 concentration of ˜4-5 nM the growth of TF1 cells is inhibited by 50%. [0046]
  • FIG. 34: Blocking of IL-4 by IL-4Rα.IL-13Rα1.Fc and IL-13Rα1.IL-4Rα.Fc. Addition of either IL-4Rα.IL-13Rα1.Fc or IL-13Rα1.IL-4Rα.Fc at a concentration of 10 nM blocks IL-4-induced growth up to ˜1 nM. At an IL-4 concentration of ˜3-4 nM the growth of TF1 cells is inhibited by 50%. [0047]
  • FIG. 35: Human IL-1 trap blocks the in vivo effects of exogenously administered huIL-1. BALB/c mice were given subcutaneous injection of huIL-1 (0.3 μg/kg) at [0048] time 0. Twenty-four hours prior to huIL-1 injection, the animals were pre-treated with either vehicle or 150-fold molar excess of huIL-1 trap. Two hours prior to sacrifice (26 hrs), the mice were re-challenged with a second injection of huIL-1 (0.3 μg/kg, s.c.). Blood samples were collected at various time points and sera were assayed for IL-1 levels (expressed as mean+/−SEM; n=5 per group).
  • FIG. 36A & FIG. 36B: Human IL-4 trap antagonizes the effects of human IL-4 in monkeys. FIG. 36A: Cynomologus monkeys were treated in three parts as indicated. Human IL-4 (25 μg/kg) was injected subcutaneously twice daily for 4 days and human IL-4 trap (8 mg/ml) and vehicle were given intravenously daily for 5 days, beginning 1 day prior to human IL-4 administration. Plasma was collected daily and assayed for MCP-1 levels. Results were expressed as mean+/−SEM; n=4. (ANOVA p<0.0007; Tukey-Kramer: [0049] Part 2 vs. Part 1, p,0.05; Part 2 vs. Part 3, p,0.05; Part 1 vs. Part 3, not significant.) FIG. 36B: Cynomologus monkeys were treated in three parts as indicated. Human IL-4 (25 μg/kg) was injected subcutaneously twice daily for 4 days and human IL-4 trap (8 mg/ml) and vehicle were given intravenously daily for 5 days, beginning 1 day prior to human IL-4 administration. Whole blood was collected daily for flow cytometry analysis for CD16. Results were expressed as mean+/−SEM; n=4. (ANOVA p<0.042; Tukey-Kramer: Part 2 vs. Part 1, p<0.05; Part 2 vs. Part 3 and Part 1 vs. Part 3, not significant.)
  • FIG. 37: Murine IL-4 trap partially prevented IL-4-mediated IgE increase in mice. BALB/C mice injected with anti-mouse IgD (100 μl/mouse, s.c.) were randomly divided into 3 groups, each received (on days 3-5) either vehicle, murine IL-4 trap (1 mg/kg, s.c.), or a monoclonal antibody to mouse IL-4 (1 mg/kg, s.c.). Sera were collected at various time points and assayed for IgE levels. Results were expressed as mean+/−SEM (n=5 per group). (ANOVA p=0.0002; Tukey-Kramer: vehicle vs. IL-4 trap, p<0.01; vehicle vs. IL-4 antibody, p<0.001; IL-4 trap vs. IL-4 antibody, not significant). [0050]
  • FIGS. [0051] 38A-38H: Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 933.
  • FIGS. [0052] 39A-39G: Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 943.
  • FIGS. [0053] 40A-40I: Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1126.
  • FIGS. [0054] 41A-41H: Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1128.
  • FIGS. [0055] 42A-42I: Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1130.
  • FIGS. [0056] 43A-43G: Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1132.
  • FIGS. [0057] 44A-44I: Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1199.
  • FIGS. [0058] 45A-45I: Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1244.
  • FIGS. [0059] 46A-46I: Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1245.
  • FIGS. [0060] 47A-47J: Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1246.
  • FIG. 48: The IL-4/IL-13 [0061] Trap 1132 can block IL-13 more potently than the IL-4/IL-13 Trap 943. Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 (E. coli; Preprotech) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ˜3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4 hrs. and cell proliferation was measured as OD at 490 nm. IL-4/IL-13 Trap 1132 exhibits an IC50 of 64 pM as compared to 184 pM for Trap 943.
  • FIG. 49: The IL-4/IL-13 [0062] Trap 1132 can block IL-4 more potently than the IL-4/IL-13 Trap 943. Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 40 pM recombinant human IL-4 (E. coli; Applicants' own material) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ˜3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4 hrs. and cell proliferation was measured as OD at 490 nm. IL-4/IL-13 Trap 1132 exhibits an IC50 of 95 pM as compared to 222 pM for Trap 943.
  • FIG. 50: IL-4/IL-13 [0063] Trap 1132 displays a higher affinity for Applicants' rhIL13. Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 Applicants' own material (CHO) or Pharmingen (E. coli) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ˜3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4hrs. and cell proliferation was measured as OD at 490 nm. IL-4/IL-13 Trap 1132 has an IC50 of 16 pM which indicates a Kd of ˜9 pM.
  • FIG. 51: IL-4/IL-13 [0064] Trap 1132 can block hIL13 more potently than IL-4/IL-13 Trap 943 with Applicants' rhIL13. Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 (CHO; Applicants' own material) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ˜3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4hrs. and cell proliferation was measured as OD at 490 nm. IL-4/IL-13 Trap 1132 has an IC50 of 17 pM as compared to 33 pM for 943.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex comprising: [0065]
  • a) a nucleotide sequence encoding a first fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the specificity determining component of the cytokine's receptor; [0066]
  • b) a nucleotide sequence encoding a second fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the signal transducing component of the cytokine's receptor; and [0067]
  • c) a nucleotide sequence encoding a third fusion polypeptide component comprising the amino acid sequence of a multimerizing component. [0068]
  • By “cytokine binding portion” what is meant is the minimal portion of the extracellular domain necessary to bind the cytokine. It is accepted by those of skill in the art that a defining characteristic of a cytokine receptor is the presence of the two fibronectin-like domains that contain canonical cysteines and of the WSXWS box (Bazan, J. F., 1990, PNAS 87: 6934-6938). Sequences encoding the extracellular domains of the binding component of the cytokine's receptor and of the signal transducing component of the cytokine's receptor may also be used to create the fusion polypeptide of the invention. [0069]
  • Similarly, longer sequences encoding larger portions of the components of the cytokine's receptor may be used. However, it is contemplated that fragments smaller than the extracellular domain will function to bind the cytokine and therefore, the invention contemplates fusion polypeptides comprising the minimal portion of the extracellular domain necessary to bind the cytokine as the cytokine binding portion. [0070]
  • The invention comprises a “specificity determining component” of a cytokine's receptor and a “signal transducing component” of the cytokine's receptor. Regardless of the nomenclature used to designate a particular component or subunit of a cytokine receptor, one skilled in the art would recognize which component or subunit of a receptor is responsible for determining the cellular target of the cytokine, and thus would know which component constitutes the “specificity determining component.”[0071]
  • Similarly, regardless of the nomenclature used, one of skill in the art would know which component or subunit of a receptor would constitute the “signal transducing component.” As used herein, the “signal transducing component” is a component of the native receptor which is not the specificity determining component and which does not bind or weakly binds the cytokine in the absence of the specificity determining component. In the native receptor, the “signal transducing component” may participate in signaling. [0072]
  • For example, while some cytokine receptors have components designated αand β, the IL-4 receptor has a signal transducing component referred to as IL-2Rγ. However, regardless of what name is associated with that component, one skilled in the art would know which component of the IL-4 receptor is the signal transducing component. Thus to practice the present invention and create a high affinity trap for IL-4, one of skill in the art would create an isolated nucleic acid comprising a nucleotide sequence encoding a first fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the specificity determining component of the IL-4 receptor (IL-4Rα); a nucleotide sequence encoding a second fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the signal transducing component of the IL-4 receptor (IL-2Rγ); and a nucleotide sequence encoding a third fusion polypeptide component comprising the amino acid sequence of a multimerizing component (for example, an Fc domain of IgG) to create a high affinity trap for IL-4. [0073]
  • Some further examples of the receptor components that may be used to prepare cytokine antagonists according to the invention are set forth in Table 1. The Table 1 sets forth, by way of example but not by way of limitation, some of the varied nomenclature used in the scientific literature to describe those components which function as specificity determining components and those which function as signal transducing components of certain cytokine receptors. [0074]
    Specificity determining Signal transducing
    Cytokine Component Component
    Interleukin-1 (IL-1) Type I IL-1R (ref. 8) IL-1R AcP (refs. 8, 11)
    Type II IL-1R (ref. 8)
    IL-1R1 (ref. 11)
    IL-1RII (ref. 11)
    Interleukin-2 (IL-2) α-subunit (ref. 2) β-chain (ref. 3)
    α-chain (ref. 3) β-subunit (ref. 2)
    IL-2Rα (ref. 1) γ-chain (ref. 3)
    IL-2Rβ (refs. 1, 10)
    IL-2Rγ (refs. 1, 10)
    Interleukin-3 (IL-3) IL-3Ra (ref. 1) βc (ref. 1)
    α-subunit (ref. 2) β-subunit (ref. 2)
    α-receptor component β-chain (ref. 3)
    (ref. 5)
    β-receptor component
    (ref. 5)
    Interleukin-4 (IL-4) IL-4R (ref. 1) γ-chain (ref. 3)
    IL-2Rγ (ref. 1)
    Interleukin-5 (IL-5) IL-5Rα (ref. 1) βc (ref. 1)
    α-subunit (ref. 2) β-subunit (ref .2)
    α-receptor component β-chain (ref. 2)
    (ref. 5)
    β-receptor component
    (ref. 5)
    Granulocyte α-receptor component β-receptor component
    macrophage-colony (ref. 5) (ref. 5)
    stimulating factor α-subunit (ref. 2) β-subunit (ref. 2)
    (GM-CSF) GMRα (refs. 1, 2) β-chain (ref. 3)
    βc (ref. 1)
    GMRβ (refs. 1, 2)
    Leukemia inhibitory LIFBP (ref. 1) gp130 (refs. 1, 3)
    factor (LIF) α-receptor component β-receptor component
    (ref. 5) (ref. 5)
    Interleukin-11 α-chain (ref. 4) gp130 (ref. 4)
    (IL-11) NR1 (ref. 4)
    Interleukin-15 IL-15Rα (ref. 10) IL-2Rβ (ref. 10)
    (IL-15) IL-2Rγ (ref. 10)
    Interferon-γ (IFNγ) IFN-γR (ref. 7) AF-1 (ref. 7)
    IFN-γR1 (ref. 7) IFN-γR2 (ref. 7)
    TGFβ Type II (refs. 6, 9) Type I (refs. 6, 9)
  • Only a few of the multitude of references are cited in Table 1, and they are set forth as follows: [0075]
  • 1. Sato and Miyajima, Current Opinions in Cell Biology 6: 174-179 (1994)—See page 176, lines 9-16; [0076]
  • 2. Miyajima, et al., Annual Review of Immunology 10: 295-331 (1992)—See page 295, [0077] line 4 to page 296, line 1; page 305, last paragraph;
  • 3. Kondo, et al, Science 262: 1874-1877 (1993)—See page 1874, cols. 1 & 2; [0078]
  • 4. Hilton, et al, EMBO Journal 13:4765-4775 (1994)—See page 4766, col. 1, [0079] lines 20 24;
  • 5. Stahl and Yancopoulos, Cell 74: 587-590 (1993)—See page 587, [0080] column 2, lines 15-22;
  • 6. Bassing, et al, Journal of Biological Chemistry 269: 14861-14864 (1994)—See page 14861, col. 2, lines 1-9 and 21-28; [0081]
  • 7. Kotenko, et al, Journal of Biological Science 270: 20915-20921 (1995)—See page 20915, lines 1-5 of the abstract; [0082]
  • 8. Greenfeder, et al., Journal of Biological Chemistry 270: 13757-13765 (1995)—See page 13757, col. 1, [0083] line 6 to col. 2, line 3 and col. 2, lines 10-12; page 13764, col. 2, last 3 lines and page 13765, col. 1, lines 1-7;
  • 9. Lebrun and Vale, Molecular Cell Biology 17: 1682-1691 (1997)—See page 1682, Abstract lines 2-6; [0084]
  • 10. Kennedy and Park, Journal of Clinical Immunology 16: 134-143 (1996)—See page 134, lines 1-7 of the abstract; page 136, col 2., lines 1-5; [0085]
  • 11. Wesche, et al., Journal of Biological Chemistry 272: 7727-7731 (1997) See page 7731, lines 20-26. [0086]
  • Kotenko, et al. recently identified the IL-10R2 (IL-10Rβ) chain which is reported to serve as an accessory chain that is essential for the active IL-10 receptor complex and for initiating IL-10 induced signal transduction events (S. V. Kotenko, et al., The EMBO Journal, 1997, Vol. 16: 5894-5903). Additional cytokines and their receptors are described in Appendix II, page A:9 of [0087] Immunobiology The Immune System In Health and Disease, 2nd Edition, by Charles A. Janeway, Jr. and Paul Travers, published by Current Biology Ltd./Garland Publishing Inc., copyright 1996.
  • In preparing the nucleic acid sequence encoding the fusion polypeptide of the invention, the first, second, and third components of the fusion polypeptide are encoded in a single strand of nucleotides which, when expressed by a host vector system, produces a monomeric species of the fusion polypeptide. The monomers thus expressed then multimerize due to the interactions between the multimerizing components (the third fusion polypeptide components). Producing the fusion polypeptides in this manner avoids the need for purification of heterodimeric mixtures that would result if the first and second components were produced as separate molecules and then multimerized. For example, U.S. Pat. No. 5,470,952 issued Nov. 28, 1995 describes the production of heterodimeric proteins that function as CNTF or IL-6 antagonists. The heterodimers are purified from cell lines cotransfected with the appropriate alpha (α) and beta (β) components. Heterodimers are then separated from homodimers using methods such as passive elution from preparative, nondenaturing polyacrylamide gels or by using high pressure cation exchange chromatography. The need for this purification step is avoided by the methods of the present invention. [0088]
  • In addition, PCT International Application WO 96/11213 published Apr. 18, 1996 entitled Dimeric IL-4 Inhibitors states that the applicant has prepared homodimers in which two IL-4 receptors are bound by a polymeric spacer and has prepared heterodimers in which an IL-4 receptor is linked by a polymeric spacer to an IL-2 receptor gamma chain. The polymeric spacer described is polyethylene glycol (PEG). The two receptor components, IL-4R and IL-2Rgamma are separately expressed and purified. Pegylated homodimers and heterodimers are then produced by joining the components together using bi-functional PEG reagents. It is an advantage of the present invention that it avoids the need for such time consuming and costly purification and pegylation steps. [0089]
  • In one embodiment of the invention, the nucleotide sequence encoding the first component is upstream of the nucleotide sequence encoding the second component. In another embodiment of the invention, the nucleotide sequence encoding the first component is downstream of the nucleotide sequence encoding the second component. Further embodiments of the invention may be prepared in which the order of the first, second and third fusion polypeptide components are rearranged. For example, if the nucleotide sequence encoding the first component is designated 1, the nucleotide sequence encoding the second component is designated 2, and the nucleotide sequence of the third component is designated 3, then the order of the components in the isolated nucleic acid of the invention as read from 5′ to 3′ may be any of the following six combinations: 1,2,3; 1,3,2; 2,1,3; 2,3,1; 3,1,2; or 3,2,1. [0090]
  • In further embodiments of the invention, the cytokine bound by the fusion polypeptide may be a member of the hematopoietin family of cytokines selected from the group consisting of interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-9, interleukin-11, interleukin-13, interleukin-15, granulocyte macrophage colony stimulating factor, oncostatin M, leukemia inhibitory factor, and cardiotrophin-1. [0091]
  • In additional embodiments of the invention, the cytokine bound by the fusion polypeptide may be a member of the interferon family of cytokines selected from the group consisting of IFN-gamma, IFN-alpha, and IFN-beta. [0092]
  • In additional embodiments of the invention, the cytokine bound by the fusion polypeptide may be a member of the immunoglobulin superfamily of cytokines selected from the group consisting of B7.1 (CD80) and B7.2 (B70). [0093]
  • In still further embodiments of the invention, the cytokine bound by the fusion polypeptide may be a member of the TNF family of cytokines selected from the group consisting of TNF-alpha, TNF-beta, LT-beta, CD40 ligand, Fas ligand, CD 27 ligand, [0094] CD 30 ligand, and 4-1BBL.
  • In additional embodiments of the invention, the cytokine bound by the fusion polypeptide may be a cytokine selected from the group consisting of interleukin-1, interleukin-10, interleukin-12, interleukin-14, interleukin-18, and MIF. [0095]
  • Because specificity determination and signal transduction occurs by a similar mechanism in the TGF-β/BMP family of cytokines (See D. Kingsley, Genes & Development, 1994, 8: 133-146; J. Wrana, Miner Electrolyte Metab, 24: 120-130 (1998); R. Derynck and X. Feng, Biochimica et Biophysica Acta 1333 (1997) F105-F150; and J. Massague and F. Weis-Garcia, “Serine/threonine Kinase Receptors: Mediators of Transforming Growth Factor Beta Family Signals” In Cancer Surveys, Vol. 27: Cell Signaling, 1996, Imperial Cancer Research Fund) the present invention may be used to produce high affinity antagonists for cytokines that are members of the TGF-β/BMP family. [0096]
  • Therefore, in additional embodiments of the invention, the cytokine bound by the fusion polypeptide may be a member of the TGF-β/BMP family selected from the group consisting of TGF-β1, TGF-β2, TGF-β3, BMP-2, BMP-3a, BMP-3b, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8a, BMP-8b, BMP-9, BMP-10, BMP-11, BMP-15, BMP-16, endometrial bleeding associated factor (EBAF), growth differentiation factor-1 (GDF-1), GDF-2, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-12, GDF-14, mullerian inhibiting substance (MIS), activin-1, activin-2, activin-3, activin-4, and activin-5. [0097]
  • In alternative embodiments of the invention, the specificity determining component, the signal transducing component, or both, may be substituted for by a single chain Fv. A single chain Fv (scFv) is a truncated Fab having only the V region of a heavy chain linked by a stretch of synthetic peptide to a V region of a light chain. See, for example, U.S. Pat. Nos. 5,565,332; 5,733,743; 5,837,242; 5,858,657; and 5,871,907 assigned to Cambridge Antibody Technology Limited incorporated by reference herein. Thus the present invention contemplates, for example, an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex comprising a nucleotide sequence encoding a first fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the specificity determining component of the cytokine's receptor; a nucleotide sequence encoding a second fusion polypeptide component comprising the amino acid sequence of an scFv capable of binding the cytokine at a site different from the site at which the cytokine binding portion of the extracellular domain of the specificity determining component of the cytokine's receptor binds; and a nucleotide sequence encoding a third fusion polypeptide component comprising the amino acid sequence of a multimerizing component. Alternatively, the specificity determining component may be substituted for by a scFv that binds to a site on the cytokine different from the site at which the signal transducing component binds. Thus the invention contemplates an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex comprising a nucleotide sequence encoding a first fusion polypeptide component comprising the amino acid sequence of a scFv that binds to a site on the cytokine different from the site at which the cytokine binding portion of the extracellular domain of the signal transducing component of the cytokine's receptor binds; a nucleotide sequence encoding a second fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the signal transducing component of the cytokine's receptor; and a nucleotide sequence encoding a third fusion polypeptide component comprising the amino acid sequence of a multimerizing component. [0098]
  • In another embodiment, the invention contemplates an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex comprising a nucleotide sequence encoding a first fusion polypeptide component comprising the amino acid sequence of a first scFv that binds to a site on the cytokine; a nucleotide sequence encoding a second fusion polypeptide component comprising the amino acid sequence a second scFv that binds to a site on the cytokine different from the site at which the first scFv binds; and a nucleotide sequence encoding a third fusion polypeptide component comprising the amino acid sequence of a multimerizing component. [0099]
  • In all of the above described embodiments comprising scFv's, the invention also contemplates embodiments in which the nucleotide sequence encoding the first component is upstream of the nucleotide sequence encoding the second component; embodiments in which the nucleotide sequence encoding the first component is downstream of the nucleotide sequence encoding the second component; and further embodiments of the invention in which the order of the first, second and third fusion polypeptide components is rearranged. For example, if the nucleotide sequence encoding the first component is designated 1, the nucleotide sequence encoding the second component is designated 2, and the nucleotide sequence of the third component is designated 3, then the order of the components in the isolated nucleic acid of the invention as read from 5′ to 3′ may be any of the following six combinations: 1,2,3; 1,3,2; 2,1,3; 2,3,1; 3,1,2; or 3,2,1. [0100]
  • In preferred embodiments of the invention, the multimerizing component comprises an immunoglobulin derived domain. More specifically, the immunoglobulin derived domain may be selected from the group consisting of the Fc domain of IgG, the heavy chain of IgG, and the light chain of IgG. In another embodiment, the multimerizing component may be an Fc domain from which the first five amino acids (including a cysteine) have been removed to produce a multimerizing component referred to as Fc(ΔC1). Alternatively, the multimerizing component may be an Fc domain in which a cysteine within the first five amino acids has been substituted for by another amino acid such as, for example, serine or alanine. [0101]
  • The present invention also provides for fusion polypeptides encoded by the isolated nucleic acid molecules of the invention. Preferably, the fusion polypeptides are in multimeric form, due to the function of the third multimerizing component. In a preferred embodiment, the multimer is a dimer. Suitable multimerizing components are sequences encoding an immunoglobulin heavy chain hinge region (Takahashi et al., 1982, Cell 29:671-679); immunoglobulin gene sequences, and portions thereof. In a preferred embodiment of the invention, immunoglobulin gene sequences, especially one encoding the Fc domain, are used to encode the third multimerizing component. [0102]
  • The present invention also contemplates a vector which comprises the nucleic acid molecule of the invention as described herein. [0103]
  • Also provided is an expression vector comprising a nucleic acid molecule of the invention as described herein, wherein the nucleic acid molecule is operatively linked to an expression control sequence. Also provided is a host-vector system for the production of a fusion polypeptide which comprises the expression vector of the invention which has been introduced into a host cell suitable for expression of the fusion polypeptide. The suitable host cell may be a bacterial cell such as [0104] E. coli, a yeast cell, such as Pichia pastoris an insect cell, such as Spodoptera frugiperda, or a mammalian cell, such as a COS, CHO, 293, BHK or NSO cell.
  • The present invention also provides for methods of producing the fusion polypeptides of the invention by growing cells of the host-vector systems described herein, under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced. [0105]
  • The present invention provides novel antagonists which are based on receptor components that are shared by cytokines such as the CNTF family of cytokines. [0106]
  • The invention described herein contemplates the production of antagonists to any cytokine that utilizes an α specificity determining component which, when combined with the cytokine, binds to a first β signal transducing component to form a nonfunctional intermediate which then binds to a second β signal transducing component causing β-receptor dimerization and consequent signal transduction. According to the invention, the soluble α specificity determining component of the receptor (sRα) and the extracellular domain of the first β signal transducing component of the cytokine receptor (β1) are combined to form heterodimers (sRα:β1) that act as antagonists to the cytokine by binding the cytokine to form a nonfunctional complex. [0107]
  • As described in Example 1, CNTF and IL-6 share the β1 receptor component gp130. The fact that CNTF forms an intermediate with CNTFRα and gp130 can be demonstrated (Example 1) in cells lacking LIFRβ, where the complex of CNTF and CNTFRα binds gp130, and prevents homodimerization of gp130 by IL-6 and IL-6Rα, thereby blocking signal transduction. These studies provide the basis for the development of the IL-6 antagonists described herein, as they show that if, in the presence of a ligand, a nonfunctional intermediate complex, consisting of the ligand, its α receptor component and its β1 receptor component, can be formed, it will effectively block the action of the ligand. Other cytokines may use other β1 receptor components, such as LIFRβ, which may also be used to produce antagonists according to the present invention. [0108]
  • Thus for example, in one embodiment of the invention, effective antagonists of IL-6 or CNTF consist of heterodimers of the extracellular domains of the α specificity determining components of their receptors (sIL-6Rα and sCNTFRα, respectively) and the extracellular domain of gp130. The resultant heterodimers, which are referred to hereinafter as sIL-6Rα:β1 and sCNTFRα:β1, respectively, function as high-affinity traps for IL-6 or CNTF, respectively, thus rendering the cytokine inaccessible to form a signal transducing complex with the native membrane-bound forms of their receptors. [0109]
  • Although soluble ligand binding domains from the extracellular portion of receptors have proven to be somewhat effective as traps for their ligands and thus act as antagonists [Bargetzi, et al., Cancer Res. 53:4010-4013 (1993); , et al., Proc. Natl. Acad. Sci. USA 89: 8616-8620 (1992); Mohler, et al., J. Immunol. 151: 1548-1561 (1993); Narazaki, et al., Blood 82: 1120-1126 (1993)], the IL-6 and CNTF receptors are unusual in that the α receptor components constitute ligand binding domains that, in concert with their ligands, function effectively in soluble form as receptor agonists [Davis, et al. Science 259:1736-1739 (1993); Taga, et al., Cell 58: 573-581 (1989)]. The sRα:β1 heterodimers prepared according to the present invention provide effective traps for their ligands, binding these ligands with affinities in the picomolar range (based on binding studies for CNTF to PC12D cells) without creating functional intermediates. The technology described herein may be applied to develop a cytokine trap for any cytokine that utilizes an α-component that confers specificity, as well as a β component which, when bound to the α-specificity component, has a higher affinity for the cytokine than either component alone. Accordingly, antagonists according to the invention include antagonists of [0110] interleukins 1 through 5 [IL-1, Greenfeder, et al. J. Biol. Chem. 270:13757-13765 (1995); Guo, et al. J. Biol. Chem. 270:27562-27568 (1995)], IL-2; [Taniguchi, et al. European Patent Nos. 0386289-A and 0386304-A (1990); Takeshita, et al. Science 257:379-382 (1992)]; IL-3; [Kitamura, et al. Cell 66:1165-1174 (1991)], IL-4; [Idzerda, et al. J. Exp. Med. 171:861-873 (1990)], IL-5; [Taverneir, et al. Cell 66:1175-1184 (1991)], IL-11 [(Cherel, et al. Direct Submission to EMBL/GenBank/DDBJ databases; accession No. Z38102)], interleukin 15 [IL-15; Hemar, et al. J. Cell Biol. 1295:55-64 (1995); Taniguchi, et al. European Patent Nos. 0386289-A and 0386304-A (1990); Takeshita, et al. Science 257:379-382 (1992)], granulocyte-macrophage colony stimulating factor [GM-CSF; Hayashida, et al. Proc. Natl. Acad. Sci. U.S.A. 97:9655-9659 (1990)], LIF, gamma interferon [IFNγ; Aguet, et al. Cell 55:273-280 (1988); Soh, et al. Cell 76:793-802 (1994)], and transforming growth factor beta [TGFβ; Inagaki, et al. Proc. Natl. Acad. Sci. USA 90:5359-5363 (1993)].
  • The α and β receptor extracellular domains may be prepared using methods known to those skilled in the art. The CNTFRα receptor has been cloned, sequenced and expressed [Davis, et al. (1991) Science 253:59-63 which is incorporated by reference in its entirety herein]. The cloning of LIFRβ and gp130 are described in Gearing et al. in EMBO J. 10:2839-2848 (1991), Hibi, et al. Cell 63:1149-1157 (1990) and in published PCT application WO 93/10151 published May 27, 1993, all of which are incorporated by reference in their entirety herein. [0111]
  • The receptor molecules useful for practicing the present invention may be prepared by cloning and expression in a prokaryotic or eukaryotic expression system. The recombinant receptor gene may be expressed and purified utilizing any number of methods. The gene encoding the factor may be subcloned into a bacterial expression vector, such as for example, but not by way of limitation, pCP110. [0112]
  • The recombinant factors may be purified by any technique which allows for the subsequent formation of a stable, biologically active protein. For example, and not by way of limitation, the factors may be recovered from cells either as soluble proteins or as inclusion bodies, from which they may be extracted quantitatively by 8M guanidinium hydrochloride and dialysis. In order to further purify the factors, conventional ion exchange chromatography, hydrophobic interaction chromatography, reverse phase chromatography or gel filtration may be used. [0113]
  • The sRα:β heterodimeric receptors may be engineered using known fusion regions, as described in published PCT application WO 93/10151 published May 27, 1993 entitled “Receptor for Oncostatin M and Leukemia Inhibitory Factor” which describes production of β receptor heterodimers, or they may be prepared by crosslinking of extracellular domains by chemical means. The domains utilized may consist of the entire extracellular domain of the α and β components, or they may consist of mutants or fragments thereof that maintain the ability to form a complex with its ligand and other components in the sRα:β1 complex. For example, as described below in Example 4, IL-6 antagonists have been prepared using gp130 that is lacking its three fibronectin-like domains. [0114]
  • In one embodiment of the invention, the extracellular domains are engineered using leucine zippers. The leucine zipper domains of the human transcription factors c-jun and c-fos have been shown to form stable heterodimers [Busch and Sassone-Corsi, Trends Genetics 6: 36-40 (1990); Gentz, et al., Science 243:1695-1699 (1989)] with a 1:1 stoichiometry. Although jun-jun homodimers have also been shown to form, they are about 1000-fold less stable than jun-fos heterodimers. Fos-fos homodimers have not been detected. [0115]
  • The leucine zipper domain of either c-jun or c-fos are fused in frame at the C-terminus of the soluble or extracellular domains of the above mentioned receptor components by genetically engineering chimeric genes. The fusions may be direct or they may employ a flexible linker domain, such as the hinge region of human IgG, or polypeptide linkers consisting of small amino acids such as glycine, serine, threonine or alanine, at various lengths and combinations. Additionally, the chimeric proteins may be tagged by His-His-His-His-His-His (His6), [SEQ. ID NO. 1] to allow rapid purification by metal-chelate chromatography, and/or by epitopes to which antibodies are available, to allow for detection on western blots, immunoprecipitation, or activity depletion/blocking in bioassays. [0116]
  • In another embodiment, as described below in Example 3, the sRα:β1 heterodimer is prepared using a similar method, but using the Fc-domain of human IgG1 [Aruffo, et al., Cell 67:35-44 (1991)]. In contrast to the latter, formation of heterodimers must be biochemically achieved, as chimeric molecules carrying the Fc-domain will be expressed as disulfide-linked homodimers. Thus, homodimers may be reduced under conditions that favor the disruption of inter-chain disulfides but do not effect intra-chain disulfides. Then monomers with different extracellular portions are mixed in equimolar amounts and oxidized to form a mixture of homo- and heterodimers. The components of this mixture are separated by chromatographic techniques. Alternatively, the formation of this type of heterodimers may be biased by genetically engineering and expressing molecules that consist of the soluble or extracellular portion of the receptor components followed by the Fc-domain of hIgG, followed by either the c-jun or the c-fos leucine zippers described above [Kostelny, et al., J. Immunol. 148: 1547-1553 (1992)]. Since these leucine zippers form predominately heterodimers, they may be used to drive formation of the heterodimers where desired. As for the chimeric proteins described using leucine zippers, these may also be tagged with metal chelates or an epitope. This tagged domain can be used for rapid purification by metal-chelate chromatography, and/or by antibodies, to allow for detection on western blots, immunoprecipitation, or activity depletion/blocking in bioassays. [0117]
  • In additional embodiments, heterodimers may be prepared using other immunoglobulin derived domains that drive the formation of dimers. Such domains include, for example, the heavy chains of IgG (Cγ1 and Cγ4), as well as the constant regions of kappa (κ) and lambda (λ) light chains of human immunoglobulins. The heterodimerization of Cγ with the light chain occurs between the CH1 domain of Cγ and the constant region of the light chain (C[0118] L), and is stabilized by covalent linking of the two domains via a single disulfide bridge. Accordingly, as described in Example 4, constructs may be prepared using these immunoglobulin domains. Alternatively, the immunoglobulin domains include domains that may be derived from T cell receptor components which drive dimerization. In another embodiment of the invention, the sRα:β1 heterodimers are prepared by expression as chimeric molecules utilizing flexible linker loops. A DNA construct encoding the chimeric protein is designed such that it expresses two soluble or extracellular domains fused together in tandem (“head to head”) by a flexible loop. This loop may be entirely artificial (e.g. polyglycine repeats interrupted by serine or threonine at a certain interval) or “borrowed” from naturally occurring proteins (e.g. the hinge region of hIgG). molecules may be engineered in which the order of the soluble or extracellular domains fused is switched (e.g. sIL6Rα/loop/sgp130 or sgp130/loop/sIL-6Rα) and/or in which the length and composition of the loop is varied, to allow for selection of molecules with desired characteristics.
  • Alternatively, the heterodimers made according to the present invention may be purified from cell lines cotransfected with the appropriate α and β components. Heterodimers may be separated from homodimers using methods available to those skilled in the art. For example, limited quantities of heterodimers may be recovered by passive elution from preparative, nondenaturing polyacrylamide gels. Alternatively, heterodimers may be purified using high pressure cation exchange chromatography. Excellent purification has been obtained using a Mono S cation exchange column. [0119]
  • In addition to sRα:β1 heterodimers that act as antagonists by binding free CNTF or IL-6, the present invention also contemplates the use of engineered, mutated versions of IL-6 with novel properties that allow it to bind to IL-6Rα and a single gp130 molecule, but fail to engage the second gp130 to complete β component homodimerization, and thus act as an effective IL-6 antagonist on any IL-6 responsive cell. Our model for the structure of the IL-6 and CNTF receptor complexes indicates that these cytokines have distinct sites for binding the α, β1, and β2 receptor components [Stahl and Yancopoulos, Cell 74: 587-590 (1993)]. Mutations of critical amino acid residues comprising each of these sites gives rise to novel molecules which have the desired antagonistic properties. Ablation of the β1 site would give a molecule which could still bind to the α receptor component but not the β1 component, and thereby comprise an antagonist with nanomolar affinity. Mutations of critical amino acid residues comprising the β2 site of IL-6 (IL-6β2-) would give a molecule that would bind to IL-6Rα and the first gp130 monomer, but fail to engage the second gp130 and thus be functionally inactive. Similarly, mutations of the CNTF β2 site would give a molecule (CNTFβ2-) that would bind CNTFRα and gp130, but fail to engage LIFRβ, thereby antagonizing CNTF action by forming the non-functional β1 intermediate. Based on the binding results described above where CNTF forms the P1 intermediate with high affinity, both CNTFβ2- and IL-6β2-would constitute antagonists with affinity in the range of 10 pM. [0120]
  • A variety of means are used to generate and identify mutations of IL-6 or CNTF that have the desired properties. Random mutagenesis by standard methods of the DNA encoding IL-6 or CNTF may be used, followed by analysis of the collection of products to identify mutated cytokines having the desired novel properties as outlined below. Mutagenesis by genetic engineering has been used extensively in order to elucidate the structural organization of functional domains of recombinant proteins. Several different approaches have been described in the literature for carrying out deletion or substitution mutagenesis. The most successful appear to be alanine scanning mutagenesis [Cunningham and Wells (1989), Science 244: [0121]
  • [0122] 1081-1085] and homolog-scanning mutagenesis [Cunningham, et al., (1989), Science 243:1330-1336].
  • Targeted mutagenesis of the IL-6 or CNTF nucleic acid sequences using such methods can be used to generate CNTFβ2- or IL-6β2-candidates. The choice of regions appropriate for targeted mutagenesis is done systematically, or determined from studies whereby panels of monoclonal antibodies against each factor are used to map regions of the cytokine that might be exposed after binding of the cytokine to the a receptor component alone, or to the αβ1 heterodimeric soluble receptors described above. Similarly, chemical modification or limited proteolysis of the cytokine alone or in a complex bound to the α receptor component or the αβ1 heterodimeric soluble receptors described above, followed by analysis of the protected and exposed regions could reveal potential β2 binding sites. [0123]
  • Assays for identifying CNTF or IL-6 mutants with the desired properties involve the ability to block with high affinity the action of IL-6 or CNTF on appropriately responsive cell lines [Davis, et al., Science 259: 1736-1739 (1993); Murakami, et al., Proc. Natl. Acad. Sci. USA 88:11349-11353 (1991)]. Such assays include cell proliferation, survival, or DNA synthesis driven by CNTF or IL-6, or the construction of cell lines where binding of factor induces production of reporters such as CAT or β-galactosidase [Savino, et al., Proc. Natl. Acad. Sci. USA 90:4067-4071 (1993)]. [0124]
  • Alternatively, the properties of various mutants may be assessed with a receptor-based assay. One such assay consists of screening mutants for their ability to bind the sRα:β1 receptor heterodimers described above using epitope-tagged [Davis et al., Science 253: 59-63 (1991)] sRα:β1 reagents. Furthermore, one can probe for the presence or absence of the β2 site by assessing whether an epitope-tagged soluble β2 reagent will bind to the cytokine in the presence of the β1 heterodimer. For example, CNTF only binds to LIFRβ (the β2 component) in the presence of both CNTFRα and gp130 [Davis, et al. Science 260:1805-1808 (1993); Stahl, et al. J. Biol. Chem. 268: 7628-7631 (1993)]. Thus a soluble LIFRβ reagent would only bind to CNTF in the presence of the soluble sRα:β1 dimer sCNTFRα:β1. For IL-6, the sRα:β1 reagent would be IL-6Rα:β1, and the probe for the β2 site would be epitope-tagged sgp130. Thus β2-mutants of CNTF would be identified as those that bound the sRα:β1 reagent, demonstrating that the α and β31 site of the cytokine were intact, yet failed to bind the β2 reagent. [0125]
  • In addition, the present invention provides for methods of detecting or measuring the activity of potential β2-mutants by measuring the phosphorylation of a β-receptor component or a signal transduction component selected from the group consisting of Jak1, Jak2 and Tyk2 or any other signal transduction component, such as the CLIPs, that are determined to be phosphorylated in response to a member of the CNTF family of cytokines. [0126]
  • A cell that expresses the signal transduction component(s) described herein may either do so naturally or be genetically engineered to do so. For example, Jak1 and Tyk-2-encoding nucleic acid sequences obtained as described in Velazquez, et al., Cell, Vol. 70:313-322 (1992), may be introduced into a cell by transduction, transfection, microinjection, electroporation, via a transgenic animal, etc., using any known method known in the art. [0127]
  • According to the invention, cells are exposed to a potential antagonist and the tyrosine phosphorylation of either the β-component(s) or the signal transduction component(s) are compared to the tyrosine phosphorylation of the same component(s) in the absence of the potential antagonist. In another embodiment of the invention, the tyrosine phosphorylation that results from contacting the above cells with the potential antagonist is compared to the tyrosine phosphorylation of the same cells exposed to the parental CNTF family member. In such assays, the cell must either express the extracellular receptor (α-component) or the cells may be exposed to the test agent in the presence of the soluble receptor component. Thus, for example, in an assay system designed to identify agonists or antagonists of CNTF, the cell may express the α-component CNTFRα, the β-components gp130 and LIFRβ and a signal transducing component such as Jak1. The cell is exposed to test agents, and the tyrosine phosphorylation of either the β-components or the signal transducing component is compared to the phosphorylation pattern produced in the presence of CNTF. Alternatively, the tyrosine phosphorylation which results from exposure to a test agent is compared to the phosphorylation which occurs in the absence of the test agent. Alternatively, an assay system, for example, for IL-6 may involve exposing a cell that expresses the β-component gp130 and a signal transducing protein such as Jak1, Jak2 or Tyk2 to a test agent in conjunction with the soluble IL-6 receptor. [0128]
  • In another embodiment of the invention the above approaches are used to develop a method for screening for small molecule antagonists that act at various steps in the process of ligand binding, receptor complex formation, and subsequent signal transduction. Molecules that potentially interfere with ligand-receptor interactions are screened by assessing interference of complex formation between the soluble receptors and ligand as described above. Alternatively, cell-based assays in which IL-6 or CNTF induce response of a reporter gene are screened against libraries of small molecules or natural products to identify potential antagonists. Those molecules showing antagonist activity are rescreened on cell-based assays responding to other factors (such as GM-CSF or factors like Neurotrophin-3 that activate receptor tyrosine kinases) to evaluate their specificity against the CNTF/IL-6/OSM/LIF family of factors. Such cell-based screens are used to identify antagonists that inhibit any of numerous targets in the signal transduction process. [0129]
  • In one such assay system, the specific target for antagonists is the interaction of the Jak/Tyk family of kinases [Firmbach-Kraft, Oncogene 5: 1329-1336 (1990); Wilks, et al., Mol. Cell. Biol. 11:2057-2065 (1991)] with the receptor β subunits. As described above, LIFRβ and gp130 preassociate with members of the Jak/Tyk family of cytoplasmic protein tyrosine kinases, which become activated in response to ligand-induced β component dimerization Stahl, et al. Science 263:92-95 (1993). Thus small molecules that could enter the cell cytoplasm and disrupt the interaction between the β component and the Jak/Tyk kinase could potentially block all subsequent intracellular signaling. Such activity could be screened with an in vitro scheme that assessed the ability of small molecules to block the interaction between the relevant binding domains of purified β component and Jak/Tyk kinase. Alternatively, one could easily screen for molecules that could inhibit a yeast-based assay of β component binding to Jak/Tyk kinases using the two-hybrid interaction system [Chien, et al., Proc. Natl. Acad. Sci. 88: 9578-9582 (1991)]. In such a system, the interaction between two proteins (β component and Jak/Tyk kinase or relevant domains thereof in this example) induces production of a convenient marker such as β- galactosidase. Collections of small molecules are tested for their ability to disrupt the desired interaction without inhibiting the interaction between two control proteins. The advantage of this screen would be the requirement that the test compounds enter the cell before inhibiting the interaction between the P component and the Jak/Tyk kinase. [0130]
  • The CNTF family antagonists described herein either bind to, or compete with the cytokines CNTF and IL-6. Accordingly, they are useful for treating diseases or disorders mediated by CNTF or IL-6. For example, therapeutic uses of IL-6 antagonists would include the following: [0131]
  • 1) In osteoporosis, which can be exacerbated by lowering of estrogen levels in post-menopausal women or through ovariectomy, IL-6 appears to be a critical mediator of osteoclastogenesis, leading to bone resorption [Horowitz, Science 260: 626-627 (1993); Jilka, et al., Science 257: 88-91 (1992)]. Importantly, IL-6 only appears to play a major role in the estrogen-depleted state, and apparently is minimally involved in normal bone maintenance. Consistent with this, experimental evidence indicates that function-blocking antibodies to IL-6 can reduce the number of osteoclasts [Jilka, et al. Science 257: 88-91 (1992)]. While estrogen replacement therapy is also used, there appear to be side effects that may include increased risk of endometrial and breast cancer. Thus, IL-6 antagonists as described herein would be more specific to reduce osteoclastogenesis to normal levels. [0132]
  • 2) IL-6 appears to be directly involved in multiple myeloma by acting in either an autocrine or paracrine fashion to promote tumor formation [van Oers, et al., Ann Hematol. 66: 219-223 (1993)]. Furthermore, the elevated IL-6 levels create undesirable secondary effects such as bone resorption, hypercalcemia, and cachexia; in limited studies function-blocking antibodies to IL-6 or IL-6Ra have some efficacy [Klein, et al., Blood 78: 1198-1204 (1991); Suzuki, et al., Eur. J. Immunol. 22:1989-1993 (1992)]. Therefore, IL-6 antagonists as described herein would be beneficial for both the secondary effects as well as for inhibiting tumor growth. [0133]
  • 3) IL-6 may be a mediator of tumor necrosis factor (TNF) that leads to cachexia associated with AIDS and cancer [Strassmann, et al., J. Clin. Invest. 89: 1681-1684 (1992)], perhaps by reducing lipoprotein lipase activity in adipose tissue [Greenberg, et al., Cancer Research 52: 4113-4116 (1992)]. Accordingly, antagonists described herein would be useful in alleviating or reducing cachexia in such patients. [0134]
  • Effective doses useful for treating these or other CNTF family related diseases or disorders may be determined using methods known to one skilled in the art [see, for example, Fingl, et al., The Pharmacological Basis of Therapeutics, Goodman and Gilman, eds. Macmillan Publishing Co., New York, pp. 1-46 ((1975)]. Pharmaceutical compositions for use according to the invention include the antagonists described above in a pharmacologically acceptable liquid, solid or semi-solid carrier, linked to a carrier or targeting molecule (e.g., antibody, hormone, growth factor, etc.) and/or incorporated into liposomes, microcapsules, and controlled release preparation (including antagonist expressing cells) prior to administration in vivo. For example, the pharmaceutical composition may comprise one or more of the antagonists in an aqueous solution, such as sterile water, saline, phosphate buffer or dextrose solution. Alternatively, the active agents may be comprised in a solid (e.g. wax) or semi-solid (e.g. gelatinous) formulation that may be implanted into a patient in need of such treatment. The administration route may be any mode of administration known in the art, including but not limited to intravenously, intrathecally, subcutaneously, by injection into involved tissue, intraarterially, intranasally, orally, or via an implanted device. [0135]
  • Administration may result in the distribution of the active agent of the invention throughout the body or in a localized area. For example, in some conditions which involve distant regions of the nervous system, intravenous or intrathecal administration of agent may be desirable. In some situations, an implant containing active agent may be placed in or near the lesioned area. Suitable implants include, but are not limited to, gelfoam, wax, or microparticle-based implants. [0136]
    • EXAMPLES Example 1 CNTF Competes with IL-6 for Binding to GP130
  • Materials and Methods [0137]
  • Materials. A clone of PC12 cells that respond to IL-6 (PC12D) was obtained from DNAX. Rat CNTF was prepared as described [Masiakowski, et al., J. Neurochem. 57:1003-10012 (1991)]. IL-6 and sIL-6Rα were purchased from R & D Systems. Antisera was raised in rabbits against a peptide derived from a region near the C-terminus of gp130 (sequence: CGTEGQVERFETVGME) [SEQ. ID. NO. 2] by the method described (Stahl, et al. J. Biol. Chem. 268:7628-7631 (1993). Anti-phosphotyrosine monoclonal 4G10 was purchased from UBI, and reagents for ECL from Amersham. [0138]
  • Signal Transduction Assays. Plates (10 cm) of PC12D were starved in serum-free medium ([0139] RPMI 1640+glutamine) for 1 hour, then incubated with IL-6 (50 ng/mL) +sIL-6R (1 mg/mL) in the presence or absence of added rat CNTF at the indicated concentrations for 5 minutes at 37° C. Samples were then subjected to anti-gp130 immunoprecipitation, SDS PAGE, and anti-phosphotyrosine immunoblotting as described (Stahl, et al. J. Biol. Chem. 268:7628-7631 (1993).
  • Results [0140]
  • The ability of CNTF to block IL-6 responses was measured using a PC12 cell line (called PC12D) that expresses IL-6Rα, gp130, and CNTFRα, but not LIFRβ. As one would predict, these cells respond to IL-6, but not to CNTF (FIG. 2) since LIFRβ is a required component for CNTF signal transduction [Davis, et al., Science 260: 59-63 (1993)]. In accordance with results on other cell lines [Ip, et al., Cell 69:1121-1132 (1992)], PC12D cells give tyrosine phosphorylation of gp130 (as well as a variety of other proteins called CLIPs) in response to 2 nM IL-6 (FIG. 2). Addition of recombinant soluble IL-6Rα (sIL-6Rα) enhances the level of gp130 tyrosine phosphorylation, as has been reported in some other systems [(Taga, et al., Cell 58: 573-581 (1989)]. However, addition of 2 nM CNTF simultaneously with IL-6 severely diminishes the tyrosine phosphorylation of gp130. Although a slight gp130 phosphorylation response remains in the presence of CNTF, IL-6, and sIL-6Rα, it is eliminated if the CNTF concentration is increased fourfold to 8 nM. Thus, in IL-6 responsive cells that contain CNTFRα but no LIFRβ, CNTF is a rather potent antagonist of IL-6 action. [0141]
    • Example 2 Binding of CNTF to the CNTFRα:β
  • Materials and Methods [0142]
  • Scatchard Analysis of CNTF Binding. [0143] 125I-CNTF was prepared and purified as described [Stahl et al. JBC 268: 7628-7631 (1993)]. Saturation binding studies were carried out in PC12 cells, using concentrations of 125I-CNTF ranging from 20 pM to 10 nM. Binding was performed directly on a monolayer of cells. Medium was removed from wells and cells were washed once with assay buffer consisting of phosphate buffered saline (PBS; pH 7.4), 0.1 mM bacitracin, 1 mM PMSF, 1 mg/ml leupeptin, and 1 mg/ml BSA. Cells were incubated in 125I-CNTF for 2 hours at room temperature, followed by 2 quick washes with assay buffer. Cells were lysed with PBS containing 1% SDS and counted in a Packard Gamma Counter at 90-95% efficiency. Non-specific binding was defined by the presence of 100-fold excess of unlabelled CNTF. Specific binding ranged from 70% to 95%.
  • Results [0144]
  • The equilibrium constant for binding of CNTF to CNTFRα:β1 was estimated from Scatchard analysis of iodinated CNTF binding on PC12D cells (FIG. 3). The data is consistent with a 2 site fit having dissociation constants of 9 pM and 3.4 nM. The low affinity site corresponds to interaction of CNTF with CNTFRα, which has a Kd near 3 nM [(Panayotatos, et al., J. Biol. Chem. 268: 19000-19003 (1993)]. We interpret the high affinity complex as the intermediate containing CNTF, CNTFRα, and gp130. A Ewing sarcoma cell line (EW-1) which does contain CNTFRα, gp130, and LIFRβ, and therefore gives robust tyrosine phosphorylation in response to CNTF, displays a very similar two site fit with dissociation constants of 1 nM and 10. Thus it is apparent that CNTF binds with equally high affinity to a complex containing only CNTFRα and gp130, as it does to a complex which additionally contains LIFRβ, thus demonstrating the feasibility of creating the sRα:β antagonists described herein. [0145]
    • Example 3 Methods of Producing Cytokine Ligand Traps
  • Virus Stock Production [0146]
  • SF21 insect cells obtained from [0147] Spodoptera frugiperda were grown at 27° C. in Gibco SF900 II medium to a density of 1×106 cells/mL. The individual virus stock for either GP130-Fc-His6 (FIGS. 4A and 4B) or IL6Ra-Fc (FIG. 5) was added to the bioreactor to a low multiplicity 0.01-0.1 PFU/cell to begin the infection. The infection process was allowed to continue for 5-7 days allowing maximum virus replication without incurring substantial cell lysis. The cell suspension was aseptically aliquoted into sterile centrifuge bottles and the cells removed by centrifugation. The cell-free supernatant was collected in sterile bottles and stored at 4° C. until further use.
  • The virus titer was determined by plaque assay as described by O'Reilly, Miller and Luckow. The method is carried out in 60 mm tissue-culture dishes which are seeded with 2×10[0148] 6 cells. Serial dilutions of the virus stock are added to the attached cells and the mixture incubated with rocking to allow the virus to adsorb to individual cells. An agar overlay is added and plates incubated for 5-7 days at 27° C. Staining of viable cells with neutral red revealed circular plaques resulting which were counted to give the virus titer.
  • Coinfection of Cells for Protein Production [0149]
  • Uninfected SF21 Cells were grown in a 60L ABEC bioreactor containing 40 L of SF900 II medium. Temperature was controlled at 27° C. and the dissolved oxygen level was maintained at 50% of saturation by controlling the flowrate of oxygen in the inlet gas stream. When a density of 2×10[0150] 6 cells/mL was reached, the cells were concentrated within the bioreactor to a volume of 20 L using a low shear steam sterilizable pump with a tangential flow filtration device with Millipore Prostak 0.65 micron membranes. After concentration fresh sterile growth medium is slowly added to the bioreactor while the filtration system continues to remove the spent growth medium by diafiltration. After two volume exchanges (40 L) have been carried out an additional 20 L of fresh medium was added to the bioreactor to resuspend the cells to the original volume of 40 L. The cell density was determined once again by counting viable cells using a hemacytometer.
  • The required amount of each virus stock was calculated based on the cell density, virus titer and the desired multiplicity of infection (MOI). Virus stock ratios of 5:1, 5:2, 10:2 and 10:4, IL6Rα-Fc to GP130-Fc-His[0151] 6 all resulted in production of significant amounts of heterodimer. The ideal virus stock ratio is highly dependent on the ease of purification of the heterodimer from each of the two homodimers. The IL6Rα-Fc homodimer is relatively easy to remove downstream by immobilized metal affinity chromatography. Virus infection ratios have been chosen to minimize the formation of the GP130-Fc-His6 homodimer which is more difficult to clear downstream. The relative amount of GP130-Fc-His6 virus stock chosen for infection has increased with successive batches as the purification method for clearing the resultant homodimer has improved.
  • The virus stocks were aseptically mixed in a single vessel then transferred to the bioreactor. This results in synchronous infection of the SF21 cells. The infection is allowed to proceed for three to four days, allowing sufficient time for maximal production of the heterodimer protein. [0152]
  • Recovery and Protein a Chromatographic Purification [0153]
  • At the conclusion of the infection phase of the bioreactor process the cells were concentrated in the bioreactor using a 10 ft[0154] 2 Millipore Prostak filter (0.65 micron) pore size. The cell-free permeate passing through the filter was collected in a clean process vessel. At the conclusion of the filtration operation the pH of permeate stream, containing the protein product, was adjusted to 8.0 with 10N NaOH. The resultant precipitate was removed by forcing the extract through a 0.8 micron depth filter (Sartorious), followed by a 0.2 micron filter. Sufficient 0.5M EDTA stock was added to give a final concentration of 5 mM. The filtered protein solution was loaded onto a 10 cm diameter column containing 100-200 mL of Pharmacia Protein A Sepharose 4 Fast Flow, equilibrated with PBS. Protein A has a very high affinity for the Fc-Fc domain of each of the 3 recombinant protein products, allowing them to bind while other proteins in the cell-free extract flow through the column. After loading the column was washed to baseline with PBS containing an additional 350 mM NaCl. The IgG-Fc tagged proteins were eluted at low pH, either with 0.5M acetic acid or with a decreasing pH gradient of 0.1M citric acid and 0.2M disodium phosphate buffers. Tris base or disodium phosphate was added to the eluted protein to avoid prolonged exposure to low pH conditions.
  • The pooled protein was diafiltered into PBS or HEPES buffer and derivitized with 1 mM iodoacetamide to protect the exposed sulfhydryl group on the free cysteine near the hinge region of each Fc domain. This prevents disulfide mediated aggregation of proteins. A 6 ft[0155] 2 Millipore spiral wound ultrafiltration membrane with nominal 30 kiloDalton cutoff was used to perform the buffer exchange. The total protein was determined by UV absorbance at 280 nm using the diafiltration buffer as a blank. The relative amounts of heterodimer and two homodimer proteins were determined by SDS PAGE gel electrophoresis using a 6% Tris-Glycine gel (Novex). Gels were Coomassie-stained then transferred into destain solution overnight. A Shimadzu scanning densitometer was used to determine the relative intensity of the individual protein bands on the SDS PAGE gel. The peak area ratios are used to compute the fraction of heterodimer and each of the homodimers in the column pool fractions.
  • Immobilized Metal Affinity Chromatographic Purification [0156]
  • The six histidine residues on the C-terminus of the GP130-Fc-His[0157] 6 fusion protein provides an excellent molecular handle for separation of the heterodimeric IL6 antagonist from the two homodimers. The imidazole group on each of the C-terminal histidines of the GP130-Fc-His6 moiety has a strong binding constant with several divalent metals, including copper, nickel, zinc, cobalt, iron and calcium. Since the IL6Rα-Fc homodimer has no C-terminal histidine residues, it clearly has the lowest affinity. The IL6Ra-Fc-GP130-Fc-His6 heterodimer has a single stand set six histidines giving it greater affinity for the metal, while the GP130-Fc-His6 homodimer has two sets of six histidines each giving it the highest affinity of the three IgG tagged proteins to the metal affinity column. Selective elution of the three proteins with increasing amounts of imidazole in the elution buffer therefore elutes the proteins in the following order:
  • 1. IL6Rα-Fc homodimer [0158]
  • 2. IL6Rα-Fc-GP130-Fc-His heterodimer [0159]
  • 3. GP130-Fc-His homodimer [0160]
  • A 26 mm diameter column containing 100 mL of Pharmacia Chelating Sepharose Fast Flow was saturated with a solution of nickel sulfate until a significant green color is observed in the column eluate. The column is then washed with several column volumes of deionized water, then equilibrated with 50 mM HEPES, 40 mM imidazole, pH 8.0. The binding of imidazole to the immobilized nickel results in a green to blue color change. Imidazole was added to the protein load to a final concentration of 40 mM. Addition of imidazole to the protein load reduces the binding of IL6Rα-Fc homodimer, increasing the surface area available for the remaining two species. After loading, the column was washed with several column volumes of 50 mM HEPES, 80 mM imidazole, pH 8.0 until a steady baseline was reestablished. The heterodimer was selectively eluted with 50 mM HEPES, 150 mM imidazole, pH 8.0 over several column volumes. The protein fractions were pooled and diafiltered into PBS as described in the section above. [0161]
    • Example 4. Alternative Methods of Constructing Ligand Traps
  • As described above, receptor activation by CNTF, and analogously by IL-6 and IL-11, follows an ordered sequence of binding events (FIG. 6). The cytokine initially binds to its cognate Rα with low affinity (Kd=3 to 10 nM); this is a required step-cells which do not express the cognate Rα do not respond to the cognate cytokine. The cytokine.Rα complex associates with the first signal transducing component, gp130, to form a high affinity complex (Kd in the order of 10 pM for the CNTF.CNTFRα.9gp 130 complex). This complex does not transduce signal, as it is the dimerization of the signal transducing components that brings about signaling (Stahl and Yancopoulos, J. Neurobiology 25: 1454-1466 (1994); Stahl et al., Science 267:1349-1353 (1995); Davis et al., Science 260:1805-1808 (1993); Stahl et al., Science 263:92-95 (1994); Murakami, et al. Science 260:1808-1810 (1993). At least in the case of IL-6, the cytokine.Rα.signal transducer heterotrimeric complex subsequently associates with another like complex, to form a hexameric complex (FIG. 6) (Ward et al., J. Biol. Chem. 269:23286-23289 (1994). The resulting dimerization of the signal transducers-gp130 in the case of IL-6 (Murakami et al., Science 260:1808-1810 (1993) and IL-1, gp130 and LIFR in the case of CNTF (Davis et al., Science 260:1805-1808 (1993)—brings about signal transduction. [0162]
  • The initial heterodimeric molecules made comprised a soluble Rα-component linked to the extracellular domain of gp130. These molecules were shown to mimic the high affinity cytokine.Rα.gp130 complex and behave as a high affinity antagonist of their cognate cytokine (FIG. 7). To make these molecules, the extracellular domain of gp130 was paired with the extracellular domain of the α-receptor components for IL-6 and CNTF, IL-6Rα and CNTFRα respectively. To link the Rα with the extracellular domain of gp130, the soluble Rα-components and gp130 were fused to the Fc portion of human IgG1 to produce Rα-Fc and gp130-Fc respectively. The Fc domain was chosen primarily but not solely because it naturally forms disulfide-linked dimers. Heterodimeric molecules comprising Rα-Fc.gp130-Fc were expressed, purified and shown to behave as highly potent antagonists of their cognate ligand. Furthermore, these molecules were found to be highly specific for their cognate cytokine since it is the choice of the α-receptor component which specifies which cytokine is bound and trapped (there is no measurable binding of the cytokine to gp130 in the absence of the appropriate Rα). [0163]
  • Here we describe an extension of this technology which allows the engineering of different heteromeric soluble receptor ligand traps which by virtue of their design may have additional beneficial characteristics such as stability, Fc-receptor-mediated clearance, or reduced effector functions (such as complement fixation). Furthermore, the technology described should prove suitable for the engineering of any heteromeric protein in mammalian or other suitable protein expression systems, including but not limited to heteromeric molecules which employ receptors, ligands, and catalytic components such as enzymes or catalytic antibodies. [0164]
  • Materials and Methods [0165]
  • Genetic Engineering of Heteromeric Immunoglobulin Heavy/light Chain Soluble Receptor-based Ligand Traps for IL-6 [0166]
  • The IL-6 traps described here were engineered using human gp130, human IL-6 α-receptor (IL-6Rα), the constant region of the heavy chains (Cγ) of human IgG1 (Cγ1) (Lewis et al., Journal of Immunology 151:2829-2838 (1993) or IgG4 (Cγ4) with or without a join-region (J), and the constant regions of kappa (κ) and lambda (λ) (Cheung, et al., Journal of Virology 66:6714-6720 (1992) light chains of human immunoglobulin (Ig), also with or without a different j-peptide (j). This design takes advantage of the natural ability of the Cγ domain to heterodimerize with κ or λ light chains. The heterodimerization of Cγ with the light chain occurs between the CH1 domain of Cγ and the constant region of the light chain (C[0167] L), and is stabilized by covalent linking of the two domains via a single disulfide bridge. We reasoned that, like the Fc domain of human IgG1, the combination of Cγ with CL could be used to produce disulfide linked heteromeric proteins comprised of the extracellular domain of gp130 on one chain and the extracellular domain of IL-6Rα on the other chain. Like their Fc-based counterparts, such proteins were postulated to be high affinity ligand traps for IL-6 and as a result to inhibit the interaction of IL-6 with the native receptor on IL-6-responsive cells, thus functioning as IL-6 antagonists. Furthermore, constructs employing the full length Cγ region would, much like antibodies, form homodimers of the Cγ chain, giving rise to antibody-like molecules comprising of two “light chains” and two “heavy chains” (FIG. 8). The potential advantage of this design is that it may more closely mimic the IL-6.IL-6Rα.gp130 complex and may display a higher affinity for the ligand than comparable single heterodimers. An additional design is incorporated by using truncated versions of Cα, comprised only of the C H1 domain. These will form heterodimeric molecules with receptors fusion proteins, and will thus resemble the Fab fragment of antibodies.
  • All the soluble receptor-Ig chimeric genes may be engineered in plasmid vectors including, but not limited to, vectors suitable for mammalian expression (COS monkey kidney cells, Chinese Hamster Ovary cells [CHO], and ras-transformed fibroblasts [MG-ras]) and include a Kozak sequence (CGC CGC CAC CAT GGT G) at the beginning of each chimeric gene for efficient translation. Engineering was performed using standard genetic engineering methodology. Each construct was verified by DNA sequencing, mammalian expression followed by western blotting with suitable antibodies, biophysical assays that determine ligand binding and dissociation, and by growth inhibition assays (XG-1, as described later). Since the domains utilized to engineer these chimeric proteins are flanked by appropriate restriction sites, it is possible to use these domains to engineer other chimeric proteins, including chimeras employing the extracellular domains of the receptors for factors such as IL-1, IL-2, IL-3, IL-4, IL-5, GM-CSF, LIF, IL-i1, IL-15, IFNγ, TGFβ, and others. The amino acid coordinates for each component utilized in making the IL-6 traps are listed below (Note: numbering starts with the initiating methionine as #1; long sequences are listed using the single letter code for the twenty amino acids): [0168]
  • (a) Constructs Employing Human gp130: [0169]
  • (i) gp130-Cγ1 was engineered by fusing in frame the extracellular domain of gp130 ([0170] amino acids 1 to 619) to a Ser-Gly bridge, followed by the 330 amino acids which comprise Cγ1 and a termination codon (FIGS. 9A and 9B).
  • (ii) gp130-J-Cγ1 was engineered in the same manner as gp130-Cγ1 except that a J-peptide (amino acid sequence: GQGTLVTVSS) was inserted between the Ser-Gly bridge and the sequence of Cγ1 (see FIGS. 9A and 9B). [0171]
  • (iii) gp130Δ3fibro-Cγ1 was engineered by fusing in frame the extracellular domain of gp130 without its three fibronectin-like domains (FIG. 10). The remaining part of this chimeric protein is identical to gp130-Cγ1. [0172]
  • (iv) gp130-[0173] J-C H1 was engineered in a manner identical for that described for gp130-Cγ1, except that in place of the Cγ1 region only the C H1 part of Cγ1 has been used (FIG. 11). The C-terminal domain of this construct includes the part of the hinge that contains the cysteine residue responsible for heterodimerization of the heavy chain of IgG with a light chain. The part of the hinge that contains the two cysteines involved in Cγ1 homodimerization has been deleted along with the C H2 and C H3 domains.
  • (v) gp130-Cγ4 was engineered in a manner identical to that described for gp130-Cγ1, except that Cγ4 was used in place of Cγ1 (FIG. 12). In addition, an RsrII DNA restriction site was engineered at the hinge region of the Cγ4 domain by introducing two silent base mutations. The RsrsII site allows for other desired genetic engineering manipulations, such as the construction of the [0174] C H1 equivalent of gp130-Cy4.
  • (vi) gp130-κ was engineered in a manner identical to that described for gp130-Cγ1, except that the constant region of the κ light chain of human Ig was used in place of Cγ1 (FIG. 13). [0175]
  • (vi) gp130-J-κ was engineered in a manner identical to that described for gp130-J-κ, except that a j-peptide (amino acid sequence: TFGQGTKVEIK) was inserted between the Ser-Gly bridge and the κ-region. [0176]
  • (viii) gp130-λ was engineered in a manner identical to that described for gp130-Cγ1, except that the constant region of the λ light chain (Cheung, et al., Journal of Virology 66:6714-6720 (1992) of human Ig was used in place of Cγ1 (FIG. 14). [0177]
  • (b) Constructs Employing Human IL-6Rα: [0178]
  • (i) IL6Rα-Cγ1 was engineered by fusing in [0179] frame amino acids 1 to 358 of IL-6Rα (Yamasaki et al., Science 241:825-828 (1988), which comprise the extracellular domain of IL-6Rα (FIG. 15), to an Ala-Gly bridge, followed by the 330 amino acids which comprise Cγ1 and a termination codon.
  • (ii) IL6Rα-κ was engineered as described for IL6Rα-Cγ1, except that the κ-domain (FIG. 13) utilized for gp130-K was used in place of Cγ1. [0180]
  • (iii) IL6Rα-j-κ was engineered as described for IL6Rα-K except that the j-peptide described for gp130-j-κ was placed between the Ala-Gly bridge and the κ-domain. [0181]
  • (iv) Three additional constructs, IL6Rα313-Cγ1, IL6Rα313-κ, and IL6Rα313-j-ε, were engineered as using a truncated form of IL-6Rα comprised of [0182] amino acids 1 to 313 (FIG. 16). Each of these constructs were made by fusing in frame IL6Rα313 with a Thr-Gly bridge followed by the Cγ1, κ-, and j-κ-domains described above. These constructs were engineered in order to complement the gp130Δ3fibro-derived constructs.
  • Expression and Purification of Ligand Traps [0183]
  • To produce covalently linked heterodimers of soluble gp130 and soluble IL-6Rα, gp130-Ig chimeric proteins were co-expressed with appropriate IL-6Rα-Ig chimeric proteins in complementing pairs. Co-expression was achieved by co-transfecting the corresponding expression vectors into suitable mammalian cell lines, either stably or transiently. The resulting disulfide-linked heterodimers were purified from conditioned media by several different methods, including but not limited to affinity chromatography on immobilized Protein A or Protein G, ligand-based affinity chromatography, ion exchange, and gel filtration. [0184]
  • An example of the type of methods used for purification of a heavy/light receptor fusion protein is as follows: gp130-Cγ1.IL-6Rα-κ was expressed in COS cells by co-transfecting two different vectors, encoding gp130-Cγ1 and IL-6Rα-κ respectively. Serum-free conditioned media (400 ml) were collected two days post-transfection and Cγ1-bearing proteins were purified by affinity chromatography over a 1 ml Protein A Sepharose (Pharmacia). The material generated in this step was further purified by a second affinity chromatography step over a 1 ml NHS-activated Sepharose (Pharmacia) which was derivatized with recombinant human IL-6, in order to remove gp130-Cγ1 dimer from gp130-Cγ1.IL-6Rα-κ complexes (the gp130-Cγ1 dimer does not bind IL-6). Proteins generated by this method were more than 90% pure, as evidenced by SDS-PAGE followed by silver-staining (FIG. 17). Similar protocols have been employed successfully towards the purification of other heavy/light receptor heterodimers. [0185]
  • Results [0186]
  • Biological Activity of Immunoglobulin Heavy/light Chain Receptor Fusion Antagonists [0187]
  • The purified ligand traps were tested for their ability to bind IL-6 in a variety of different assays. For example, the dissociation rate of IL-6 bound to the ligand trap was measured in parallel with the dissociation rate of IL-6 from the anti-IL-6 monoclonal neutralizing antibody B-E8 [Brochier, et al., Int. J. Immunopharmacology 17:41-48 (1995), and references within]. An example of this type of experiment is shown in FIG. 18. In this [0188] experiment 20 pM 125I-IL-6 (1000 μCi/mmol; Amersham) was preincubated with 500 pM of either gp130-Cγ1.IL-6Rα-κ or mAb B-E8 for 20 hours. At this point a 1000-fold excess (20 nM) of “cold” IL-6 was added. Periodically, aliquots of the reaction were removed, the ligand trap or B-E8 were precipitated with Protein G-Sepharose, and the number of cpm of 125I-IL-6 that remained bound was determined. Clearly, the dissociation rate of human 125I-IL6 from the ligand trap was very slow—after three days, approximately 75% of the initial counts were still bound to the ligand trap. In contrast, less than 5% of the counts remained associated with the antibody after three days. This result demonstrates that the dissociation rate of the ligand from these ligand traps is very slow.
  • In a different set of experiments the ability of the ligand traps to multimerize in the presence of ligand was tested. An example of this is shown in FIG. 19. IL-6-induced association of gp130-Fc.IL-6Rα-Fc with gp130-C[0189] H1.IL-6Rα-κ was determined by testing whether gp130-CH1.IL-6Rα-κ, which does not by itself bind Protein A, could be precipitated by Protein A-Sepharose in the presence of gp130-Fc.IL-6Rα-Fc in an IL-6-depended manner (FIG. 9). Precipitation of gp130-CH1.IL-6Rα-κ by Protein A-Sepharose was determined by western blotting with an anti-kappa specific HRP conjugate, which does not detect gp130-Fc.IL-6Rα-Fc. gp130-CH1.IL-6Rα-κ could be precipitated by Protein A-Sepharose only when both gp130-Fc.IL-6Rα-Fc and IL-6 were present. This result conclusively indicates that IL-6 can induce ligand trap multimerization, and further indicate that the ligand trap can mimic the hexameric cytokine.Rα.signal transducer complex (FIG. 1). Ligand-induced multimerization may play a significant role in the clearance of cytokine ligand trap complexes in vivo.
  • The biological activity of the different ligand traps may be further tested in assays which measure ligand-depended cell proliferation. Several cell proliferation assays exist for IL-6 and they employ cell lines such as B9, CESS, or XG-1. An example of this type of assay using the XG-1 cell line is presented below: XG-1 is a cell line derived from a human multiple myeloma (Zhang, et al., Blood 83:3654-3663 (1994). XG1 depends on exogenously supplied human IL-6 for survival and proliferation. The EC[0190] 50 of IL-6 for the XG-1 line is approximately 50 pmoles/ml. The ability of several different IL-6 traps to block IL-6-depended proliferation of XG-1 cells was tested by incubating increasing amounts of purified ligand traps with 50 pg/ml IL-6 in XG-1 cultures. The ligand traps which were tested had been expressed and purified by methods similar to those described above. All of the ligand traps tested were found to inhibit IL-6-dependent proliferation of XG1 in a dose dependent manner (FIG. 20). Of the five different traps tested gp130-Cγ1.IL-6Rα-κ was the most active and essentially display the same neutralizing activity towards IL-6 as the antibody B-E8. As little as a 10-fold molar excess of either gp130-Cγ1.IL-6Rα-κ or B-E8 completely blocked the activity of IL-6 (a reading of A570-650=0.3 AU corresponds to no proliferation of the XG1 cells). At a 100-fold molar excess all of the ligand traps tested completely blocked the activity of IL-6. This observed inhibition is highly selective as neither a gp130-Fc.CNTFRα-Fc ligand trap which blocks CNTF activity, nor gp130-Fc homodimer exhibit any blocking activity towards IL-6 even when used at a 1000-fold molar excess over IL-6 (data not shown). This data demonstrates that the heteromeric immunoglobulin heavy/light chain receptor-based ligand traps function as selective high affinity antagonists of their cognate ligand.
    • EXAMPLE 5 Cloning of Fusion Polypeptide Components
  • The extracellular domains of the human cytokine receptors were obtained by standard PCR techniques using tissue cDNAs (CLONTECH), cloned into the expression vector, pMT21 (Genetics Institute, Inc.), and the sequences were sequenced by standard techniques using an ABI 373A DNA sequencer and Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, Calif.). For the IL-4Rα, nucleotides 241 through 868 (corresponding to the amino acids 24-231) from the Genbank sequence, X52425, were cloned. For the IL-2Rγ, [0191] nucleotides 15 through 776 (corresponding to amino acids 1-233) from the Genbank sequence, D11086, were cloned. For the IL-6Rα, nucleotides 52 through 1044 (corresponding to the amino acids 1-331) from the Genbank sequence, X52425, were cloned. For gp130, nucleotides 322 through 2112 (corresponding to the amino acids 30-619) from the Genbank sequence, M57230, were cloned. For the IL-1RAcP, nucleotides 1 through 1074 (corresponding to the amino acids 1-358) from the Genbank sequence, AB006357, were cloned. For the IL-1RI, nucleotides 55 through 999 (corresponding to the amino acids 19-333) from the Genbank sequence, X16896, were cloned.
    • Example 6 Production of Fusion Polypeptides (Cytokine Traps)
  • The nucleotide sequences encoding the cytokine traps were constructed from the individual cloned DNAs (described supra) by standard cloning and PCR techniques. In each case, the sequences were constructed in frame such that the sequence encoding the first fusion polypeptide component was fused to the sequence encoding the second fusion polypeptide component followed by an Fc domain (hinge, CH2 and CH3 region of human IgG1) as the multimerizing component. In some cases extra nucleotides were inserted in frame between sequences encoding the first and second fusion polypeptide components to add a linker region between the two components (See FIG. 21A-FIG. 21D-trap 424; FIG. 24A-FIG. 24F-trap 412; and FIG. 26A-FIG. 26E-trap 569). [0192]
  • For the IL-4 traps, 424 (FIG. 21A-FIG. 21D), 603 (FIG. 22A-FIG. 22D) and 622 (FIG. 23A-FIG. 23D), the IL-2Rγ component is 5′, followed by the IL4Rα component and then the Fc component. For the IL-6 traps, 412 (FIG. 24A-FIG. 24F) and 616 (FIG. 25A-FIG. 25F), the IL-6Rα component is 5′ followed by the gp130 component and then the Fc domain. For the IL-1 trap 569 (FIG. 26A-FIG. 26E), the IL-1RAcP component is 5′ followed by the IL-1RI component and then the Fc domain. The final constructs were cloned into the mammalian expression vector pCDNA3.1 (STRATAGENE). [0193]
  • In the 569 sequence (FIG. 26A-FIG. 26E), nucleotides 1-1074 encode the IL1RAcP component, nucleotides 1075-1098 encode a linker region, nucleotides 1099-2043 encode the IL1RI component and nucleotides 2044-2730 encode the Fc domain. [0194]
  • In the 412 sequence (FIG. 24A-FIG. 24F), nucleotides 1-993 encode the IL6Rα component, nucleotides 994-1023 encode a linker region, nucleotides 1024-2814 encode the gp130 component and nucleotides 2815-3504 encode the Fc domain. [0195]
  • In the 616 sequence (FIG. 25A-FIG. 25F), nucleotides 1-993 encode the IL6Rα component, nucleotides 994-2784 encode the gp130 component and nucleotides 2785-3474 encode the Fc domain. [0196]
  • In the 424 (FIG. 21A-FIG. 21D) and 622 (FIG. 23A-FIG. 23D) sequences, nucleotides 1-762 encode the IL2Rγ component, nucleotides 763-771 encode a linker region, nucleotides 772-1395 encode the IL4Rα component and nucleotides 1396-2082 encode the Fc domain. [0197]
  • Finally, in the 603 sequence (FIG. 22A-FIG. 22D), nucleotides 1-762 encode the IL2Rγ component, nucleotides 763-1386 encode the IL4Rα component and nucleotides 1387-2073 encode the Fc domain. [0198]
  • DNA constructs were either transiently transfected into COS cells or stably transfected into CHO cells by standard techniques well known to one of skill in the art. Supernatants were collected and purified by Protein A affinity chromatography and size exclusion chromatography by standard techniques. (See for example Harlow and Lane, Antibodies—A Laboratory Manual, Cold Spring Harbor Laboratory, 1988). [0199]
    • Example 7 IL-4 Bioassay Protocol Using TF-1 (ATCC) Cells
  • Reagents and Equipment Needed [0200]
  • MTT Dye Solution [0201]
  • MTT(3-[4,5-Dimethylthiazole-2-yl]) (Sigma catalog# M2128) [0202]
  • Working concentration: Dissolve 5 mg of anhydrous MTT in 200 ml PBS without Ca[0203] +2, Mg+2.
  • Sterile filter and store aliquoted at −20° C. [0204]
  • Solubilization Solution [0205]
  • For 1000 ml, combine 100 g SDS, 950 ml dH[0206] 2O, 50 ml Dimethyl Formamide, and 850 μl concentrated HCl.
  • Filter sterilize with a 0.45 μm filter unit. [0207]
  • Store at room temperature [0208]
  • TF-1 Cell Growth Medium [0209]
  • [0210] RPMI 1640, 10% FBS, Pen/Strep, 2 mM L-glutamine
  • Other [0211]
  • 0.4% Trypan Blue Stain, sterile tubes for dilutions, sterile 96 well cell culture plates (Falcon #3072), hemacytometer, centrifuge, ELISA plate reader, multichannel pipet for 15, 25, 50 and 100 μl volume, sterile reagent reservoirs, sterile pipet tips, gloves. [0212]
  • Assay Protocol [0213]
  • A. Preparation of Assay Plates [0214]
  • 1. Prepare sterile 96 well tissue culture plates to contain 50 μl of growth medium per well with various concentrations of IL-4 and 10 nM IL-4 antagonist. This can be done by preparing a working dilution of IL-4 that is 4 times the highest concentration to be assayed. In separate tubes, do a two-fold serial dilution of the IL-4. Add 25 μl of each dilution to one row across the plate (i.e. row A gets highest concentration, row G gets lowest concentration). Add 25 μl of growth medium without IL-4 to row H. Prepare the antagonists to be tested by making a stock that is 4 times the final concentration. Add 25 μl to a triplicate set of IL-4 containing wells ([0215] columns 1,2,3, A through H). Be sure to include antagonist in row H.
  • 2. As a positive control, leave one set with no antagonist. These wells will contain IL-4 and media only. [0216]
  • 3. Incubate the plate for 1-2 hours at 37° C. in a humidified 5% CO[0217] 2 incubator before preparing cells to be used for assay.
  • B. Preparation of Cells [0218]
  • 4. Wash cells twice by centrifugation in assay medium free of growth factor. [0219]
  • 5. Determine cell number and trypan blue viability and suspend cells to a final concentration of 8×10[0220] 5/ml in assay medium.
  • 6. Dispense 50 μl of the cell suspension (40,000 cells) into all wells of the plates. Total volume should now be 100 μl/well. [0221]
  • 7. Incubate the plate at 37° C. for 68 hours in a humidified 5% CO[0222] 2 incubator.
  • C. Color Development [0223]
  • 8. After incubating for 68 hours, add 15 μl of the MTT dye solution to each well. [0224]
  • 9. Incubate the plate at 37° C. for 4 hours in a humidified 5% CO[0225] 2 incubator.
  • 10. After 4 hours, add 100 μl of the solubilization solution to each well. Allow the plate to stand overnight in a sealed container to completely solubilize the formazan crystals. [0226]
  • 11. Record the absorbance at 570/650 nm. [0227]
  • Results [0228]
  • FIG. 27 shows that an IL-4 trap designated 4SC375, which is a fusion polypeptide of IL-2Rγ-scb-IL4Rα-FcΔC1, is several orders of magnitude better as an IL-4 antagonist than IL4RαFcΔC1 alone in the TF1 cell bioassay. [0229]
  • FIG. 28 shows that the IL-4 trap designated 4SC375 shows antagonistic activity in the TF1 cell bioassay equivalent to an IL-4 trap designated 4SC424 which is a fusion polypeptide of IL-2Rγ-IL4Rα-FcΔC1 having the IL-2Rγ component flush with the IL-4Rα component. [0230]
    • Example 8 IL-6 Bioassay Protocol Using XG1 Cells
  • Reagents and Equipment Needed [0231]
  • MTT Dye Solution [0232]
  • MTT(3-[4,5-Dimethylthiazole-2-yl]) (Sigma catalog# M2128) [0233]
  • Working concentration: Dissolve 5 mg of anhydrous MTT in 200 ml PBS without Ca[0234] +2, Mg+2.
  • Sterile filter and store aliquoted at −20° C. [0235]
  • Solubilization Solution [0236]
  • For 1000 ml, combine 100 g SDS, 950 ml dH[0237] 2O, 50 ml Dimethyl Formamide, and 850 μl concentrated HCl.
  • Filter sterilize with at 0.45 μm filter unit. [0238]
  • Store at room temperature [0239]
  • Assay Medium [0240]
  • [0241] RPMI 1640, 10%FBS, Pen/Strep, 2 mM L-glutamine, 50 μM mercapto-ethanol.
  • Other [0242]
  • 0.4% Trypan Blue Stain, sterile tubes for dilutions, sterile 96 well cell culture plates (Falcon#3072), hemacytometer, centrifuge, ELISA plate reader, multichannel pipet for 15, 25, 50 and 100 μl volume, sterile reagent reservoirs, sterile pipet tips, gloves. [0243]
  • Assay Protocol [0244]
  • A. Preparation of Assay Plates [0245]
  • 1. Prepare sterile 96 well tissue culture plates to contain 5 μl of growth medium per well with various concentrations of IL-6 and 10 nM IL-6 antagonist. This can be done by preparing a working dilution of IL-6 that is 4 times the highest concentration to be assayed. In separate tubes, do a two-fold serial dilution of the IL-6. Add 25 μl of each dilution to one row across the plate (i.e. row A gets highest concentration, row G gets lowest concentration). Add 25 μl of growth medium without IL-6 to row H. Prepare the antagonists to be tested by making a stock that is 4 times the final concentration. Add 25 μl to a triplicate set of IL-6 containing wells ([0246] columns 1,2,3, A through H). Be sure to include antagonist in row H. A typical IL-6 titration starts at 200 ng/ml down to 3.1 ng/ml.
  • 2. As a positive control, leave one set with no antagonist. These wells contain IL-6 and media in place of antagonist. [0247]
  • 3. Incubate the plate 1-2 hours at 37° C. in a humidified 5% CO[0248] 2 incubator before preparing cells to be used for assay.
  • B. Preparation of Cells [0249]
  • 4. Wash cells twice by centrifugation (5 min at 1000 RPM) in assay medium free of growth factor. [0250]
  • 5. Determine cell number and trypan blue viability and suspend cells to a final concentration of 8×10[0251] 5/ml in assay medium.
  • 6. Dispense 50 μl of the cell suspension (40000 cells) into all wells of the plates. Total volume should now be 100 μl/well. [0252]
  • 7. Incubate the plate at 37° C. for 68 hours in a humidified 5% CO[0253] 2 incubator.
  • C. Color Development [0254]
  • 8. At 68 hours add 15 μl of the dye solution to each well. [0255]
  • 9. Incubate the plate at 37° C. for 4 hours in a humidified 5% CO[0256] 2 incubator.
  • 10. After 4 hours, add 100 μl of the solubilization solution to each well. Allow the plate to stand overnight in a sealed container to completely solubilize the formazan crystals. [0257]
  • 11. Record the absorbance at 570/650 nm. [0258]
  • Results [0259]
  • FIG. 29 shows that the IL6 trap (6SC412 IL6R-scb-gpx-FcΔC1) described in FIG. 24A-FIG. 24F is a better antagonist of IL-6 in the XG1 bioassay than the neutralizing monoclonal antibody to human IL-6-BE8. [0260]
    • Example 9 MRC5 Bioassay for IL1 Traps
  • MRC5 human lung fibroblast cells respond to IL-1 by secreting IL-6 and thus were utilized to assay the ability of IL-1 traps to block the IL-1-dependent production of IL-6. IL1 Trap 1SC569 (FIG. 26A-FIG. 26E) was tested against IL-1-RI.Fc which is the extracellular domain of the IL-1 Type I receptor fused to an Fc domain. [0261]
  • MRC5 cells are suspended at 1×10[0262] 5 cells per ml in medium and 0.1 ml of cells are plated (10,000 cells per well) into the wells of a 96 well tissue culture plate. Plates are incubated for 24 hours at 37° C. in a humidified 5% CO2 incubator.
  • IL-1 trap and recombinant human IL-1 at varying doses are pre-incubated in a 96 well tissue culture dish and incubated for 2 hours at 37° C. 0.1 ml of this mixture is then added to the 96 well plate containing the MRC5 cells such that the final concentration of IL-1 Trap is 10 nM and the final concentrations of the IL-1 ranges from 2.4 pM to 5 nM. Control wells contain trap alone or nothing. [0263]
  • Plates are then incubated at 37° C. for 24 hours in a humidified 5% CO[0264] 2 incubator. Supernatant is collected and assayed for levels of IL-6 using R&D Systems Quantikine Immunoassay Kit according to the manufacturer's instructions.
  • Results [0265]
  • FIG. 30 shows that the trap 569 (FIG. 26A-FIG. 26E) is able to antagonize the effects of IL-1 and block the IL-6 production from [0266] MRC 5 cells upon treatment with IL-1. At a concentration of 10 nM, the trap 569 is able to block the production of IL-6 up to an IL-1 concentration of 3 nM. In contrast, the IL-1RI.Fc is a much poorer antagonist of IL-1. It is only able to block the effects of IL-1 up to about 10-20 pM. Thus, the trap 569 is approximately 100× better at blocking IL-1 than IL1RI.Fc.
    • Example 10 Construction of IL-13/IL-4 Single Chain Traps
  • 1. To create the IL-13/IL-4 dual trap designated IL-4Rα.IL-13Rα1.Fc, the human IL-4Rα extracellular domain (corresponding to nucleotides #1-693 of FIG. 31A-FIG. 31G) and the human IL-13Rα1 extracellular domain (corresponding to nucleotides #700-1665 of FIG. 31A-FIG. 31G) were amplified by standard PCR techniques and ligated into an expression vector pMT21 which contained the human Fc sequence (corresponding to nucleotides #1671-2355 of FIG. 31A-FIG. 31G), thus creating a fusion protein consisting of the IL-4Rα, IL-13Rα1, and the hinge, CH2 and CH3 region of human IgG1 from the N to C terminus. In addition, a two amino acid linker (corresponding to nucleotides #694-699 of FIG. 31A-FIG. 31G) with the amino acid sequence SerGly was constructed in frame between the IL-4Rα and the IL-13Rα1 and a two amino acid linker (corresponding to nucleotides #1666-1671 of FIG. 31A-FIG. 31G) with the amino acid sequence ThrGly was constructed in frame between the IL-13Rα1 and the Fc portion. All sequences were sequence-verified by standard techniques. The IL-4Rα.IL-13Rα1.Fc coding sequence was then subcloned into the expression vector pCDNA3.1 (Stratagene) using standard molecular biology techniques. [0267]
  • 2. To create the IL-13/IL-4 dual trap designated IL-13Rα1.IL-4Rα.Fc, the IL-13Rα1 extracellular domain (corresponding to nucleotides #1-1029 of FIG. 32A-FIG. 32G) and the human IL-4Rα (corresponding to nucleotides # 1060-1692 of FIG. 32A-FIG. 32G) were amplified by standard PCR techniques and ligated into the expression vector pJFE14, which contains the human Fc sequence (corresponding to nucleotides #1699-2382 of FIG. 32A-FIG. 32G) to create a fusion protein consisting of the IL-13Rα1, IL-4Rα, and the hinge, CH2 and CH3 region of human IgG1 from the N to C terminus. In addition, a ten amino acid linker with the amino acid sequence GlyAlaProSerGlyGlyGlyGlyArgPro (corresponding to nucleotide #1030-1059 of FIG. 32A-FIG. 32G) was constructed in frame between the IL-13Rα1 and the IL-4Rα and a two amino acid linker (corresponding to nucleotides #1693-1698 of FIG. 32A-FIG. 32G) with the amino acid sequence SerGly was constructed in frame between IL-4Rα and the Fc portion. All sequences were sequence-verified using standard techniques. The coding sequence of IL-13Rα1l.IL-4Rα.Fc was then subcloned into the expression vector pCDNA3.1 (Stratagene) using standard molecular biology techniques. [0268]
    • Example 11 Expression of IL-4RαIL-13Rα1.Fc and IL-13Rα1.IL-4Rα.Fc
  • Large scale (1 L) cultures of the pCAE801 (the DNA vector construct encoding IL-4Rα.IL-13Rα1.Fc) and pCAE802 (the DNA plasmid construct encoding IL-13Rα1.IL-Rα.Fc) in DH10B cells were grown overnight in LB+ ampicillin and the plasmid DNA was extracted using a Qiagen Endofree Mega Kit following the manufacturer's protocol. The concentration of the purified plasmid DNA was determined in a UV spectrophotometer and fluorometer. The plasmid DNA was also verified by digestion of aliquots with BbsI, XmnI and NcoI restriction enzymes. All restriction enzyme digest fragments corresponded to the predicted sizes in a 1% agarose gel. [0269]
  • Forty 15 cm petri plates were seeded with CHO-K1/E1A cells at a density of 4×10[0270] 6 cells/plate. Plating media was Gibco Ham's F-12 w/10% Hyclone Fetal Bovine Serum (FBS)+ penicillin/streptomycin and supplemented with glutamine. The following day each plate was transfected with 6 μg of pCAE801, or pCAE802, using Gibco Optimem and Gibco Lipofectamine in 12 ml volume, following the manufacturer's protocol. Four hours after adding the transfection mix to the cells 12 ml/plate of Optimem w/ 10% FBS was added. Plates were incubated at 37° C. in a 5% CO2 incubator overnight. The following day the media was removed from each plate and 25 ml expression media (Gibco CHO-S-SFM II w/ glutamine+1 mM sodium butyrate) was added. The plates were incubated at 37° C. for 3 days.
  • After 3 days of incubation the media was removed from each plate and centrifuged at 400 rpm in a swinging bucket rotor to pellet cells. The supernatant was decanted into sterile 1 L bottles and expressed protein was purified as described infra. [0271]
    • Example 12 Purification of IL-4Rα.IL-13Rα1.Fc and IL-13Rα1.IL-4Rα.Fc Protein from Culture Media
  • 1. Purification of IL-4Rα.IL-13Rα1.Fc. [0272]
  • Human IL-4Rα.IL-13Rα1.Fc was transiently expressed in CHO cells and supernatants were harvested from plate transfections as described supra. Expression of the secreted protein was determined by a sandwich ELISA using goat anti-hIgG (γ chain specific; Sigma 1-3382) and goat anti-hIgG (Fc specific)-FITC conjugate (Sigma F9512) capture and report antibodies, respectively. The yield ranged from 5.8 to 9.2 mg (average of 7.5 mg) per liter of conditioned media. Complete™ protease inhibitor tablets (Roche Diagnostics Corp.) were dissolved into the media (1 tablet/L). The conditioned media was sterile filtered (0.22 μm pore size) prior to loading onto a pre-equilibrated, 5 mL HiTrap® Protein A affinity column (Amersham Pharmacia Biotech) in Dulbecco's PBS buffer (Life Technologies), pH 7.4 at 4° C. The flow rate was ˜1-2 mL/min. The column was extensively washed with PBS buffer to remove nonspecifically bound proteins from the column. IL-4Rα.IL-13Rα1. Fc was eluted using 20 mM sodium citrate, 150 mM NaCl, pH 3.5. The eluate was immediately neutralized by titrating with 1 M Tris-OH. The fractions containing protein were pooled and immediately dialyzed in PBS buffer, pH 7.4 at 4° C. The recovery from Protein A purification was 6.8 mg (73%). IL-4Rα.IL-13Rα1.Fc was further purified by size exclusion chromatography using a [0273] superose 6 column (25 mL bed volume; Amersham Pharmacia Biotech) pre-equilibrated in PBS, 5% v/v glycerol, pH 7.4 at ambient temperature. The flow rate was 0.5 mL/min. Protein fractions were assessed from a Coomassie stained non-reduced and reduced SDS-PAGE (Novex NuPAGE 4-12% Bis-Tris gels). Fractions were conservatively pooled to reduce the amount of aggregated protein. The overall yield was 51% (4.4 mg) with a purity of 97% as judged by SDS-PAGE. Purified IL-4Rα.IL-13Rα1.Fc was analyzed by non-reduced and reduced SDS-PAGE (4-12% Bis-Tris), analytical size exclusion chromatography (Tosohaas TSKG4000SWXL), N-terminal sequencing, and immunoblotting with goat anti-hIgG-HRP conjugate (Promega W403B), and also mouse monoclonal anti-hIL-4R (R&D MAB230) followed by anti-mIgG-HRP conjugate (Promega W402B) as the secondary antibody.
  • 2. Purification of IL-13Rα1.IL-4Rα.Fc [0274]
  • Human IL-13Rα1.IL-4Rα.Fc was transiently expressed in CHO cells and supernatants were harvested from plate transfections as described supra. Expression of the secreted protein was determined by a sandwich ELISA using goat anti-hIgG (γ chain specific; Sigma 1-3382) and goat anti-hIgG (Fc specific)-FITC conjugate (Sigma F9512) capture and report antibodies, respectively. The yield was 8.8 mg per liter of conditioned media. Complete™ protease inhibitor tablets (Roche Diagnostics Corp.) were dissolved into the media (1 tablet/L). The conditioned media was sterile filtered (0.22 μm pore size) prior to loading onto a pre-equilibrated, 5 mL HiTrap® Protein A affinity column (Amersham Pharmacia Biotech) in Dulbecco's PBS buffer (Life Technologies), pH 7.4 at 4° C. The flow rate was ˜1-2 mL/min. The column was extensively washed with PBS buffer to remove nonspecifically bound proteins from the column. IL-13Rα1.IL-4Rα.Fc was eluted using 20 mM sodium citrate, 150 mM NaCl, pH 3.5. The eluate was immediately neutralized by titrating with 1 M Tris-OH. The fractions containing protein were pooled and immediately dialyzed in PBS buffer, pH 7.4 at 4° C. The recovery from Protein A purification was 3.8 mg (43%). IL-13Rα1.IL-4Rα.Fc was further purified by size exclusion chromatography using a [0275] superose 6 column (25 mL bed volume; Amersham Pharmacia Biotech) pre-equilibrated in PBS, 5% v/v glycerol, pH 7.4 at ambient temperature. The flow rate was 0.5 mL/min. Protein fractions were assessed from a Coomassie stained non-reduced and reduced SDS-PAGE (Novex NuPAGE 4-12% Bis-Tris gels). Fractions were conservatively pooled to reduce the amount of aggregated protein. The overall yield was 17% (1.5 mg) with a purity of 95% as judged by SDS-PAGE. Purified IL-13Rα1.IL-4Rα.Fc was analyzed by non-reduced and reduced SDS-PAGE (4-12% Bis-Tris), analytical size exclusion chromatography (Tosohaas TSKG4000SWXL), N-terminal sequencing, and immunoblotting with goat anti-hIgG-HRP conjugate (Promega W403B), and also mouse monoclonal anti-hIL-4Rα (R&D MAB230) followed by anti-mIgG-HRP conjugate (Promega W402B) as the secondary antibody.
    • Example 13 Blocking of IL-4 AND IL-13 BY IL-4Rα.IL-13Rα1.Fc and IL-13Rα1.IL-4Rα.Fc
  • Materials and Methods [0276]
  • TF1 Bioassay. TF1 cells were maintained in growth media (10 ng/ml GM-CSF, [0277] RPMI 1640, 10% FBS, L-glutamine, Penicillin, Streptomycin). For the bioassay, cells were washed 2 times in assay media (as above but without GM-CSF) and then plated at 2×105 cells in 50 μl of assay media. The purified IL-4Ra.IL-13Rα1.Fc and IL-13Rα1.IL-4Rα.Fc proteins were diluted into assay media at a concentration of 40 nM. 25 ul of each of the traps was added to the cells. Either IL-13 or IL-4 were diluted to 40 nM in assay media and then 2-fold dilution series in assay media were made. 25 μl of either IL-13 or IL-4 was then added to the wells containing the cells and the traps. Cells were then incubated at 37° C., 5% CO2 for ˜70 hrs. The extent of TF1 cell proliferation was measured by the MTS assay according to the manufacturer's protocol (Promega, Inc.).
  • Results [0278]
  • The ability of the IL-4Rα.IL-13Rα1.Fc and IL-13Rα1.IL-4Rα.Fc traps to block both human IL-13 and human IL-4 activity was measured in the TF1 bioassay described supra. IL-13 stimulates proliferation of TF1 cells, with half-maximal growth at a concentration of 0.2 nM. Addition of either IL-4Rα.IL-13Rα1.Fc or IL-13Rα1.IL-4Rα.Fc trap at a concentration of 10 nM blocks IL-13-induced growth up to ˜2 nM (FIG. 33). At an IL-13 concentration of ˜4-5 nM the growth of TF1 cells is inhibited by 50%. TF1 cells are more sensitive to IL-4, which stimulates their proliferation with half-maximal growth at ˜0.02 nM. Addition of either IL-4Rα.IL-13Rα1.Fc or IL-13Rα1.IL-4Rα.Fc at a concentration of 10 nM blocks IL-4-induced growth up to ˜1 nM (FIG. 34). At an IL-4 concentration of ˜3-4 nM the growth of TF1 cells is inhibited by 50%. These results show that both IL-4Rα.IL-13Rα1.Fc and IL-13Rα1.IL-4Rα.Fc can block the ability of both IL-13 and IL-4 to stimulate cellular responses. [0279]
    • Example 14 Blocking of Injected IL-1 by IL-1 Trap in Vivo
  • IL-1 is a pro-inflammatory cytokine. Systemic administration of IL-1 has been shown to elicit acute responses in animals, including transient hyperglycemia, hypoinsulinemia, fever, anorexia, and increased serum levels of interleukin-6 (IL-6) (Reimers, 1998). Since mice are responsive to both murine and human IL-1, human IL-1 can be used and in vivo binding effects of human specific IL-1 antagonists can be evaluated. This acute mouse model was used to determine the ability of a human IL-1 trap to antagonize the in vivo effects of exogenously administered human IL-1. This provides a rapid indication of in vivo efficacy of the human IL-1 trap and can be used as an assay to help molecule selection. [0280]
  • Experimental Design [0281]
  • Mice were given subcutaneous injections of human IL-1 (0.3 ag/kg). Twenty-four hours prior to human IL-1 injection, the animals were pre-treated with either vehicle or 150-fold molar excess of human IL-1 trap (0.54 mg/kg). Two hours prior to sacrifice (26 hrs), the mice were given a second injection of human IL-1 (0.3 Ag/kg). Blood samples were collected at various time points and sera were assayed for IL-6 levels. [0282]
  • Results [0283]
  • Exogenous administration of human IL-1 resulted a dramatic induction of serum IL-6 levels. At 150-fold molar excess, the human IL-1 trap completely blocked the IL-6 increase (FIG. 35). Furthermore, the effects of the human IL-1 trap persisted for at least another 24 hours, preventing an IL-6 increase even when IL-1 was re-administered (FIG. 35). Such long-lasting efficacy suggests that daily injection of an IL-1 trap may not be necessary for chronic applications. [0284]
    • Example 15 Evaluating the Ability of an IL-4 Trap to Block the Physiological Responses to Human IL-4 in Cynomologus Monkeys
  • Systemic administration of human IL-4 elicits systemic responses in Cynomologus monkeys (Gundel et al., 1996). Thus, the effectiveness of the IL-4 trap in blocking human IL-4 can be demonstrated by measuring these responses. [0285]
  • Experimental Design [0286]
  • The experiment consisted of 3 parts: human IL-4 +vehicle (part 1), human IL-4+IL-4 Trap (part 2), and human IL-4 +vehicle (part 3). Human IL-4 (25 μg/kg) was injected subcutaneously twice daily for 4 days and IL-4 Trap (8 mg/kg) and vehicle were given intravenously daily for 5 days, beginning 1 day prior to human IL-4 administration. Whole blood was collected daily for flow cytometry analysis for CD16 and plasma was obtained to assay for the cytokine monocyte chemotactic protein 1 (MCP-1). CD16 and MCP-1 are markers of IL-4-mediated inflammation in both humans and monkeys. [0287]
  • Results [0288]
  • In the presence of human IL-4, MCP-1 increased 2.5-fold and was significantly blocked by the IL-4 Trap (FIG. 36A). Similarly, the decrease in the percent of CD16 positive lymphocytes in peripheral blood was attenuated by the IL-4 trap (FIG. 36B). After a rest period, the monkeys were re-injected with human IL-4 and the responsiveness of the animals to human IL-4 was re-confirmed (FIGS. 36A and 36B), suggesting that inhibition of the MCP-1 and [0289] CD 16 responses is specifically mediated by the IL-4 trap.
    • Example 16 The Effects of IL-4 Trap on 1L-4-Induced IgE Secretion
  • It has been shown that injection of anti-mouse IgD antibody stimulates an IL-4-mediated IgE increase in normal mice. This model has been widely used to evaluate IL-4 antagonists, such as soluble IL-4 receptor and anti-IL-4 monoclonal antibodies (Sato et al., 1993). We decided to use this model to evaluate the ability if the IL-4 trap to block IL-4-mediated increases of IgE. [0290]
  • Experimental Design [0291]
  • BALB/C mice injected with anti-mouse IgD (100 μl/mouse, s.c.) were randomly divided into 3 groups. Each received (on days 3-5) either vehicle, murine IL-4 trap (1 mg/kg, s.c.), or a monoclonal antibody to mouse IL-4 (1 mg/kg, s.c.). Serum was collected at various time points and assayed for IgE levels. [0292]
  • Results [0293]
  • Treatment with the murine IL-4 trap or the mouse IL-4 antibody both significantly antagonized the IL-4-mediated IgE increase in this mouse model (FIG. 37). This suggests that the murine IL-4 trap binds murine IL-4 and antagonizes physiological responses elicited by endogenous IL-4 in vivo. [0294]
    • Example 17 Construction of Additional IL-4/IL-13 Traps
  • The following IL-4/IL-13 Traps were constructed using standard molecular biology techniques familiar to the skilled artisan. [0295]
  • IL-4/IL-13 Trap 933 [0296]
  • The IL-4/IL-13 Trap 933 sequence consists of the extracellular domain of human IL-13Rα1 (nucleotides #-78 to 951 of FIG. 38A-[0297] 38H), followed by the extracellular domain of human IL-4Rα (nucleotides #952-1575 of FIGS. 38A-38H) containing a mutation at nucleotide # 1501 (T->A) to change a cysteine to a serine, followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides # 1576-2265 of FIGS. 38A-38H).
  • IL-4/IL-13 [0298] Trap 943
  • The IL-4/IL-13 [0299] Trap 943 sequence consists of the extracellular domain of human IL-4Rα (nucleotides # -69 to 624 of FIGS. 39A-39G) containing a mutation at nucleotide #550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13Rα1 (nucleotides #625-1575 of FIGS. 39A-39G) followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides #1576-2262 of FIGS. 39A-39G).
  • IL-4/IL-13 Trap 1126 [0300]
  • The IL-4/IL-13 Trap 1126 sequence consists of the extracellular domain of human IL-13Rα1 (nucleotides #-78 to 951 of FIGS. [0301] 40A-40I), containing a mutation at nucleotide #58 (T to A) to change a cysteine to a serine, followed by the extracellular domain of human IL-4Rα (nucleotides #952-1575 of FIGS. 40A-40I) containing a mutation at nucleotide #1501 (T->A) to change a cysteine to a serine, followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides # 1576-2265 of FIGS. 40A-40I).
  • IL-4/IL-13 Trap 1128 [0302]
  • The IL-4/IL-13 Trap 1128 sequence consists of the extracellular domain of human IL-4Rα (nucleotides # -69 to 624 of FIGS. [0303] 41A-41P) containing a mutation at nucleotide #550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13Rα1 (nucleotides #625-1575 of FIGS. 41A-41P) containing a mutation at nucleotide #682 (T to A) to change a cysteine to a serine, followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides #1576-2262 of FIGS. 41A-41H).
  • IL-4/IL-13 [0304] Trap 1130
  • The IL-4/IL-13 [0305] Trap 1130 sequence consists of the extracellular domain of human IL-13Rα1 (nucleotides # -78 to 951 of FIGS. 42A-42I), containing a mutation at nucleotides #58-60 (TGC to GCG) to change a cysteine to an alanine, followed by the extracellular domain of human IL-4Rα (nucleotides #952-1575 of FIGS. 42A-42I), containing a mutation at nucleotide #1501 (T->A)to change a cysteine to a serine, followed by part of the hinge region, the CH2 and CH3 domains of human IgGI (nucleotides # 1576-2265 of FIGS. 42A-42I).
  • IL-4/IL-13 [0306] Trap 1132
  • The IL-4/IL-13 [0307] Trap 1132 sequence consists of the extracellular domain of human IL-4Rα (nucleotides #-69 to 624 of FIGS. 43A-43G) containing a mutation at nucleotide #550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13Rα1 (nucleotides #625-1575 of FIGS. 43A-43G) containing a mutation at nucleotides #682-684 (TGC to GCG) to change a cysteine to an alanine, followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides #1576-2262 of FIGS. 43A-43G).
  • IL-4/IL-13 Trap 1199 [0308]
  • The IL-4/IL-13 Trap 1199 sequence consists of the extracellular domain of human IL-4Rα (nucleotides #-69 to 624 of FIGS. [0309] 44A-44I) containing a mutation at nucleotide #550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13Rα1 (nucleotides #625-1575 of FIGS. 44A-44I) containing a mutation at nucleotide #682-684 (TGC to GCG) to change a cysteine to an alanine, followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides # 1576-2268 of FIG. 44A-44I).
  • IL-4/IL-13 Trap 1244 [0310]
  • The IL-4/IL-13 Trap 1244 sequence consists of the extracellular domain of human IL-13Rα1 (nucleotides #-78 to 951 of FIGS. [0311] 45A-45I), containing a mutation at nucleotide #58-60 (TGC to GCG) to change a cysteine to an alanine, followed by the extracellular domain of human IL-4Rα (nucleotides #952-1575 of FIGS. 45A-45I) containing a mutation at nucleotide #1501 (T->A)to change a cysteine to a serine, followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides # 1576-2271 of FIGS. 45A-45I).
  • IL-4/IL-13 Trap 1245 [0312]
  • The IL-4/IL-13 Trap 1245 sequence consists of the extracellular domain of human IL-4Rα (nucleotides #-69 to 624 of FIGS. [0313] 46A-46I) containing a mutation at nucleotide #550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13Rα1 (nucleotides #625-1575 of FIGS. 46A-46I) containing a mutation at nucleotide #682 (T to A) to change a cysteine to an serine, followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides # 1576-2268 of FIGS. 46A-46I).
  • IL-4/IL-13 Trap 1246 [0314]
  • The IL-4/IL-13 Trap 1246 sequence consists of the extracellular domain of human IL-13Rα1 (nucleotides #-78 to 951 of FIG. 47A-[0315] 47J) containing a mutation at nucleotide #58 (T to A) to change a cysteine to a serine, followed by the extracellular domain of human IL-4Rα (nucleotides #952-1575 of FIGS. 47A-47J) containing a mutation at nucleotide #1501 (T->A) to change a cysteine to a serine, followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides # 1576-2271 of FIGS. 47A-47J).
    • Example 18 IL-4/IL-13 Trap Properties
  • The IL-4/IL-13 [0316] Trap 943 blocked IL-4 and IL-13 in a TF1 bioassay more potently than the IL-4/IL-13 Trap 933. In addition, in CHO transient transfection systems, IL-4/IL-13 Trap 943 had a slightly higher protein expression level.
  • Disulfide mapping and stoichiometry using standard BIAcore methodologies suggested that the IL-4/IL-13 Trap 933 and IL-4/IL-13 [0317] Trap 943 molecules were misfolded. Therefore, second generation of IL-4/IL-13 Traps were constructed. It was found that the IL-4/IL-13 Trap constructs 1126, 1128, 1130, and 1132, in which the cysteine at position 20 of mature human IL-13Rα1 was mutated to either an alanine or a serine, exhibited less aggregation upon expression, had ˜2 to 3-fold better activity than IL-4/IL-13 Trap 943 in the TF1 bioassay in blocking both IL-4 and IL-13, and exhibited a consistent and homogenous pattern of disulfide formation.
  • The IL-4/IL-13 [0318] Trap 1132 molecule had additional advantages over IL-4/IL-13 Traps 1126, 1128, and 1130. A higher percentage of the total protein (>95%) had the correct N-terminal sequence as compared to the IL-4/IL-13 Traps 1126 or 1130 (80-90%). Stoichiometric studies indicated a stoichiometry of 1 for the IL-4/IL-13 Trap 1132 whereas the IL-4/IL-13 Trap 1130 showed a stoichiometry of 1.5. Preliminary mouse pharmacokinetic experiments suggest that the IL-4/IL-13 Trap 1132 molecule has a higher Cmax (maximal serum concentration) and a longer t1/2 (serum half-life) than the others. The IgG4 versions of the IL-4/IL-13 Traps containing the cysteine mutations may be preferred if it is desired to reduce the effector functions of the Fc portion of the Traps. The cysteine to serine mutation in IL-4/IL-13 Traps 1126 and 1128 molecules creates a novel N-glycosylation site which may be desirable in certain circumstances.
    • Example 19 IL-4/IL-13 Traps Potently Block Both IL-4 and IL-13 in TF1 Bioassays
  • Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 (E. coli; Preprotech) and varying concentrations of IL-4/IL-13 [0319] Trap 943 or 1132 for ˜3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4 hrs. and cell proliferation was measured as OD at 490 nm. FIG. 48 shows the results of this experiment. The IL-4/IL-13 Trap 1132 can block IL-13 more potently than the IL-4/IL-13 Trap 943. IL-4/IL-13 Trap 1132 exhibits an IC50 of 64 pM as compared to 184 pM for Trap 943.
  • The above experiment was performed with [0320] E. coli-produced IL-13. To confirm that the IL-4/IL-13 Trap will bind human IL-13 in vivo, IL-13 was produced and purified from a mammalian cell line (CHO). The CHO-derived human IL-13 was then utilized in the TF1 bioassay to determine the ability of the IL-4/IL-13 Trap to bind and block activity. The IL-4/IL-13 Trap 1132 displays a higher affinity for human IL-13 produced by CHO cells (IC5=17 pM) than for human IL-13 made in E. coli (64 pM). This result predicts that the IL-4/IL-13 Trap will successfully bind human IL-13 with high affinity in vivo.
  • Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 40 pM recombinant human IL-4 ([0321] E. coli; Applicants' own material) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ˜3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4hrs. and cell proliferation was measured as OD at 490 nm. FIG. 49 shows the results of this experiment. The IL-4/IL-13 Trap 1132 can block IL-4 more potently than the IL-4/IL-13 Trap 943. IL-4/IL-13 Trap 1132 exhibits an IC50 of 95 pM as compared to 222 pM for Trap 943.
  • As shown in FIG. 50, IL-4/IL-13 [0322] Trap 1132 displays a higher affinity for Applicants' rhIL13. Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 Applicants' own material (CHO) or Pharmingen (E. coli) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ˜3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4hrs. and cell proliferation was measured as OD at 490nm. IL-4/IL-13 Trap 1132 has an IC50 of 16 pM which indicates a Kd of ˜9 pM.
  • As shown in FIG. 51, IL-4/IL-13 [0323] Trap 1132 can block hIL13 more potently than IL-4/IL-13 Trap 943 with Applicants' own rhIL13. Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 (CHO; Applicants' own material) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for ˜3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4hrs. and cell proliferation was measured as OD at 490 nm. IL-4/IL-13 Trap 1132 has an IC50 of 17 pM as compared to 33 pM for 943.
  • The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims. [0324]

Claims (20)

We claim,
1. An isolated nucleic acid molecule having the nucleotide sequence set forth in FIGS. 38A-38H encoding a fusion polypeptide having the amino acid sequence set forth in FIGS. 38A-38H, wherein the fusion polypeptide forms a multimer that is capable of binding a cytokine to form a nonfunctional complex.
2. An isolated nucleic acid molecule having the nucleotide sequence set forth in FIGS. 39A-39G encoding a fusion polypeptide having the amino acid sequence set forth in FIGS. 39A-39G, wherein the fusion polypeptide forms a multimer that is capable of binding a cytokine to form a nonfunctional complex.
3. An isolated nucleic acid molecule having the nucleotide sequence set forth in FIGS. 40A-40I encoding a fusion polypeptide having the amino acid sequence set forth in FIGS. 40A-40I, wherein the fusion polypeptide forms a multimer that is capable of binding a cytokine to form a nonfunctional complex.
4. An isolated nucleic acid molecule having the nucleotide sequence set forth in FIGS. 41A-41H encoding a fusion polypeptide having the amino acid sequence set forth in FIGS. 41A-41H, wherein the fusion polypeptide forms a multimer that is capable of binding a cytokine to form a nonfunctional complex.
5. An isolated nucleic acid molecule having the nucleotide sequence set forth in FIGS. 42A-42I encoding a fusion polypeptide having the amino acid sequence set forth in FIGS. 42A-42I, wherein the fusion polypeptide forms a multimer that is capable of binding a cytokine to form a nonfunctional complex.
6. An isolated nucleic acid molecule having the nucleotide sequence set forth in FIGS. 43A-43G encoding a fusion polypeptide having the amino acid sequence set forth in FIGS. 43A-43G, wherein the fusion polypeptide forms a multimer that is capable of binding a cytokine to form a nonfunctional complex.
7. An isolated nucleic acid molecule having the nucleotide sequence set forth in FIGS. 44A-44I encoding a fusion polypeptide having the amino acid sequence set forth in FIGS. 44A-44J, wherein the fusion polypeptide forms a multimer that is capable of binding a cytokine to form a nonfunctional complex.
8. An isolated nucleic acid molecule having the nucleotide sequence set forth in FIGS. 45A-45I encoding a fusion polypeptide having the amino acid sequence set forth in FIGS. 45A-45I, wherein the fusion polypeptide forms a multimer that is capable of binding a cytokine to form a nonfunctional complex.
9. An isolated nucleic acid molecule having the nucleotide sequence set forth in FIGS. 46A-461 encoding a fusion polypeptide having the amino acid sequence set forth in FIGS. 46A-46I, wherein the fusion polypeptide forms a multimer that is capable of binding a cytokine to form a nonfunctional complex.
10. An isolated nucleic acid molecule having the nucleotide sequence set forth in FIGS. 47A-47J encoding a fusion polypeptide having the amino acid sequence set forth in FIGS. 47A-47J, wherein the fusion polypeptide forms a multimer that is capable of binding a cytokine to form a nonfunctional complex.
11. A fusion polypeptide having the amino acid sequence set forth in FIGS. 38A-38H encoded by the isolated nucleic acid molecule of claim 1.
12. A fusion polypeptide having the amino acid sequence set forth in FIGS. 39A-39G encoded by the isolated nucleic acid molecule of claim 2.
13. A fusion polypeptide having the amino acid sequence set forth in FIGS. 40A-40I encoded by the isolated nucleic acid molecule of claim 3.
14. A fusion polypeptide having the amino acid sequence set forth in FIGS. 41A-41H encoded by the isolated nucleic acid molecule of claim 4.
15. A fusion polypeptide having the amino acid sequence set forth in FIGS. 42A-42I encoded by the isolated nucleic acid molecule of claim 5.
16. A fusion polypeptide having the amino acid sequence set forth in FIGS. 43A-43G encoded by the isolated nucleic acid molecule of claim 6.
17. A fusion polypeptide having the amino acid sequence set forth in FIGS. 44A-44I encoded by the isolated nucleic acid molecule of claim 7.
18. A fusion polypeptide having the amino acid sequence set forth in FIGS. 45A-45I encoded by the isolated nucleic acid molecule of claim 8.
19. A fusion polypeptide having the amino acid sequence set forth in FIGS. 46A-46I encoded by the isolated nucleic acid molecule of claim 9.
20. A fusion polypeptide having the amino acid sequence set forth in FIGS. 47A-47J encoded by the isolated nucleic acid molecule of claim 10.
US09/935,868 1998-09-25 2001-08-23 Receptor based antagonists and methods of making and using Abandoned US20020164690A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/935,868 US20020164690A1 (en) 1998-09-25 2001-08-23 Receptor based antagonists and methods of making and using
US10/287,035 US7083949B2 (en) 1998-09-25 2002-11-01 Receptor based antagonists and methods of making and using

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10185898P 1998-09-25 1998-09-25
US09/313,942 US6472179B2 (en) 1998-09-25 1999-05-19 Receptor based antagonists and methods of making and using
US09/935,868 US20020164690A1 (en) 1998-09-25 2001-08-23 Receptor based antagonists and methods of making and using

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/022045 Continuation-In-Part WO2000018932A2 (en) 1998-09-25 1999-09-22 Receptor based antagonists and methods of making and using
US09787835 Continuation-In-Part 1999-09-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/287,035 Continuation-In-Part US7083949B2 (en) 1998-09-25 2002-11-01 Receptor based antagonists and methods of making and using

Publications (1)

Publication Number Publication Date
US20020164690A1 true US20020164690A1 (en) 2002-11-07

Family

ID=26798712

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/313,942 Expired - Fee Related US6472179B2 (en) 1998-09-25 1999-05-19 Receptor based antagonists and methods of making and using
US09/935,868 Abandoned US20020164690A1 (en) 1998-09-25 2001-08-23 Receptor based antagonists and methods of making and using

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/313,942 Expired - Fee Related US6472179B2 (en) 1998-09-25 1999-05-19 Receptor based antagonists and methods of making and using

Country Status (19)

Country Link
US (2) US6472179B2 (en)
EP (3) EP1115876B1 (en)
JP (1) JP3902728B2 (en)
CN (1) CN100345970C (en)
AT (2) ATE336583T1 (en)
AU (1) AU758970C (en)
BE (1) BE2010C021I2 (en)
CA (1) CA2345109C (en)
DE (3) DE69922269T2 (en)
DK (1) DK1229047T3 (en)
ES (2) ES2267300T3 (en)
FR (1) FR10C0025I2 (en)
HK (2) HK1035377A1 (en)
IL (2) IL142103A0 (en)
NO (2) NO329976B1 (en)
NZ (1) NZ510720A (en)
PL (1) PL201246B1 (en)
PT (1) PT1229047E (en)
WO (1) WO2000018932A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060040852A1 (en) * 2004-08-17 2006-02-23 Daniel Dix IL-1 antagonist formulations

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP4271850B2 (en) 1998-01-23 2009-06-03 イミュネックス・コーポレーション IL-18 receptor
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
ES2614260T3 (en) * 2000-05-26 2017-05-30 Immunex Corporation Use of antibodies against the interleukin-4 receptor and compositions thereof
WO2001096565A2 (en) * 2000-06-16 2001-12-20 Asterion Limited Binding agents: chimeric ligand/receptor proteins
AU2001290524A1 (en) 2000-08-08 2002-02-18 Zymogenetics Inc. Soluble zcytor 11 cytokine receptors
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US6846520B2 (en) * 2002-01-17 2005-01-25 Canon Kabushiki Kaisha Epoxy resin composition, surface treatment method, liquid-jet recording head and liquid-jet recording apparatus
AU2003243189B2 (en) 2002-05-01 2008-01-24 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
US6919012B1 (en) 2003-03-25 2005-07-19 Olimex Group, Inc. Method of making a composite article comprising a ceramic coating
AU2004224122A1 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Improved Fc fusion proteins
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
WO2004098596A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
MXPA05013508A (en) * 2003-06-11 2006-04-05 Wyeth Corp Method for producing a polypeptide.
HUE050171T2 (en) * 2003-07-28 2020-11-30 Genentech Inc Reducing protein a leaching during protein a affinity chromatography
JP2007503820A (en) * 2003-09-05 2007-03-01 ナショナル・リサーチ・カウンシル・オブ・カナダ Coiled-coil fusion proteins containing cell receptor domains
AU2004290017B2 (en) 2003-11-07 2012-05-03 Immunex Corporation Antibodies that bind interleukin-4 receptor
WO2005085284A1 (en) * 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 sepecific polypetides and therapeutic uses thereof
EP1750746A1 (en) 2004-06-04 2007-02-14 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
US7709605B2 (en) 2004-07-23 2010-05-04 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
DK1630232T3 (en) * 2004-08-27 2008-10-20 Conaris Res Inst Ag Optimized nucleotide sequences encoding sgp130
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
EP1804835B9 (en) * 2004-09-13 2012-05-02 Genzyme Corporation Multimeric constructs
US20080292628A1 (en) * 2004-10-12 2008-11-27 Amprotein Corporation Chimeric Protein
KR101238684B1 (en) 2004-10-22 2013-03-04 지모제넥틱스, 인코포레이티드 Anti-il-22ra antibodies and binding partners and methods of using in inflammation
US20090142294A1 (en) * 2005-01-25 2009-06-04 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
US20060217311A1 (en) * 2005-03-25 2006-09-28 Daniel Dix VEGF antagonist formulations
US7732167B2 (en) * 2005-06-17 2010-06-08 Regeneron Pharmaceuticals, Inc. Interferon-α/β binding fusion proteins and therapeutic uses thereof
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
SI2298815T1 (en) 2005-07-25 2015-08-31 Emergent Product Development Seattle, Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US7889347B2 (en) 2005-11-21 2011-02-15 Plexera Llc Surface plasmon resonance spectrometer with an actuator driven angle scanning mechanism
CN105001320A (en) * 2005-11-23 2015-10-28 阿塞勒隆制药公司 Activin-ActRIIa antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
CA3149553C (en) 2006-06-12 2023-11-21 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
LT2944306T (en) 2006-06-16 2021-02-25 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
SI1873166T1 (en) 2006-06-30 2011-01-31 Conaris Res Inst Ag Improved sgp 130Fc dimers
US7666423B2 (en) * 2006-07-28 2010-02-23 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
DK2124997T3 (en) * 2006-10-20 2012-08-27 Regeneron Pharma Use of IL-1 antagonists in the treatment of gout and pseudo-gout
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5272735B2 (en) * 2007-01-30 2013-08-28 国立大学法人 新潟大学 Biologics
ES2415666T3 (en) 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIa antagonists for use in the prevention or treatment of breast cancer metastases or bone loss related to breast cancer
TW201940502A (en) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 Variants derived from ActRIIB and uses therefor
TWI667038B (en) 2007-02-09 2019-08-01 美商艾瑟勒朗法瑪公司 Pharmaceutical composition comprising an actriia-fc fusion protein; use of an actriia-fc fusion protein for treatment or prevention of cancer-related bone loss; use of an actriia-fc fusion protein for the treatment or prevention of multiple myeloma
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI454479B (en) 2007-03-06 2014-10-01 Amgen Inc Variant activin receptor polypeptides and uses thereof
EP2140005B1 (en) * 2007-03-19 2013-12-11 National Research Council of Canada Fusion proteins comprising two tgf-beta binding domains
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US20110008332A1 (en) * 2007-10-31 2011-01-13 The Scripps Research Institute Combination Therapy to Treat Persistent Viral Infections
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
WO2010031168A1 (en) * 2008-09-17 2010-03-25 National Research Council Of Canada HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY
MX340204B (en) 2008-04-11 2016-06-30 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof.
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PT3750552T (en) 2008-08-14 2023-06-28 Acceleron Pharma Inc Gdf traps
EA201100832A1 (en) 2008-11-26 2011-12-30 Амген Инк. OPTIONS OF POLYPEPTIDES OF ACTIVIN IIB RECEPTOR AND THEIR APPLICATION
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
MX2011013364A (en) 2009-06-12 2012-03-16 Acceleron Pharma Inc Truncated actriib-fc fusion proteins.
JP6267425B2 (en) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド ACTRIIB protein and its variants and uses thereof for utrophin induction for the treatment of muscular dystrophy
EP2638065A4 (en) 2010-11-08 2014-04-09 Acceleron Pharma Inc Actriia binding agents and uses thereof
EP2697260A1 (en) 2011-04-15 2014-02-19 Merck Patent GmbH Anti- il-1r1 inhibitors for use in cancer
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
MX358358B (en) 2011-12-19 2018-08-15 Amgen Inc Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof.
KR102279522B1 (en) 2012-11-02 2021-07-19 셀진 코포레이션 Activin-actrii antagonists and uses for treating bone and other disorders
EP2928916B1 (en) * 2012-12-10 2019-03-13 Vib Vzw Novel interleukin-33 inhibitors
CA2899889A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
AU2013378122B2 (en) 2013-02-15 2019-05-02 R-Pharm International, Limited Liability Company IL-1beta inhibitor composition and use thereof
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
PL3170005T3 (en) 2014-07-18 2019-10-31 Sanofi Sa Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
MA41116A (en) * 2014-12-01 2017-10-10 Ferring Bv SELECTIVE IL-6 TRANS-SIGNALING INHIBITOR COMPOSITIONS
RS61947B1 (en) 2014-12-01 2021-07-30 Ferring Bv Administration of a selective il-6-trans-signalling inhibitor
WO2016090077A1 (en) 2014-12-03 2016-06-09 Celgene Corporation Activin-actrii antagonists and uses for treating anemia
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
EP3519442A4 (en) 2016-09-27 2020-06-17 EpicentRx, Inc. Immunomodulatory fusion proteins
WO2018195388A1 (en) * 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
BR112020006115A2 (en) 2017-09-27 2020-11-17 Epicentrx, Inc. immunomodulatory fusion proteins
EP3762421A2 (en) 2018-03-09 2021-01-13 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
JP2021530507A (en) 2018-07-18 2021-11-11 マンザニータ ファーマシューティカルズ，インク． Conjugates for delivering anticancer drugs to nerve cells, their usage and manufacturing methods
CN110950965B (en) * 2018-09-26 2021-10-15 重庆精准生物技术有限公司 Chimeric antigen receptor of anti-human CD123 and application thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
AU651596B2 (en) * 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
EP0835939B8 (en) * 1990-06-28 2006-01-11 Sanofi-Aventis Deutschland GmbH Fusion proteins with parts of immunoglobulins, their production and use
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
US5770401A (en) * 1991-10-15 1998-06-23 Mullarkey; Michael F. Methods and compositions for treating allergic reactions
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
CA2131719C (en) * 1992-03-09 2003-09-16 Jean-Christophe Renauld Nucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptor
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
ATE242322T1 (en) * 1992-03-30 2003-06-15 Immunex Corp FUSION PROTEIN CONTAINING TWO TUMOR NECROSIS FACTOR RECEPTORS
JP3255699B2 (en) 1992-04-23 2002-02-12 味の素株式会社 Human IL-2 receptor gamma chain molecule
EP0693084A4 (en) * 1993-04-06 1999-06-02 Hutchinson Fred Cancer Res Chimeric cytokine receptors in lymphocytes
WO1995006737A1 (en) * 1993-09-03 1995-03-09 Kenneth Francis Prendergast Glycophorin binding protein (gbp130) fusion compositions
CA2174098C (en) * 1993-10-14 2011-01-25 Douglas A. Melton Method of inducing and maintaining neuronal cells
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
IL114825A0 (en) * 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
WO1996011213A1 (en) 1994-10-07 1996-04-18 Amgen Boulder Inc. Dimeric il-4 inhibitors
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
US5837816A (en) * 1995-05-10 1998-11-17 Chiron Corporation Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU3668897A (en) * 1996-07-17 1998-02-09 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
AU7011696A (en) * 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
JP4271850B2 (en) * 1998-01-23 2009-06-03 イミュネックス・コーポレーション IL-18 receptor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060040852A1 (en) * 2004-08-17 2006-02-23 Daniel Dix IL-1 antagonist formulations

Also Published As

Publication number Publication date
EP1115876A2 (en) 2001-07-18
EP1405915A1 (en) 2004-04-07
ATE283365T1 (en) 2004-12-15
IL142103A0 (en) 2002-03-10
NO20011513L (en) 2001-05-25
IL142103A (en) 2007-07-04
AU758970B2 (en) 2003-04-03
EP1115876B1 (en) 2006-08-16
CA2345109C (en) 2012-12-18
JP3902728B2 (en) 2007-04-11
EP1229047B1 (en) 2004-11-24
JP2002525119A (en) 2002-08-13
CA2345109A1 (en) 2000-04-06
HK1045847B (en) 2005-03-24
PL348529A1 (en) 2002-06-03
AU6499499A (en) 2000-04-17
WO2000018932A2 (en) 2000-04-06
ES2267300T3 (en) 2007-03-01
NO20011513D0 (en) 2001-03-23
AU758970C (en) 2007-05-03
US20020012962A1 (en) 2002-01-31
EP1229047A2 (en) 2002-08-07
DE122010000023I1 (en) 2012-04-26
HK1035377A1 (en) 2001-11-23
US6472179B2 (en) 2002-10-29
DE69922269T2 (en) 2005-12-01
BE2010C021I2 (en) 2018-12-04
NO2011003I2 (en) 2011-04-11
NZ510720A (en) 2003-11-28
ES2233733T3 (en) 2005-06-16
ATE336583T1 (en) 2006-09-15
EP1229047A3 (en) 2002-10-02
WO2000018932A3 (en) 2000-11-02
FR10C0025I1 (en) 2010-05-21
NO2011003I1 (en) 2011-05-02
DE122010000023I2 (en) 2012-04-26
DE69932832D1 (en) 2006-09-28
CN100345970C (en) 2007-10-31
PL201246B1 (en) 2009-03-31
NO329976B1 (en) 2011-01-31
FR10C0025I2 (en) 2011-04-01
PT1229047E (en) 2005-03-31
CN1357049A (en) 2002-07-03
WO2000018932A9 (en) 2000-08-31
DK1229047T3 (en) 2005-02-21
HK1045847A1 (en) 2002-12-13
DE69922269D1 (en) 2004-12-30
DE69932832T2 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
AU758970C (en) Receptor based antagonists and methods of making and using
US6927044B2 (en) IL-1 receptor based cytokine traps
US5844099A (en) Cytokine antagonists
AU694232B2 (en) Receptor for oncostatin M
AU651596B2 (en) Type II interleukin-1 receptors
US5464937A (en) Type II Interleukin-1 receptors
JP3308534B2 (en) New cytokine
CA2222914C (en) Novel cd40l mutein
US7083949B2 (en) Receptor based antagonists and methods of making and using

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION